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Chapter 1
General introduction

9General introduction
LEukEMia
In the bone marrow the normal hematopoeisis (formation of blood cells) takes place. The 
main function of the bone marrow is to maintain the number of mature blood cells in the 
peripheral blood at a constant level throughout life. Leukemia is a type of cancer, character-
ized by abnormal growth of immature white blood cells in the bone marrow. This overgrowth 
of non-functional leukemic cells compromises the formation of normal mature blood cells, 
leading to anemia (due to the loss of functional red blood cells), infections (due to the loss 
of functional white blood cells), bleedings or bruising (due to the loss of functional white 
blood cells). Once the bone marrow is overgrown, leukemic cells are capable of infiltrating 
other organs, like the spleen, liver, skin, testes and central nervous system. Leukemia can be 
classified in several subtypes, based on cell-growth and immunophenotype. Fast-growing 
leukemias are characterized as “acute” and slow-growing as “chronic”. Based on immuno-
phenotype leukmias are classified into “lymphoblastic” or “myeloid”, depending on the type 
of with blood cells the leukemic cells rises from.
infant aCutE LyMPhobLastiC LEukEMia
Acute lymphoblastic leukemia (ALL) in infants (<1 year of age) is a rare and aggressive 
malignancy with early onset, high frequencies of early relapse during treatment, and a poor 
clinical outcome1, 2. Infant ALL accounts for approximately 4% of all pediatric ALL cases. 
Infants have a distinctive biology compared to older children with ALL. Translocation of 
the Mixed Lineage Leukemia (MLL) gene are found in ~6% of childhood ALL cases, of 
which 80% is associated with infant ALL3. The presence of an MLL-rearrangement in their 
leukemic cells, is a strong independent predictor of poor outcome in infant ALL patients1-3. 
More than 70 different MLL partner genes have been identified4. The most common MLL 
translocation in infant ALL is t(4;11), in which the N-terminus of MLL (chromosome 
11q23) fuses to the C-terminus of AF4 (chromosome 4q23). Other recurrent in-frame 
MLL-rearrangements found among infant ALL patients are t(11;19) and t(9;11), giving rise 
to the fusion proteins MLL-ENL and MLL-AF9 respectively2, 5. MLL germline infant ALL 
patients are patients, who lack an MLL-translocation in their leukemic cells.
The past decades survival rates for pediatric ALL patients have improved dramatically, with 
event-free survival (EFS) of 80% in older children with ALL. In contrast with the ~50% 
EFS for infant ALL patients (Figure 1), regardless of the more aggressive chemotherapy 
treatment they usually recieve2, 6. Although most infant ALL patients (~90-95%) achieve 
morphological complete remission (CR) after initial induction therapy, their prognosis is 
hampered by high relapse-rates. Most relapses occur very early, i.e. within the first year 
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after diagnosis2, 7-9. The poor outcome of infant ALL patients in general is caused by the 
very poor outcome of infants which harbor an MLL-translocation in their leukemic cells 
(EFS of ~30-40%). This is in contrast to the outcome of infants lacking MLL-rearrangement 
in their leukemic cells, which nearly reaches the survival rates of older children with ALL 
(Figure 2)2. Other prognostic factors in infant ALL, associated with poor outcome are, high 
white blood cell (WBC) counts at diagnosis, very immature pro-B ALL phenotype, and 
glucocorticoid resistance2, 3, 10-12. More insights in the prognostic factors, molecular biol-
ogy and clinical outcome of infant ALL, and in particular MLL-rearranged infant ALL, are 
needed in order to improve risk stratification and therapeutic strategies.
Insights into the biology and pathogenesis of MLL-rearranged ALL are hampered by the 
lack of genuine animal models accurately recapitulating this severe malignancy. Various 
attempts have been made to develop mouse models mimicking leukemogenesis of human 
t(4;11)-positive ALL, these mice displayed propensities towards developing lymphomas or 
leukemia with phenotypes that significantly differ from those found in humans13-15. Recent 
studies suggest involvement of the RAS-pathway, additional to the MLL-fusion, in the 
pathogenesis of MLL-rearranged leukemia 16-19. The RAS-pathway regulates diverse cellular 
functions including cell proliferation, survival, differentiation, angiogenesis, and migration 
20, 21. Studies on the incidence of RAS mutations (NRAS and KRAS) in MLL-rearranged 
ALL demonstrate various frequencies 10-34% in MLL-rearranged and 26-63.9% in t(4;11)-
positive childhood leukemia 16, 17, 22-24. Deregulation of the RAS-pathway is a common event 
in childhood ALL and may guide new therapy strategies for MLL-rearranged infant ALL21.
figure 1: Clinical outcome of infant aLL patients (Kaplan-Meier curve is adapted from Pieters et al. 2007).
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outLinE of this thEsis
In Chapter 2 we detail the clinical outcome and prognostic factors of infant ALL patients, 
who relapsed on or after receiving the Interfant-99 treatment protocol. Relapsed infant ALL 
is assumed to be inevitably fatal. However, published data on outcome of relapsed infant 
ALL is limited. In Chapter 3 we report on the correlation of in vitro drug sensitivity with 
clinical outcome in a relatively large cohort of primary MLL-rearranged infant ALL cases. 
To further identify prognostic factors in infant ALL patients we investigated the frequencies 
and prognostic value of RAS mutations in our cohort of primary infant ALL cases. As we re-
port in Chapter 4 we found that the presences of a RAS mutation in MLL-rearranged infant 
ALL cases is an independent prognostic factor for outcome. Therefore we hypothesized that 
inhibiting the RAS-pathway could be beneficial for infant ALL patients. In Chapter 5 we 
report the effect of MEK inhibitors targeting primary RAS-mutated MLL-rearranged infant 
ALL cells in vitro and the relation with prednisolone sensitization. Chapter 6 describes the 
role of Casitas B lineage lymphoma (CBL), a protein involved in the RAS-pathway, in acute 
myeloid leukemia and MLL-rearranged infant ALL. In Chapter 7 we address our study of 
the relation of high Versican expression and clinical outcome in MLL-rearranged infant ALL 
patients. In Chapter 8 we report on the effect of minimal contaminating stromal cells in in 
vitro co-culture experiments. Chapter 9 summarizes this thesis and comprises a general 
discussion and Chapter 10 covers a layman’s summary in Dutch.
figure 2: Clinical outcome of infant aLL patients, dissected by type of MLL-translocation (Kaplan-
Meier curve is adapted from Pieters et al. 2007).
12 Chapter 1
REfEREnCEs
 1. Greaves MF. Infant leukaemia biology, aetiology and treatment. Leukemia. 1996;10(2):372-7.
 2. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, et al. A treatment protocol for 
infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational 
study and a multicentre randomised trial. Lancet. 2007;370(9583):240-50.
 3. Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. Blood. 
2000;96(1):24-33.
 4. Meyer C, Hofmann J, Burmeister T, Groger D, Park TS, Emerenciano M, et al. The MLL recombi-
nome of acute leukemias in 2013. Leukemia. 2013;27(11):2165-76.
 5. Jansen MW, Corral L, van der Velden VH, Panzer-Grumayer R, Schrappe M, Schrauder A, et al. 
Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and 
type of MLL gene rearrangement. Leukemia. 2007;21(4):633-41.
 6. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030-43.
 7. Frankel LS, Ochs J, Shuster JJ, Dubowy R, Bowman WP, Hockenberry-Eaton M, et al. Therapeutic 
trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). 
J Pediatr Hematol Oncol. 1997;19(1):35-42.
 8. Reaman GH, Sposto R, Sensel MG, Lange BJ, Feusner JH, Heerema NA, et al. Treatment outcome and 
prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of 
the Children’s Cancer Group. J Clin Oncol. 1999;17(2):445-55.
 9. Stam RW, den Boer ML, Pieters R. Towards targeted therapy for infant acute lymphoblastic leukae-
mia. Br J Haematol. 2006;132(5):539-51.
 10. Dordelmann M, Reiter A, Borkhardt A, Ludwig WD, Gotz N, Viehmann S, et al. Prednisone response 
is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 
1999;94(4):1209-17.
 11. Kaspers GJ, Pieters R, Van Zantwijk CH, Van Wering ER, Van Der Does-Van Den Berg A, Veerman 
AJ. Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and 
cross-resistance to other drugs. Blood. 1998;92(1):259-66.
 12. Pieters R, den Boer ML, Durian M, Janka G, Schmiegelow K, Kaspers GJ, et al. Relation between age, 
immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--
implications for treatment of infants. Leukemia. 1998;12(9):1344-8.
 13. Chen W, Li Q, Hudson WA, Kumar A, Kirchhof N, Kersey JH. A murine Mll-AF4 knock-in model 
results in lymphoid and myeloid deregulation and hematologic malignancy. Blood. 2006;108(2):669-
77.
 14. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, et al. H3K79 methylation profiles 
define murine and human MLL-AF4 leukemias. Cancer Cell. 2008;14(5):355-68.
 15. Metzler M, Forster A, Pannell R, Arends MJ, Daser A, Lobato MN, et al. A conditional model of 
MLL-AF4 B-cell tumourigenesis using invertor technology. Oncogene. 2006;25(22):3093-103.
 16. Liang DC, Shih LY, Fu JF, Li HY, Wang HI, Hung IJ, et al. K-Ras mutations and N-Ras mutations in 
childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements. Cancer. 
2006;106(4):950-6.
 17. Mahgoub N, Parker RI, Hosler MR, Close P, Winick NJ, Masterson M, et al. RAS mutations in pedi-
atric leukemias with MLL gene rearrangements. Genes Chromosomes Cancer. 1998;21(3):270-5.
 18. Ng MH, Ng RK, Kong CT, Jin DY, Chan LC. Activation of Ras-dependent Elk-1 activity by MLL-AF4 
family fusion oncoproteins. Exp Hematol. 2010;38(6):481-8.
13General introduction
 19. Tamai H, Miyake K, Takatori M, Miyake N, Yamaguchi H, Dan K, et al. Activated K-Ras protein 
accelerates human MLL/AF4-induced leukemo-lymphomogenicity in a transgenic mouse model. 
Leukemia. 2011;25(5):888-91.
 20. Chung E, Kondo M. Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leuke-
mia development. Immunol Res. 2011;49(1-3):248-68.
 21. Knight T, Irving JA. Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic 
Leukemia and Its Therapeutic Targeting. Front Oncol. 2014;4:160.
 22. Prelle C, Bursen A, Dingermann T, Marschalek R. Secondary mutations in t(4;11) leukemia patients. 
Leukemia. 2013;27(6):1425-7.
 23. Andersson AK, Ma J, Wang J, Chen X, Gedman AL, Dang J, et al. The landscape of somatic mutations 
in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet. 2015;47(4):330-7.
 24. Trentin L, Bresolin S, Giarin E, Bardini M, Serafin V, Accordi B, et al. Deciphering KRAS and NRAS 
mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis. Sci 
Rep. 2016;6:34449.

Chapter 2
Outcome of relapsed infant acute 
lymphoblastic leukemia treated on 
the Interfant-99 protocol
E.M.C. Driessen1, P. de Lorenzo2, M. Campbell2, M. Felice2, 
A. Ferster2, I. Hann2, A.Vora2, L. Hovi2, G. Escherich2, C.K. Li2, 
G. Mann2, T. Leblanc2, F. Locatelli2 ,A. Biondi2, J. Rubnitz2, 
M. Schrappe2, L. Silverman2, J.Stary2 R. Suppiah2, T. 
Szczepanski2, M. Valsecchi2 *, R. Pieters1,2,3*
*Shared last co-authorship
1 Pediatric Oncology/Hematology, Erasmus MC-Sophia Children’s Hospital, 
Rotterdam, The Netherlands;
2 Interfant-99 Collaborative Study Group
3 Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
Leukemia; May 2016; 30(5): 1184-7

17Outcome of relapsed infant ALL
intRoDuCtion
Acute lymphoblastic leukemia (ALL) in infants (<1 year of age) is an aggressive disease. 
About 80% of infant ALL patients harbor a Mixed Lineage Leukemia (MLL) translocation, 
which is a strong independent predictor of poor outcome1. Furthermore, infant ALL is as-
sociated with higher white blood cell (WBC) counts at diagnosis, very immature pro-B ALL 
phenotype, and glucocorticoid resistance1, 2. Although most infant ALL patients (~95%) 
achieve morphological complete remission (CR) after induction therapy, due to high relapse 
rates their outcome is poor1. Most relapses occur early, within the first year after diagnosis. 
The largest series of infant ALL, described by the Interfant-99 study group, reported a re-
lapse rate of 34%. Relapsed infant ALL is generally assumed to be inevitably fatal. Published 
data on outcome of relapsed infant ALL is very limited, and available ones report on small 
cohorts.3 Here, we describe the clinical outcome of 202 infant ALL patients, who relapsed 
on or after receiving the Interfant-99 treatment protocol1.
MEthoDs
Design and inclusion criteria of the Interfant-99 trial have been described previously1. 
Therapy after relapse differed in participating countries according to local policy and in-
dividual choice. We retrospectively asked the physicians whether the therapy was based on 
curative or palliative intent.
Outcome measure was overall survival (OS), defined as time from relapse until death from 
any cause. Curves were estimated with the Kaplan-Meier method and compared by sub-
groups with the log-rank test. Follow-up was updated at December 31 2009 and median 
follow-up (range) was 5.2 years (1 month–10.1 years). Survival analyses regarding hemato-
poietic stem cell transplantation (HSCT) were corrected for waiting time to transplantation. 
Association between prognostic characteristics at first diagnosis of ALL and at relapse with 
risk group and with assignment to curative or palliative care was evaluated with the Fisher 
exact test. To account for imbalances in characteristics between patients, a propensity score 
was derived, reflecting the probability that a patient would undergo curative treatment, by 
performing a multivariable logistic regression analysis. Any residual association between 
the covariates and treatment allocation was assessed by the Cochran–Mantel–Haenszel test. 
Cox model was used to evaluate outcome of curative and palliative treatment and of HSCT 
vs chemotherapy alone as curative treatment after relapse. Hazard ratios were tested accord-
ing to Wald. SAS version 9.2 statistical software was used for data analysis.
18 Chapter 2
REsuLts
Out of 478 patients, 448 patients achieved first CR, 70.1% patients were allocated in the 
standard risk (SR, i.e. good prednisone response) and 29.9% in high risk (HR, i.e. poor 
prednisone response) group. Two-hundred and two patients (45.1%) relapsed, 37.6% and 
62.7% in the SR and HR group, respectively. 56.9% (115/202) of the relapses occurred in 
the first year after diagnosis, with a median time to relapse of 10.0 months (range: 1.7-
50.7 months). Most relapses occurred in the bone marrow (BM, 71.8%), while others were 
isolated extramedullary (n=23) or combined relapses (n=32). Patients in the HR group 
relapsed earlier than patients in the SR group (median: 9 vs. 12 months, p=0.042).
The 3-year OS after relapse was 20.9% (SE 3.5%). Infants with germline-MLL ALL relapsed 
later (>24 months) than infants with MLL-rearrangements (p=0.03). There was no differ-
ence in site of relapse (BM involvement vs. extramedullary) between germline-MLL and 
MLL-rearranged infant ALLs.
Out of 202 patients, 159 (78.7%) received relapse treatment with curative intent and 32 
(15.8%) received supportive care only. For 11 patients (5.5%) treatment after relapse was 
not reported and these were excluded from further analyses. The 3-year OS after relapse 
of patients treated with curative intent was 24.9% (SE 4.0%), of whom 76.1% (121/159) 
died due to progressive ALL (n=93), HSCT-related causes (n=21) and other, mainly infec-
tious, causes (n=7). All patients who received palliative care (n=32) died within 1 year after 
relapse, due to disease progression (Figure 1A, p<0.0001). As expected, this straightforward 
outcome comparison is biased by imbalances in the characteristics of the two groups. Cura-
tive treatment was more likely to be adopted for patients with a long duration of first CR 
(p=0.0005).
All patients (n=28), who relapsed after 24 months received curative treatment. 84.4% of pa-
tients receiving palliative care relapsed in the first year, compared to 50.3% of curative treated 
patients. Almost all patients carrying germline-MLL underwent curative treatment, whereas 
87.5% of patients with palliative care had an MLL-rearrangement. Similarly, patients with 
higher WBC counts (>300x109/L) at first diagnosis received palliative care more frequently. In 
order to account for these imbalances, we derived a propensity score which predicted whether 
a patient would undergo curative treatment as a function of clinical characteristics likely af-
fecting treatment choice. We used the propensity score in a stratified Cox model in order to 
perform a fair comparison of outcome in the two groups. The model which was also adjusted 
by relevant covariates, revealed that curative treatment was associated with a significantly 
superior OS (hazard ratio=0.17, 95% CI (0.10–0.27), p<0.0001). Interestingly, the time of 
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figure 1: overall survival of relapsed infant aLL patients
Overall survival, defined as time from relapse until death, (A) by treatment given after relapse, (B) of patients 
treated with curative intents by MLL status at initial diagnosis, (C) of patients treated with curative intents 
by time at relapse after initial diagnosis, (D) of patients treated with curative intents by site at relapse, (E) 
of patients treated with HSCT vs. chemotherapy only of early relapses (within 24 months from initial diag-
nosis), (F) of patients treated with HSCT vs. chemotherapy only of late relapses (beyond 24 months from 
initial diagnosis). Curves were estimated using the Kaplan-Meier method and analyzed by Log-rank tests. 
Follow-up was updated at December 31 2009 and median follow-up(range) was 5.2 years(1 month–10.1 
years). Survival analyses regarding HSCT were corrected for waiting time to transplantation.
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relapse retained prognostic relevance. Patients who relapsed within 24 months after diagnosis 
had a 1.5-fold increase in the risk of death (hazard ratio=1.40, 95% CI (0.97–2.01), p=0.016).
We then restricted our attention to the outcome of 159 patients treated with curative intent 
(Table 1 and Figure 1B-F). We did not observe a significant difference in OS after relapse 
between infants with and without 11q23 abnormalities (p=0.328). Infants with a t(4;11)-re-
table 1: outcome of relapsed infant aLL patients treated with curative intent
  Patients Deaths 3-year OS (SE) p-value
Risk group   0.487
SR 94 72 25.3 (5.2)
HR 65 49 24.4 (6.2)
11q23 abnormalities   0.328*
MLL germline 15 10 33.3 (12.9)
t(4;11) 65 54 16.9 (6.2)
t(9;11) 18 15 27.8 (11.8)
t(11;19) 21 14 32.7 (10.9)
Other positive 20 12 40.0 (11.2)
Not known 20 16 20.0 (11.2)
Age at diagnosis   0.078
< 3 months 42 34 19.1 (7.7)
3 - 6 months 50 41 16.8 (7.1)
6 - 9 months 39 28 30.8 (8.0)
9 – 12 months 28 18 39.3 (9.4)
WBC counts (cell/L)   0.017
< 100 x 109 58 38 36.2 (6.6)
100-300 x 109 50 38 25.1 (7.1)
≥ 300 x 109 51 45 11.8 (7.0)
Time of relapse   0.001
0-12 months 80 67 17.5 (5.6)
12-24 months 51 38 25.5 (7.0)
> 24 months 28 16 44.4 (9.7)
Site of relapse   0.030§
Bone marrow 113 91 20.2 (4.7)
Bone marrow + other 26 18 34.2 (9.8)
Isolated Extramedullary 19 11 42.1 (11.3)
Not known 1 1 -
Overall survival, defined as time from relapse until death, of curative treatments after relapse by relevant 
prognostic factors at initial diagnosis and at relapse, including risk group (based on prednisone response), 
11q23-abnormalities, age at initial diagnosis, WBC counts at initial diagnosis, time of relapse, defined as 
time from initial diagnosis until relapse, and site of relapse. Subgroups were analyzed by using the Log-rank 
test. *p-value comparing positive vs. negative. §p-value comparing BM involvements vs. extramedullary.
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arrangement showed a worse 3-year OS compared to those with other 11q23-abnormalities 
(p=0.037). Age at diagnosis had a significant impact on outcome after first relapse, with 
a 3-year OS of 17.9% (SE 5.2%) in patients below 6 months of age and 34.3% (SE 6.1%) 
in older patients (p=0.012). Higher WBC count at diagnosis was associated with inferior 
OS after relapse (p=0.017), while risk group stratification by initial prednisone response 
showed no impact (p=0.487). In addition, we found that infants relapsing within one year 
after diagnosis had a 3-year OS of 17.5% (SE 5.6%) compared to 25.5% (SE 7.0%) and 44.4% 
(SE 9.7%) of those who relapsed between 12-24 and beyond 24 months after diagnosis, 
respectively (p=0.001). Patients with relapse involving BM, either isolated or combined, had 
a worse OS compared to patients with isolated extramedullary relapse (p=0.030).
Among patients treated for relapse, 87 (54.7%) underwent HSCT, the majority in second 
CR (n=66, 75.9%) and from an HLA-matched unrelated donor (n=41, 47.1%). The median 
time from relapse to HSCT was 4.2 months (range: 1.1-9.1). According to the results of the 
Cox model corrected for waiting time to transplantation, patients receiving HSCT after 
relapse had a better OS compared to patients receiving chemotherapy alone (p=0.021); 
similar results were found after adjusting for known prognostic factors at initial diagnosis. 
The advantage of HSCT over chemotherapy did not change significantly over time of follow-
up, contrary to what was observed for HSCT in CR1 in the Interfant-99 study4. Interestingly, 
there was a significant interaction between treatment and time at relapse (p=0.010), while 
the interaction between treatment and site of relapse was not significant. The analysis in 
subgroups defined by the time at relapse showed that HSCT significantly reduced the risk 
of death compared to chemotherapy alone in 131 patients who relapsed within 24 months 
from initial diagnosis (hazard ratio=0.52, 95% CI(0.32–0.85), p=0.009), while no advantage 
over chemotherapy was observed for patients who relapsed later (hazard ratio=1.28, 95% 
CI(0.420–3.89), p=0.667). After fitting the Cox model to subgroups of early relapses, site of 
relapse retained its significant impact over survival (hazard ratio for BM and combined vs. 
extramedullary relapses was 2.00, 95% CI(1.04-3.85), p=0.038).
DisCussion
Here, we demonstrate in a large cohort that relapsed infant ALL is not inevitable fatal. We 
found a 3-year OS of 20.9% for all relapsed infant ALL patients and 24.9% for those treated 
with curative intent. This is in concordance with the previous reported 5-year OS of 25.6% 
of Tomizawa et al.3. Even after adjusting for imbalances of prognostic factors in the treat-
ment groups, patients treated with curative intent had a significant better outcome. Young 
age and a high WBC count at initial diagnosis were associated with inferior outcome after 
first relapse, but response to prednisone prophase during first line treatment did not. Fur-
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thermore, patients who relapsed earlier and with patients BM involvement (either isolated 
or combined) had a worse outcome. These findings are consistent with previous studies in 
other ALL subtypes5-7.
The use of HSCT in infant ALL is a matter of debate. Previous studies demonstrated that 
routine use of HSCT does not improve outcome for infants1, 8-10. However, data from the 
Interfant-99 study group suggested that a small subset with high risk features (young age 
combined with poor response to prednisone prophase or high WBC) may benefit from 
HSCT in first CR4. The present study showed that HSCT improved outcome of infants who 
relapsed ‘early’ (i.e. within 2 years after initial diagnosis), a subset which in our cohort 
accounts for 82% of all relapses.
In conclusion, we demonstrated that relapsed infant ALL was not invariably lethal and 
underline the relevance of offering treatments with curative intents. New therapeutic 
strategies, such as FLT3 inhibitors, epigenetic drugs, glucocorticoid sensitization and RAS-
pathway inhibition, could be beneficial for infant ALL patients11-15.
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abstRaCt
Despite the current successful treatment results in pediatric acute lymphoblastic leukemia 
(ALL), the prognosis for MLL-rearranged infant ALL patients remains poor, and novel 
strategies are needed to identify and predict patients at high risk of therapy failure. We 
explored to what extent in vitro drug resistance is associated with clinical outcome and 
established prognostic markers, such as age <6 months, MLL rearrangement and white 
blood cell count (WBC) at diagnosis.
We found that in vitro response to none of the drugs tested by itself is capable of predicting 
clinical outcome, although an association between in vitro glucocorticoid (i.e. prednisolone 
and dexamethasone) resistance and a poor outcome was observed. Also, in vitro resistance 
to glucocorticoids was associated with age <6 months and high WBC. The combined in vitro 
response to prednisolone, vincristine and L-asparaginase (PVA) was found to be predictive 
for an adverse outcome in MLL-rearranged infant ALL. PVA-resistant MLL-rearranged 
infant ALL patients are at high risk of therapy failure. PVA-resistant MLL-rearranged infant 
ALL patients showed cross-resistance towards dexamethasone but not to other drugs.
Taken together, we conclude that in vitro PVA-sensitivity testing in MLL-rearranged ALL 
may be useful to stratify patients at high risk of therapy failure, and that this approach 
allows identification of patients urgently requiring effective novel treatment options.
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intRoDuCtion
Over the last decades, the outcome for childhood acute lymphoblastic leukemia (ALL) in 
general has improved tremendously. Yet, the clinical outcome for infants (< 1 year of age) 
diagnosed with ALL remained dismal1-5. Infant ALL is characterized by a high incidence of 
balanced chromosomal translocations involving the Mixed Lineage Leukemia (MLL) gene 
located on chromosome 11, which are detected in ~80% of the cases6-8. As a result of such 
translocations, the N-terminal region of MLL fuses to the C-terminal region of one of its 
many translocation partner genes. Among infant ALL patients, the most recurrent MLL 
translocations are t(4;11), t(11;19) and t(9;11), which generate the chimeric fusion proteins 
MLL-AF4, MLL-ENL and MLL-AF9, respectively. The presence of leukemia-specific MLL 
translocations on its own represents a strong predictor of an unfavorable clinical out-
come2, 3, 5, 9, 10. Additional parameters predicting a poor outcome include age at diagnosis (<6 
months of age and white blood cell count (WBC) at disease presentation5. Moreover, infant 
ALL cells are resistant to glucocorticoids and L-asparaginase11, 12. The in vitro responses 
of prednisolone, vincristine and L-asparaginase combined (known as the PVA score), 
appeared highly predictive for clinical outcome in childhood ALL13, 14. To date it remains 
unclear whether in vitro drug resistance patterns obtained in primary infant ALL cells 
influence prognosis, or to what extent cellular resistance is associated with abovementioned 
prognostic factors. Therefore we generated in vitro cytotoxicity profiles in a cohort of infant 
ALL patients enrolled in the Interfant treatment protocols, and investigated the relation 
between in vitro drug responses, clinical outcome, and known prognostic factors, in order 
to attain evidence-based progression towards personalized medicine.
MEthoDs
Patient samples
In the present study we used a total of 67 samples obtained from infant ALL patients (<1 
year of age) enrolled in either the Interfant-99 or the Interfant-06 study, for whom a com-
plete overview of clinical parameters and follow up data was available, as well as sufficient 
material for in vitro cytotoxicity testing. This cohort of infant ALL patients consists of MLL-
rearranged infant ALL cases (n=55) as well as patients carrying germline (or wild-type) MLL 
genes (i.e. no translocation (n=12). The MLL-rearranged infant ALL patient group consists 
of patients carrying t(4;11) (n=28), t(11;19) (n=18) and other 11q23 translocations (n=9), 
as determined by fluorescence in situ hybridization (FISH) and RT-PCR analyses. Bone 
marrow aspirates or peripheral blood was collected at the Erasmus MC-Sophia Children’s 
Hospital, and within 24 hours leukemic cells were isolated by density gradation centrifuga-
tion (Lymphoprep; density 1.077 g/ml, Nycomed Pharma, Oslo, Norway). Samples were 
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enriched for leukemic blasts by removal of contaminating normal cells using monoclonal 
antibodies linked to magnetic beads as described by Kaspers et al.15. Consequently, all 
samples used for in vitro drug testing contained >90% leukemic cells, as determined mor-
phologically on May-Grunwald Giemsa (Merck, Darmstadt, Germany) stained cytospins.
In vitro drug response and in vivo prednisone response
For all samples, in vitro drug cytotoxicity was assessed by MTT assays as described previ-
ously16. Briefly, leukemic cells were incubated for 4 days in a humidified incubator at 37oC 
and 5% CO2, both in the absence and presence of a range of drug concentrations. Then, 10 µl 
of yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazoliumbromide (MTT) was added 
to the cells, following an additional 6-hour incubation under the same conditions, during 
which the yellow MTT is reduced to blue formazan crystals by viable cells only. Next, the 
blue formazan crystals were dissolved using HCL-isopropyl alcohol, allowing spectropho-
tometrical measurement of the optical density. Culture medium without cells nor drugs 
served as blanks (i.e. 0% survival), and leukemic cells cultured in the absence of drugs (i.e. 
controls) were adjusted to 100% survival and used to calculate the LC50-value. Results were 
considered evaluable only if the mean control OD, after correction for the background (as 
determined by the blanks), at day 4 exceeded 0.05 arbitrary units. The following drugs and 
concentration ranges (6 dosages per drug) were used: prednisolone, 0.08-250 ug/mL (PRED; 
Bufa, Uitgeest, The Netherlands); Vincristine, 0.05-50 ug/mL (VCR; Pharmacy Erasmus 
Medical Center, Rotterdam, The Netherlands); L-Asparaginase, 0.003-10 IU/mL (L-ASP; 
Nycomed BV, Hoofddorp, The Netherlands); Daunorubicin, 0.002-2.0 ug/mL (DNR; Sanofi 
Aventis, Gouda, The Netherlands); Cytarabine, 0.04-2.5 ug/mL (Ara-C; Hospira Benelux 
BVBA, Brussel, Belgium) and Dexamethasone, 0.0002-6.0 ug/mL (DEX; Pharmacie Eras-
mus Medical Center, Rotterdam, The Netherlands). The PVA score was based on the in 
vitro drug responses (i.e. LC50-values) of prednisolone, Vincristine and L-Asparaginase, in 
which sensitivity towards each drug individually was scored as 1, intermediate responses 
as 2, and resistance was scored as 3. For this, the cut-off LC50-values were: prednisolone 
sensitivity: <0.1 µg/mL and resistance: >150 µg/mL; vincristine sensitivity: <0.3906 µg/mL 
and resistance: >1.7578 ug/mL; L-asparaginase sensitivity: <0.033 IU/mL and resistance: 
>0.912 IU/mL. Hence, the PVA scores vary between 3 (sensitive to all three drugs) and 9 
(resistant to all three drugs).
The in vivo response to prednisone was determined after one intrathecal dose of methotrex-
ate and a 7-day window of prednisone mono-therapy (before the initiation of combination 
chemotherapy). Patients were defined as prednisone poor responders (PPRs) when >1000 
leukemic cells/µL remained present in the peripheral blood17. When the amount of leukemic 
cells dropped below 1000/µL patients were defined as prednisone good responders (PGRs).
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statistical analysis
Differences in the distribution of variables between patient groups were analyzed using the 
Mann-Whitney U-test or the Kruskall-Wallis test. Cross–resistance patterns were studied 
by correlating the LC50 values for different drugs using the Kruskall-Wallis test and the 
Spearman’s Rho-test. The probability of event-free survival (EFS) was calculated using the 
Kaplan-Meier method and the Log-rank (Mantel-Cox) test was performed to analyze dif-
ferences in outcome between patient groups. Furthermore, a correlation between in vitro 
prednisolone response and age at diagnosis was analyzed using the Spearman’s Rho-test. 
The EFS rate is defined as time from diagnosis to death in induction, failure to achieve 
complete remission after induction, disease relapse, the emergence of secondary malignan-
cies, or death in complete remission. Patients who did not achieve complete remission were 
assigned an event at time-point zero in the EFS analyses. All analyses were two-tailed and 
differences with p-value <0.05 were considered statistically significant.
REsuLts
Prognostic relevance of in vitro PVa scoring in infant aLL
The combined in vitro responses to prednisolone, vincristine and L-asparaginase (i.e. PVA 
score) has been shown to be predictive for clinical outcome in pediatric ALL (i.e. children >1 
year of age)13, 14, 17. We analyzed whether this also accounts for infants with ALL (<1 year of 
age). Patients were divided into a sensitive (PVA scores of 3-4), a intermediate (PVA scores 
of 5-6), or a resistant (PVA scores of 7-9) group. PVA-resistant infant ALL cases (including 
both patients with and without MLL translocations) tended to have a worse outcome when 
compared to patients with sensitive and intermediate PVA scores (Figure 1A); although 
this did not reach statistical significance (p=0.0686). As the presence of MLL translocations 
represents a strong and independent prognostic factor5, we also analyzed the influence of 
the PVA score on clinical outcome excluding patients with wild-type MLL genes. PVA-
resistant MLL-rearranged infant ALL patients showed worse EFS compared with both 
PVA-sensitive and PVA-intermediate MLL-rearranged infant ALL cases (Log-rank; p<0.05, 
Figure 1B). The 5-year EFS for PVA-resistant MLL-rearranged infant ALL patients is with 
~10% very poor. Furthermore, we also analyzed whether in vitro sensitivity towards single 
chemotherapeutics (prednisolone, vincristine, L-asparaginase, daunorubicin, cytarabine or 
dexamethasone) is predictive for EFS. MLL-rearranged infant ALL patients in vitro resistant 
to these single chemotherapeutics have worse outcome when compared to their sensitive 
counterpart. However, these differences were not significant (prednisolone, p=0.1756, L-
asparaginase, p=0.2970, daunorubicin, p=0.1396).
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Next, we analyzed whether PVA resistance showed cross-resistance to other drugs. In 
MLL-rearranged infant ALL patients, PVA resistance was correlated to dexamethasone 
resistance, but not to resistance to daunorubicin or Ara-C (Figure 2A). Interestingly, when 
analyzing cross-resistance between prednisolone, vincristine and L-asparaginase, only a 
correlation was found between prednisolone and vincristine (Spearman’s Rho-test=0.5520, 
p<0.005) (Figure 2B); no correlation was found between prednisolone and L-asparaginase 
(Spearman’s Rho-test=0.044, p=0.7494) nor between vincristine and L-asparaginase 
(Spearman’s Rho-test=0.247, p=0.0688). Furthermore, MLL-rearranged infant ALL patient 
samples which were in vitro sensitive to prednisolone or vincristine only displayed in vitro 
sensitivity to the glucocorticoid dexamethasone (Spearman´s Rho-test prednisolone-dexa-
methasone=0.8951, p<0.0001; Spearman´s Rho-test vincristine-dexamethasone=0.6611, 
p<0.0001) and the antracycline daunorubicin (Spearman´s Rho-test prednisolone-
daunorubicin=0.4036, p=0.0025; Spearman´s Rho-test vincristine-daunorubicin=0.3681, 
p=0.0061) (Figure 2C). No cross-resistance or cross-sensitivity was observed for neither 
L-asparaginase nor Ara-C with other drugs (data not shown).
Both the in vitro prednisolone response, as well as the in vivo prednisone response have 
been identified as prognostic makers in pediatric ALL17 and infant ALL2, 5. Here, we investi-
gated to what degree the clinical prednisone response correlates with in vitro prednisolone 
response as determined by MTT assays. As shown in Figure 3, PGRs are more frequent 
sensitive to prednisolone in vitro as compared with PPRs. Similar results are obtained when 
analyzing infant ALL in general (Figure 3A), or when analyzing only MLL-rearranged 
infant ALL cases (Figure 3B). Although the observed differences are statistically significant 
      A                                                                    B 
figure 1: Prognostic relevance of prednisolone, vincristine and L-asparaginase (PVa) in infant acute 
lymphoblastic leukemia
EFS analysis of (A) total infant ALL patients (with and without MLL-rearranged infant ALL) and (B) MLL-
rearranged infant ALL cases only. Infant ALL patient samples were divided based on their in vitro response 
to prednisolone, vincristine and L-asparaginase (PVA): PVA-sensitive (score 3 or 4), PVA-intermediate (score 
5 or 6) and PVA-resistant (score 7-9). Differences in outcome were statistically analyzed using the Log-rank 
test.
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      A                                                                  
      B                                                                  
Prednisolone Vincristine 
      C                                                                  
figure 2: In vitro cross-resistance of PVa to other induction-therapeutic drugs
(A) LC50 values of dexamethasone, daunorubicin or cytarabine (Ara-C) of MLL-rearranged patient samples 
divided into in vitro sensitive, intermediate or resistant to PVA. P-values were determined by the Kruskall 
Wallis-test. (B) LC50 values of vincristine of MLL-rearranged patient samples divided into in vitro sensitive, 
intermediate or resistant to prednisolone. The indicated Spearman´s Rho index was determined by com-
paring LC50 values of prednisolone with LC50 values of vincristine. (C) LC50 values of dexamethasone, dauno-
rubicin or cytarabine (Ara-C) of MLL-rearranged patient samples divided into in vitro sensitive, intermediate 
or resistant to either prednisolone or vincristine. Indicated p-value was determined by Kruskall Wallis test. 
Correlation index was determined by Spearman’s Rho-test, in which LC50 values of both indicated drugs 
were correlated to each other.
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(p<0.005) and the median LC50 values of the patient groups show that PPRs are >1000-fold 
more resistant to prednisolone in vitro, a discrepancy was found in 8/39 of the PGRs that 
appeared to be in vitro resistant to prednisolone, whereas 3/21 of the PPRs appeared to be 
sensitive to prednisolone in vitro. We found a trend of a better outcome in MLL-rearranged 
infant ALL patients that were PGR and in vitro sensitive for prednisolone (not significant, 
Figure 3C). Among PPR patients no differences in outcome between in vitro prednisolone 
respons was found (Figure 3D).
In vitro drug responses and MLL translocations
MLL-rearranged infant ALL patients have an inferior outcome when compared with infant 
ALL patients who do not carry translocations of the MLL gene5. We compared in vitro 
drug responses between MLL-rearranged and wild-type MLL infant ALL samples. MLL-
rearranged infant ALL appeared to be more resistant to vincristine, and a trend was found 
for increased resistance to glucocorticoids (i.e. prednisolone and dexamethasone) and to 
cytarabine (Ara-C) (Figure 4). Analysis by type of MLL rearrangement showed that t(4;11)-
positive infant ALL samples were significantly more resistant to prednisolone, dexametha-
sone and vincristine (Figure 4). Samples of t(11;19)-positive infant ALL patients displayed a 
remarkable sensitivity towards the glucocorticoids prednisolone and dexamethasone, with 
median LC50 values comparable to that of wild-type MLL infant ALL samples.
Relation between in vitro drug response and prognostic factors in MLL-
rearranged infant aLL
Among MLL-rearranged infant ALL patients, predictors of an adverse outcome identified 
in the Interfant-99 study, include young age, high WBC and poor prednisone response5. 
Central nervous system (CNS) involvement and a highly immature (CD10 negative) pro-B 
cell immunophenotype have been identified as factors adversely influencing outcome3, 18, 
but were not significantly contributing to prognosis in the Interfant-99 study5. Infant ALL 
patients <6 months of age have a worse outcome than infant ALL patients >6 month of age2-5 
and therefore we analyzed in vitro drug sensitivity in MLL-rearranged infant ALL samples 
in both age groups. Significant differences in in vitro drug response were only observed for 
the glucocorticoids prednisolone and dexamethasone and for the anthracycline daunoru-
bicin (Figure 5).
MLL-rearranged infant patients with high WBC (>300x106 cells/mL), had a worse outcome 
when compared with to patients with low WBC numbers (<100x106 cells/mL) or intermedi-
ate WBC numbers (100-300x106 cells/mL)3-5. Here we show that samples from MLL-rear-
ranged patients with high WBC numbers are in vitro more resistant to L-asparaginase when 
compared to samples from patients with low WBC numbers (Kruskall-Wallis Test p<0.05), 
and tend to be more resistant to prednisolone (Figure 6; Kruskall-Wallis Test p=0.1446).
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DisCussion
In vitro cytotoxicity testing (MTT assays) has been very informative in childhood ALL, 
providing an indication of therapy effectiveness before the initiation of actual treatment. 
Prospective analyses showed that patients who are in vitro sensitive to several drugs have a 
superior prognosis over patients displaying in vitro resistance13, 14.
Here we provide evidence of a marked association between clinical parameters (e.g. WBC, 
age at diagnosis, in vivo prednisone response) and in vitro cytotoxicity for a variety of drugs 
used in the treatment of MLL-rearranged infant ALL patients.
We show that the in vitro sensitivity to none of the drugs tested individually is capable 
of predicting clinical outcome. However, MLL-rearranged infant ALL patients displaying 
combined in vitro resistance to prednisolone, vincristine and L-asparaginase (i.e. PVA 
score), had inferior EFS rates. This is in concordance with studies in pediatric ALL13, 14. 
Moreover, the in vitro sensitivity to prednisolone appeared to correlate with the clinical 
response to prednisone. Interestingly, both in vitro prednisolone resistance as well as in vivo 
prednisone resistance have been identified as predictors of an adverse prognosis in pediatric 
ALL14, 17. For infant ALL patients the in vitro prednisolone is indicative for clinical outcome, 
but not significantly (data not shown). Additionally, within the PGR patient group, in vitro 
prednisolone sensitivity showed to be predictive for a better prognosis in childhood ALL17 
and in MLL-rearranged infant ALL. Hence, the strongest indicator for an adverse outcome 
in infant ALL patients in terms of drug resistance is the combined in vitro resistance to 
prednisolone, vincristine, and L-asparaginase (PVA), especially for MLL-rearranged infant 
ALL cases.
Furthermore, infant ALL patients samples carrying high risk features such as a t(4;11) 
translocation or age <6 months, or a WBC >100x106 cells/mL demonstrated to be in vitro 
resistant to the glucocorticoids prednisolone and dexamethasone. In contrast, infant ALL 
patients carrying translocation t(11;19) appeared to be more sensitive to these glucocor-
ticoids. Although, t(4;11)-positive and t(11;19)-positive infant ALL patients, as well as 
patients carrying other types of MLL translocations (designated 11q23-rearranged) show 
a comparable poor clinical outcome5, no similarity was observed based in terms of in vitro 
drug response profiles. Ramakers-van Woerden et al. observed no differences in in vitro 
drug responses in infant ALL patients by age12. Here we investigated age at presentation 
within only MLL-rearranged infant ALL patients; and demonstrated that MLL-rearranged 
infant ALL patients <6 months of age at diagnosis were in vitro more resistant to the glu-
cocorticoids prednisolone and dexamethasone, when compared to MLL-rearranged infant 
ALL patients >6 months of age at diagnosis.
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In summary, we show that for MLL-rearranged infant ALL patients the in vitro drug cyto-
toxicity profile can predict clinical outcome, but only by combining the responses of pred-
nisolone, vincristine, and L-asparaginase (PVA). Moreover, established prognostic markers 
such as high WBC and young age at diagnosis are associated with resistance to prednisolone 
in vitro. We therefore conclude that in vitro PVA testing identifies MLL-rearranged infant 
ALL patients at very high risk of therapy failure, and that PVA-scoring may be used to 
stratify these patients more accurately if confirmed in an independent patient cohort. 
Clearly, PVA-resistant MLL-rearranged infant ALL cases form a patient group that needs 
alternative, more effective therapeutic strategies.
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abstRaCt
Acute lymphoblastic leukemia (ALL) in infants represents an aggressive malignancy as-
sociated with a high incidence(~80%) of translocations involving the Mixed Lineage 
Leukemia(MLL) gene. Attempts to mimic MLL fusion driven leukemogenesis in mice 
raised the question whether these fusion proteins require secondary hits. RAS mutations 
are suggested as candidates. Earlier results on the incidence of RAS mutations in MLL-
rearranged acute lymphoblastic leukemia are inconclusive. Therefore, we studied frequen-
cies and relation with clinical parameters of RAS mutations in a large cohort of infant acute 
lymphoblastic leukemia patients.
Using conventional sequencing analysis, we screened neuroblastoma RAS viral (v-ras) onco-
gene homolog gene(NRAS), v-Ki-ras Kirsten rat sarcoma viral oncogene homolog gene(KRAS), 
and v-raf murine sarcoma viral oncogene homolog B1 gene(BRAF) for mutations in a large 
cohort(n=109) of infant ALL patients and studied the mutations in relation to several clini-
cal parameters, and in relation to Homeobox gene A9 expression and the presence of ALL1 
fused gene 4-Mixed Lineage Leukemia(AF4-MLL).
Mutations were detected in ~14% of all cases, with a higher frequency of ~24% in t(4;11)-
positive patients(p=0.04). Furthermore, we identified RAS mutations as an independent 
predictor(p=0.019) for poor outcome in MLL-rearranged infant acute lymphoblastic leuke-
mia, with a hazard ratio of 3.194(95% confidence interval:1.211-8.429). Also, RAS-mutated 
infants have higher white blood cell counts at diagnosis(p=0.013), and are more resistant to 
glucocorticoids in vitro(p<0.05). Finally, we demonstrate that RAS mutations, and not the 
lack of Homeobox gene A9 expression nor the expression of AF4-MLL are associated with 
poor outcome in t(4;11)-rearranged infants.
We conclude that the presence of a RAS mutations in MLL-rearranged infant acute lym-
phoblastic leukemia is an independent predictor for a poor outcome. Therefore, future 
risk-stratification based on abnormal RAS-pathway activation and RAS-pathway inhibition 
could be beneficial in RAS-mutated infant acute lymphoblastic leukemia patients.
43RAS mutations in MLL-rearranged infant ALL
intRoDuCtion
Acute lymphoblastic leukemia (ALL) in infants (<1 year of age) represents an aggressive, 
early onset type of leukemia characterized by high relapse rates during treatment, and an 
unfavorable clinical outcome1. This poor prognosis is associated with a high incidence of 
balanced chromosomal translocations involving the Mixed Lineage Leukemia (MLL) gene, 
which occur in ~80% of the infant ALL cases1. The most common MLL translocation in 
infant ALL is t(4;11), in which the N-terminus of MLL (chromosome 11q23) fuses to the 
C-terminus of AF4 (chromosome 4q23). As the joining of MLL and AF4 occurs in-frame, 
the t(4;11) translocation generates a unique fusion gene encoding the chimeric, and suppos-
edly oncogenic MLL-AF4 fusion protein. Other recurrent in-frame MLL-rearrangements 
found among infant ALL patients are t(11;19) and t(9;11), giving rise to the fusion proteins 
MLL-ENL and MLL-AF9 respectively. The presence of an MLL translocation is the strongest 
independent predictor of an adverse outcome in infant ALL patients2.
Over the past decades numerous studies provided important insights into the biology and 
pathogenesis of MLL-rearranged ALL, but so far in vivo validation of these achievements 
are hampered by the lack of genuine animal models accurately recapitulating this severe 
malignancy. Although various attempts have been made to develop mouse models mimicking 
leukemogenesis of human t(4;11)-positive ALL, these mice displayed propensities towards de-
veloping lymphomas or leukemia with phenotypes that significantly differ from those found in 
humans3-5. Another discrepancy between murine MLL-AF4 models and t(4;11)-positive ALL in 
infants is disease latency. In human infants, MLL translocations arise in utero and rapidly lead to 
the development of overt leukemia, often at or shortly after birth6. In contrast, most MLL-AF4 
mouse models show mean latency periods of ~12-14 months3, 5. Moreover, in MLL-rearranged 
infant ALL, short disease latency is strongly associated with a poor clinical outcome2, 7.
Collectively, these inconsistencies form the basis of the question whether MLL fusion proteins 
(like MLL-AF4) alone are sufficient to induce ALL, or that these chimeric proteins require 
cooperative genetic lesions. Bursen et al. recently found that not MLL-AF4 but its reciprocal 
fusion protein AF4-MLL (independent of the presence of MLL-AF4) was capable of induc-
ing pro-B ALL in mice, suggesting that in t(4;11)-positive ALL both fusions may function as 
cooperative oncoproteins8. Tamai et al showed that in a transgenic mouse model the latency 
period of MLL-AF4-induced B-cell leukemia/lymphoma can significantly be shortened by 
the addition of a KRAS mutation9. Moreover, recent observations demonstrated that the 
MLL-AF4 fusion protein can activate Elk-1 through the RAS-pathway, which supports the 
involvement of RAS signaling in the pathogenesis of MLL-rearranged leukemia10. Based on 
these findings it may be hypothesized that RAS mutations represent important secondary 
“hits”. Recent studies on the incidence of RAS mutations in MLL-rearranged ALL demon-
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strate inconsistent results in limited patient groups. For instance, Liang et al. reported RAS 
mutations in 10/20 (50%) of the cases, while Mahgoub et al. could not identify RAS mutations 
among thirteen MLL-rearranged ALL samples11, 12. Besides, Tamai et al. speculate that the 
short latency in their KRAS mutation-positive mouse model is likely due to an acceleration 
of leukemo-lymphomagenesis by a collaborative up-regulation of HOXA99. HOXA over-
expression is often believed to be a hallmark of MLL-rearranged leukemia and has recently 
been proposed to be required for leukemia survival of MLL-rearranged acute myeloid leuke-
mia (AML) cells13. Our recent gene expression profiling study revealed the presence of two 
distinctive subgroups of MLL-AF4 positive ALL cases; those with and those without HOXA 
expression, with patients lacking HOXA expression being at high risk of disease relapse14. 
Based on this finding, as well as on the report demonstrating a prominent oncogenic role 
for AF4-MLL8, and the results demonstrating accelerated MLL-AF4-driven leukemogenesis 
in the presence of a KRAS mutation, Tamai et al proposed the following subdivision of 
t(4;11)-positive ALL: one group representing AF4-MLL-driven and HOXA-independent 
leukemogenesis, and another group displaying MLL-AF4 and HOXA dependence requiring 
additional genetic hits, such as RAS mutations, to accelerate leukemogenesis9.
Yet, the precise frequencies and the potential role (in terms of disease aggressiveness) of 
RAS mutations in MLL-rearranged infant ALL, and their relation with HOXA expression 
and/or the presence of AF4-MLL remain unclear. Therefore, we screened a large cohort 
(n>100) of primary infant ALL samples for NRAS, KRAS and BRAF mutations. To further 
determine the clinical relevance, these mutations were studied in relation to several clinical 
parameters, as well as to HOXA expression and the presence of AF4-MLL.
MEthoDs
Patient samples and cell lines
Bone marrow or peripheral blood samples from untreated infants (below one year of age) 
diagnosed with ALL were collected at the institutes participating in the international col-
laborative Interfant protocol2. Informed consent was obtained according to the Helsinki 
declaration, and approved by the Institutional Review Board of the Erasmus University 
Medical Center. All samples were processed as described before15.
The t(4;11)-positive cell lines SEM, RS4;11, and MV4-11 were purchased from the German 
Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany), BEL-
1 was a kind gift from Dr. Tang (University Paris, France). The t(11;19)-positive cell line 
KOPN-8 was purchased from The Global Biosource Center (ATCC, Middlesex, UK). All 
cell lines were maintained as suspension cultures in RPMI 1640 with L-Alanyl-L-Glutamine 
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(Invitrogen Life Technologies, Breda, the Netherlands) supplemented with 10% FCS (Inte-
gro, Zaandam, the Netherlands).
Dna and Rna extraction
Genomic DNA and RNA were extracted from ~5x106 leukemic cells using TRIzol reagent 
(Invitrogen) according to the manufacturer’s instructions, and quantified on a Nanodrop 
ND-1000 spectrophotometer (Isogen). The integrity of DNA and RNA was assessed on 
standard 0.8% or 1.5% agarose gels, respectively.
Detection of NRAS, KRAS and BRAF mutations
Using PCR and sequence analysis, mutation hotspots were screened in NRAS and KRAS exon 
one and two, and in BRAF exon 1511, 16. Amplicons were generated on a 2720 Thermal cycler 
(Applied Biosystems, Foster City, CA, USA), PCR mixture and cycling conditions are described 
in Supplementary Table S1. Primer sequences were adapted from previous publications11, 16 and 
modified by additional M13 tags (Supplementary Table S1). Sequence analysis of both sense 
and antisense strands was carried out using M13 primers, and the BigDye terminator v1.1 
Cycle Sequencing kit (Applied Biosystems) according to the manufacturers’ recommenda-
tions, and analyzed on an Applied Biosystems 3130x/Genetic Analyzer. The CLC Workbench 
software (CLCbio, Aarhus, Denmark) was used to analyze the sequences, references are listed 
in Supplementary Table S2. All mutations were confirmed in replicate sequences.
In vivo prednisone and in vitro prednisolone responses
In vivo prednisone responses, assessed during a prophase of one week of daily systemic predni-
sone (60 mg/m2) administration before preceding combination chemotherapy, were available 
for a subset of patients. Responses are defined as good, when blast counts in the peripheral blood 
dropped below 1000 cells/µL, and poor when more than 1000 cells/µL remained detectable2, 17.
In vitro drug cytotoxcity was determined using 4-day MTT assays as described elsewhere18. 
Due to our recently published gene expression profiling (GEP) study14 microarray data (Af-
fymetrix HU133plus2.0) was available for a part of the patient samples used in this study. 
Generation of these gene expression profiles has been described before14. Data was deposited 
in the GEO database19 under accession number GSE19475. Because of our interest in the 
relation of HOXA expression and RAS mutations, we extracted and studied the expression 
of HOXA9 from the existing dataset (probe sets: 209905_at, and 214651_s_at). GEP data 
was available for 27 of the 38 t(4;11)-positive infant ALL cases.
statistical analysis
Fisher’s Exact Test was used to compare mutation frequencies in different patient groups 
and Mann-Whitney U-Test to compare the median age at diagnosis.
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Event-free survival (EFS) and overall survival (OS) curves were estimated using the Kaplan-
Meier method and analyzed by Log-rank (Mantel-Cox) tests. EFS is defined as time from 
diagnosis to death in induction, disease relapse, the emergence of secondary malignancies, 
or death in complete remission. OS is defined as time from diagnosis to death from any 
cause. Cumulative incidence of relapse (CIR) is defined as time from complete remission to 
disease relapse, adjusted for death as competing risk. Patients who did not achieve complete 
remission were allocated an event at time-point zero in the EFS and CIR analyses. Multi-
variate analysis of prognostic factors was performed by Cox regression model based on EFS 
and the Wald Backward Test (entry probability p=0.05 and removal probability p=0.10) 
was used for the joint analysis of age at diagnosis, white blood cell (WBC) counts, in vitro 
prednisolone response (LC50: lethal concentration to 50% of the leukemic cells), in vivo 
prednisone response, and RAS mutations. RAS mutations and in vivo prednisone response 
analyzed as dichotomous variables, the other variables as continuous.
Infant ALL patients without MLL-rearrangements were excluded from these analyses as 
the prognosis of these patients is significantly more favorable2. CIR was computed with 
the statistical environment R version 2.14.0 using Bioconductor packages (R Development 
Core Team, 2011). The other analyses, were performed with SPSS Statistics version 17.0 
(SPSS Inc. Chicago, IL, USA). All tests were two-tailed and a p-value less than 0.05 was 
considered significant.
REsuLts
RAS and BRAF mutations in infant aLL
RAS and BRAF mutation screening was performed in 109 primary infant ALL samples, as 
well as in an additional four matched relapsed samples. Patients characteristics are listed 
in Supplementary Table S3. Overall, in 15/109 (13.8%) of the patients a RAS mutation was 
detected, comprising 7/109 (6.4%) patients carrying an NRAS mutation, and 8/109 (7.2%) 
patients bearing a KRAS mutation (Table 1 and Figure 1). No BRAF mutations were found. 
Among patients carrying NRAS mutations two harbored an exon one mutation at codon 
12, and five an exon two mutation at codon 61. All observed KRAS mutations were located 
in exon one, of which four at codon 12 and four in codon 13. (Table 1 and Figure 1). One 
mutation was found among the four matched relapse samples and displayed a NRAS Gln-
61Lys mutation that was not present in the corresponding primary diagnosis sample. For 
the MLL-rearranged ALL cell lines, only KOPN-8 carried a KRAS mutation at exon one, at 
codon 12 (Gly12Asp) (Figure 1E).
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table 1: RAS mutations
Patient MLL AF4-MLL Gender
Age at Dx 
(months)
Immuno-
phenotype
WBC at Dx 
(x109/ L)
NRAS 
mutation
KRAS 
mutation
1 t(4;11) negative male 5.5 pro-B 677   Gly12Val
2 t(4;11) negative female 10.8 pre-B 813.7 Gly12Ser
3 t(4;11) positive male 1.9 pro-B 555 Gly13Asp
4 t(4;11) positive female 4.1 pro-B 326 Gln61Arg
5 t(4;11) negative female pro-B 1101.1 Gln61Lys
6 t(4;11) positive female 1.6 pro-B 358.3 Gly13Asp
7 t(4;11) positive male 3.4 pro-B 348.6 Gly13Asp
8 t(4;11) positive male 6.3 pro-B 204 Gln61Lys
9 t(4;11) positive female 2.3 204 Gly12Ser
10 t(11;19) female 3.6 common 916 Gly12Val
11 t(11;19) male 8.1 Gly12Asp
12 t(9;11) male 0.8 pro-B 740 Gln61Lys
13 11q23* male 10.8 pro-B 5.1 Gln61Lys
14 11q23* female 11.8 Gly12Asp
15 GL-MLL†   female 11.0 common 1.4   Gly13Asp
*11q23; MLL-rearranged infant ALL patients with unknown partner gene,† Germline-MLL; infant ALL pa-
tients without MLL-rearrangement. Mutation in patient 8 occurred in a relapse sample, which was not 
present in the corresponding diagnostic sample. Abbreviations: Gly; Glycine, Val; Valine, Ser; Serine, Asp; 
Aspartic acid, Gln; Glutamine, Lys; Lysine.
figure 1: RAS mutations
(A) NRAS exon1 condon12 (Gly>Ser) mu-
tation, corresponding with patient 2, (B) 
NRAS exon1 condon12 (Gly>Asp) muta-
tion, corresponding with patient 14, (C) 
NRAS exon2 condon61 (Gln>Arg) muta-
tion, corresponding with patient 4, (D) 
NRAS exon2 condon61 (Gln>Lys) muta-
tion, corresponding with patient 13, (E) 
KRAS exon1 codon12 (Gly>Asp) mutation, 
corresponding with KOPN-8 cell line, (F) 
KRAS exon1 condon13 (Gly>Asp) muta-
tion, corresponding with patient 6, (G) 
KRAS exon1 condon13 (Gly> Asp) muta-
tion, corresponding with patient 7.
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frequency of RAS mutations among different infant aLL subtypes
Next we compared the frequencies of RAS mutations among different infant ALL subtypes 
including patients with t(4;11), t(11;19), t(9:11), and infant ALL patients without MLL 
translocations. Interestingly, we found a significantly higher frequency of 9/38 (23.7%) RAS 
mutations in t(4;11)-positive infants (p=0.04) compared to the remaining infant ALL cases, 
with a frequency of 6/71 (7.8%). In the other infant ALL subtypes the frequencies were not 
significantly different from the total patient cohort (Table 2).
time of disease onset and RAS mutations
Early onset in MLL-rearranged infant ALL is associated with a poor clinical outcome2, 7. 
The median age at diagnosis of primary RAS mutation-negative MLL-rearranged infant 
ALL patients (3.8 months; range 0.0–11.5 months) was not different from the RAS-mutated 
group (5.3 months; range 0.8-11.8 months) (p=0.89). Likewise, RAS mutations did not seem 
to affect disease latency when we analyzed t(4;11)-positive infant ALL patients alone. Also, 
dividing patients by their age at diagnosis in the following ordinal categories: <3 months, 
3-6 months, 6-9 months, 9-12 months, demonstrated no increased frequencies in any of the 
age groups for neither the total MLL-rearranged cohort (p=0,51), nor for t(4;11)-positive 
patients (p=0.31).
table 2: frequencies of RAS mutations in MLL-subtypes of infant aLL
Patient MLL AF4-MLL Gender
Age at Dx 
(months)
Immuno-
phenotype
WBC at Dx 
(x109/ L)
NRAS 
mutation
KRAS 
mutation
1 t(4;11) negative male 5.5 pro-B 677   Gly12Val
2 t(4;11) negative female 10.8 pre-B 813.7 Gly12Ser
3 t(4;11) positive male 1.9 pro-B 555 Gly13Asp
4 t(4;11) positive female 4.1 pro-B 326 Gln61Arg
5 t(4;11) negative female pro-B 1101.1 Gln61Lys
6 t(4;11) positive female 1.6 pro-B 358.3 Gly13Asp
7 t(4;11) positive male 3.4 pro-B 348.6 Gly13Asp
8 t(4;11) positive male 6.3 pro-B 204 Gln61Lys
9 t(4;11) positive female 2.3 204 Gly12Ser
10 t(11;19) female 3.6 common 916 Gly12Val
11 t(11;19) male 8.1 Gly12Asp
12 t(9;11) male 0.8 pro-B 740 Gln61Lys
13 11q23* male 10.8 pro-B 5.1 Gln61Lys
14 11q23* female 11.8 Gly12Asp
15 GL-MLL†   female 11.0 common 1.4   Gly13Asp
Differences in frequencies of RAS mutations between MLL-subtypes. Patient groups were statistically ana-
lyzed using Fisher’s Exact Test (2-sided) and p-value of less than 0.05 was considered significant. *11q23; 
MLL-rearranged infant ALL patients, with unknown or rare partner gene (including one t(1;11)-, one t(3;11)-, 
and three t(10;11)-positive patients, †Germline-MLL; infant ALL patients without MLL-rearrangement.
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WbC count at diagnosis and RAS mutations
High WBC counts at diagnosis have previously been identified as a poor prognostic factor in 
infant ALL2. Interestingly, RAS-mutated MLL-rearranged infants appeared to have signifi-
cant higher WBCs at diagnosis (p=0.013). Approximately 82% (9/11) of the RAS mutation-
positive cases showed WBCs higher than 300x109 cells/L, compared to ~45% (33/73) of the 
RAS mutation-negative infants. Similarly, among t(4;11)-positive cases, WBCs higher than 
300x109 cells/L were found in 87,5% (7/8) of the mutated cases, and in 41.4% (12/29) of the 
mutation-negative cases (p=0.018).
Drug resistance of RAS-mutated infant aLL patients
A poor in vivo response to prednisone represents an adverse prognostic factor in MLL-
rearranged infant ALL17, and MLL-rearranged infant ALL patients cells are highly resistant 
to prednisolone and dexamethasone in vitro20. MLL-rearranged infant ALL cells bearing a 
RAS mutation at diagnosis appeared significantly (p<0.05) more resistant to both glucocor-
tocoids (Figure 2A-B). For t(4;11)-positive samples alone a comparable trend was observed, 
although the differences did not reach statistical significance (Figure 2C-D). No differences 
were found comparing the in vivo prednisone response of RAS-mutated and non-mutated 
MLL-rearranged infant ALL patients (p=0.451), nor by comparing RAS-mutated and non-
mutated t(4;11)-positive cases alone (p=0.635). Besides, studying the control cells (without 
glucocorticoid treatment) in our in vitro cytotoxicity assays, we found RAS-mutated MLL-
rearranged infant ALL cells to display significantly (p=0.022) higher endogeneous viability 
(Supplementary Figure S4). Furthermore, we asked whether exposure to glucocorticoids 
would invoke a positive selection for RAS-mutated cells in samples that ostensibly carry 
subclonal mutations. Therefore we performed a time lapse prednisolone exposure experi-
ment and sequenced the RAS mutations in order determine whether the sequence graphs 
revealed a positive selection of the mutated clone. However, we did not find any signs of 
positive selection in both patients: the intensity of the peak corresponding to the mutated 
nucleotide remained equal throughout the experiment (Supplementary Figure S5). Suggest-
ing that, either the subclone was stable during the experiment or that these mutations may 
not have been subclonal.
Clinical outcome of RAS-mutated infant aLL patients
Clinical outcome data was available for 79 MLL-rearranged infant ALL cases, with 33 of 
them being t(4;11)-positive. The presence of a RAS mutation at diagnosis was associated 
with poor outcome in both the MLL-rearranged infant ALL patients, as well as in t(4;11)-
positive cases alone. Among all MLL-rearranged infant ALL patients, the 5-year EFS rates 
for the RAS mutation-positive and negative cases was 0.0±0.0 % vs. 32.7±6·0% (p=0.042), 
and the 5-year OS was 11.1±10.5% vs. 45.3±6.0% (p=0.08), respectively (Figure 3A,B). CIR 
analysis showed a slight tendency towards a higher relapse risk for RAS-mutated cases, with 
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a 3-year CIR of 66.7±15.7% vs. 48.1±6.1% in RAS wild-type patients (p=0.119) (Figure 3C). 
Among the t(4;11)-positive cases comparable, but more distinctive, results were found for 
the 5-year EFS (p=0.019), 5-year OS (p=0.020), and 3-year CIR (p=0.012) (Figure 3D-F).
A C 
B D 
figure 2: Drug Cytotoxicity of RAS-mutated and non-mutated infant aLL patients
(A) In vitro prednisolone cytotoxicity in MLL-rearranged infant ALL patients, (B) In vitro dexamethasone cy-
totoxicity in MLL-rearranged infant ALL patients, (C) In vitro prednisolone cytotoxicity in t(4;11)-rearranged 
infant ALL patients, (D) In vitro dexamethasone cytotoxicity in t(4;11)-rearranged infant ALL patients. Mean 
in vitro cytotoxicity responses in RAS-mutated and non-mutated infant ALL patients were statistically ana-
lyzed using Mann-Whitney U-test. Error bars represent standard error of the mean. Cytotoxicity data for 
prednisolone and dexamethasone was available for 63 and 44 MLL-rearranged infants ALL patients and 26 
and 18 t(4;11)-rearranged infants respectively.
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RAS mutations in relation to AF4-MLL and HOXA expression in t(4;11)-
rearranged infants
We studied the relation between the presence of AF4-MLL and HOXA9 expression in 
t(4;11)-positive infant ALL samples and the incidence of RAS mutations. The occurrence of 
RAS mutations did not differ significantly between cases with AF4-MLL (3/15) or without 
AF4-MLL (6/23). Re-analyzing our previously published gene expression profiling data 
we found that all RAS mutation-positive cases lacked HOXA9 expression (Supplementary 
Figure S6). Our earlier observations suggested that t(4;11)-positive infants lacking HOXA 
expression have a worse prognosis than patients expressing high HOXA levels14. However, 
when excluding the RAS mutation-positive cases from this analysis, the association of 
HOXA expression and clinical outcome was lost (p=0.857). Also, no association between 
AF4-MLL expression and clinical outcome was detected (p=0.354), even after excluding 
the RAS-mutated t(4;11)-positive infants (p=0.177). Thus, not the level of HOXA nor the 
presence of AF4-MLL expression, but the presence of RAS mutations seems to dictate the 
poor prognosis in these patients. Next, we asked whether RAS mutations influenced the 
previously reported prognostic value of high-level FLT3 expression as well21. Therefore we 
studied the overlap between high FLT3 expression and the presence of RAS mutations in 
our patient cohort, but we could not find any correlation between FLT3 expression and 
RAS mutations at all. The RAS-mutated infants are equally divided between the patients 
with either FLT3 high or low expression. Because this equal distribution we had no rational 
for re-analyzing the previous published prognosis data for FLT3 expression in the same 
manner as we did with the HOXA expression, where all RAS-mutated patients had low 
HOXA expression.
Multivariate analysis of RAS mutations and clinical parameters
Because the previously described clinical parameters in this study are interdependent we 
performed a Cox regression multivariate analysis, to evaluate the independent prognostic 
value of RAS mutations. This multivariate analysis was fitted on MLL-rearranged infants 
(n=50) from whom all prognostic variables were available. We identified the presence of 
a RAS mutation at diagnosis as an independent predictor (p=0.019) for poor outcome in 
MLL-rearranged infant ALL, with a hazard-ratio (HR) of 3.194 (95% confidence interval 
(CI): 1.211-8.429) (Table 3). Besides RAS mutations, low age at diagnosis was identified 
as an independent predictor (p=0.006, HR: 0.834, 95%-CI: 0.731-0.950) for poor outcome 
in our MLL-rearranged infant ALL cohort. Other variables in the final model were WBC 
counts at diagnosis (p=0.062, HR: 1.001, 95%-CI: 1.000-1.001) and in vitro prednisolone 
response (p=0.069, HR: 0.997, 95%-CI: 0.997-1.000) (Table 3).
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DisCussion
Activating RAS mutations, resulting in a proliferative advantage, have been observed in 
several hematopoietic malignancies including, ALL, AML, chronic myelomonocytic leu-
kemia, and juvenile chronic myelogenous leukemia22-28. Here we report a RAS mutation 
frequency of ~14% in a large (n>100) cohort of infant ALL cases, and a frequency of ~24% 
in infant ALL patients carrying MLL translocation t(4;11). These results are not consistent 
table 3: univariate and multivariate analysis of prognostic factors of MLL-rearranged infant aLL pa-
tients
Univariate analysis Multivariate analysis
Patients Events 5-year EFS (SE) p-value HR (95%-CI) p-value
RAS mutation 0.043 3.194 (1.211-8.429) 0.019
Negative 70 46 32.2% (5.9)
Positive 9 9 0.0% (0.000)
Age at diagnosis (months) 0.020 0.834 (0.731-0.950)* 0.006
< 3 26 22 15.4% (7.1)
3-6 25 17 32.0% (9.3)
6-9 17 10 38.6% (12.4)
9-12 11 6 39.8% (16.3)
WBC count (x 109/ L) 0.022 1.001 (1.000-1.001)† 0.062
< 100 11 7 34.1% (15.0)
100-300 27 15 40.0% (10.5)
>300 39 31 19.0% (6.6)
Response to prednisone prophase 0.602
Good respons 34 22 34.4% (8.3)
Poor response 28 17 36.7% (9.8)
In vitro prednisolone response LC50 (ug/ ul) 0.282 0.997 (0.994-1.000)§ 0.069
≤ 0.100 19 13 33.7% (11.8)
> 0.100 < 150 12 10 16.7% (10.8)
≥ 150 27 17 35.3% (9.35)      
Univariate and multivariate analysis of the prognostic factors, including age at diagnosis, white blood cell 
(WBC) count at diagnosis, in vivo prednisone response, in vitro prednisolone response and RAS mutation 
status, in MLL-rearranged infant ALL patients. Multivariate analysis of prognostic factors was performed 
by Cox regression model based on EFS and the Wald backward test (entry probability p=0.05 and removal 
probability p=0.1). RAS mutations and in vivo prednisone response were in the Cox regression model ana-
lyzed as dichotomous variables, the other variables were analyzed continuous. This multivariate analysis 
was fitted on 50 MLL-rearranged infants from whom all variables were available. *Hazard-ratio (HR) per unit 
(months) increase of age, †HR per unit (1 x 109/L) increase of WBC, § HR per unit (1 ug/ ul) increase of in vitro 
prednisolone response.
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with previously published studies that reported either high RAS mutation frequency of 50%, 
or a total absence of RAS mutations in MLL-rearranged ALL11, 12. The observed frequencies 
in these studies may have been compromised by the small patient numbers. However, these 
frequencies are in concordance with the previously reported frequencies of 6-20.8% RAS 
mutations found in childhood ALL11, 29-31.
To determine the role of RAS mutations in respect of aggressiveness in MLL-rearranged 
infant ALL, we compared several clinical parameters in RAS mutation-positive and negative 
patients. Early onset of a KRAS mutation in a MLL-AF4-positive transgenic mouse model 
was associated with an early disease onset, and therefore suggested to represent a more 
aggressive leukemia9. We could not confirm an association between the presence of RAS 
mutations and an early onset of MLL-rearranged infant ALL. However, our data showed 
that RAS mutations independently contribute to a poor outcome in MLL-rearranged infant 
ALL patients. Besides, MLL-rearranged infant ALL patients carrying RAS mutations also 
display significantly higher WBC counts at diagnosis, and appeared significantly more 
resistant to the glucocorticoids in vitro.
Although conventional Sanger sequencing certainly is not quantitative, 4/7 (57%) of the 
NRAS mutations and 5/8 (62%) of the KRAS mutations appeared to be subclonal in our 
sequencing graphs. Repeated sequence runs on these samples persistently showed that 
the peak corresponding to the mutated nucleotide remained markedly smaller than the 
wild-type nucleotide (e.g. Figure 1D). If indeed a relatively high number of RAS mutations 
is subclonal, suggesting that not all leukemic cells carry the genetic abnormality, it seems 
plausible that RAS mutations are acquired as secondary hits after the MLL-fusions arise (for 
instance during a MLL-fusion-positive pre-leukemic state, or even during overt leukemia). 
An alternative explanation could be that RAS mutations are necessary for leukemogenesis 
and that patients harboring the wild-type RAS gene carry mutations in other genes sup-
porting MLL fusion driven leukemogenesis. As we only use highly pure leukemic samples 
(>90% leukemic blasts), this supposed subclonality may not only indicate that a certain 
portion of the leukemic cells remained unaffected, but also it shows that these mutations 
are leukemia-specific and are unlikely to be present in germline. Unfortunately, we had no 
opportunity to validate this, as no germline samples were available. Nonetheless, although 
several of the identified RAS mutations may suggest subclonality, we did not find any differ-
ences in clinical parameters or outcome between patients harboring “subclonal” or “clonal” 
RAS mutation (data not shown). In order to confirm subclonality of the RAS mutations as 
implied by our Sanger sequencing results, we used TOPO® TA Cloning (Invitrogen Life 
Technologies, Breda, the Netherlands) to sequence single PCR-amplified DNA fragments in 
three patient samples (Supplementary Table S7). We found that in all patients the number 
of mutated fragments was lower than the expected percentage of ~50% in case the mutation 
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would have been clonal. Hence, these results demonstrate that RAS mutations in infant ALL 
patients can indeed be of a subclonal nature.
The observed presence of a RAS mutation in one of the relapse samples, which was not 
present in the patient-matched primary diagnostic sample, supports the hypothesis of RAS 
mutations as a secondary hit. In line with this, Case et al. recently demonstrated that in 
matched presentation/relapse samples of childhood ALL patients, KRAS mutations are pre-
dominantly found at relapse, and were observed at very low levels in the matched diagnostic 
samples32. In combination, these data could suggest that RAS mutations represent second-
ary hits and that RAS-mutated clones may very well contribute to disease aggressiveness, 
progression, and relapse.
Finally, our data indicates that RAS-pathway inhibition could be beneficial for infants. 
Therapy with specific RAS-inhibitors would eradicate the RAS-mutated leukemic clones, 
but possibly leave the non-mutated MLL-rearranged leukemic cells, especially in the infants 
that seem to harbor subclonal RAS mutations. Although, specific RAS-pathway inhibitors 
maybe not eradicate all leukemic clones, we strongly believe, based on our data, that target-
ing the RAS-mutated clones could lead to a less aggressive disease period and increased 
survival-rates. Therefore, we would not suggest RAS-pathway inhibition as a mono-therapy, 
but alongside the current infant ALL therapy. Interestingly, several RAS-pathway inhibitors, 
like tipifarib and sorafenib, are already available and currently studied in hematologic ma-
lignancies in phase I/II trials. Both compounds are well tolerated, however tipifarib activity 
did not seem to correlate with RAS mutations or RAS pathway-dependent activation33. On 
the other hand, phase I/II studies using sorafenib in AML and myelodysplastic syndrome 
patients, showed promising results and targeted inhibition of both ERK phosphorylation, 
as well as FLT3 signaling34-36. A combined inhibitory effect on both RAS and FLT3 signaling 
may well be highly effective in the treatment of MLL-rearranged infant ALL, as the majority 
of these patients are also characterized by constitutive FLT3 activation15.
In conclusion, we demonstrate that RAS mutations frequently occur in MLL-rearranged 
infant ALL cases and especially in t(4;11)-positive infant ALL patients, and their presence 
represents an independent poor prognostic factor. Therefore the RAS-signaling pathway 
could be a potential target for therapeutic intervention, but also provides a rationale for 
future risk-stratification strategies. However, although RAS mutation-positive patients are 
at high risk of relapse, the prognosis for RAS mutation-negative patients remains far from 
favorable. Thus, a continued search for additional mutations, for instance in other compo-
nents of the RAS pathway, that typify an unfavorable outcome, may be beneficial.
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supplementary table s1:
Primer Sequence (5’-3’)
NRAS Exon 1 Fw GTTTTCCCAGTCACGACGACTGAGTACAAACTGGTGG
NRAS Exon 1 Rv CAGGAAACAGCTAGTACTGCATAACTGAATGTATACCC
NRAS Exon 2 Fw GTTTTCCCAGTCACGACCAAGTGGTTATAGATGGTGAAACC
NRAS Exon 2 RV CAGGAAACAGCTATGACAAGATCATCCTTTCAGAGAAAATAAT
KRAS Exon 1 Fw GTTTTCCCAGTCACGACGGTGAGTTTGTATTAAAAGGTACTGGTG
KRAS Exon 1 Rv CAGGAAACAGCTATGACCCTGTATTGTTGGATCATATTCGTCC
KRAS Exon 2 Fw GTTTTCCCAGTCACGACGGATTCCTACAGGAAGCAAGTAGTAA
KRAS Exon 2 Rv CAGGAAACAGCTATGACCTATAATGGTGAATATCTTCAAATGATTTAGT
BRAF Exon 15 Fw GTTTTCCCAGTCACGACTCATAATGCTTGCTCTGATAGGA
BRAF Exon 15 Rv CAGGAAACAGCTATGACGGCCAAAATTTAATCAGTGGA
M13 Fw CAGGAAACAGCTATGAC
M13 Rv GTTTTCCCAGTCACGAC
A PCR mixture 25 µl containing 2.5 units of Amplitaq Gold polymerase (Applied Biosystems), PCR Buffer II 
(Applied Biosystems), 1.5 mM MgCl2, 0.3 mM deoxyribonucleotide triphosphates (dNTPs) (Promega, Madi-
son, WI, USA), 1 µM of forward and reverse primer, and ~40 ng of gDNA as a template was used. Cycling 
conditions were: polymerase activation at 94ºC for 5 min, following 40 cycles of 94ºC for 1 min, 60ºC for 1 
min, and 72ºC for 1 min, and one additional hold at 72ºC for 10 min. NRAS Exon 1 primers target the entire 
exon 1, with the exception of the first 2 nucleotides. NRAS Exon 2 primers target the entire exon 2, with the 
exception of the first15 nucleotides. KRAS 1 and KRAS 2 primers target the entire exons 1 and 2.
supplementary table s2:
Primer References
NRAS Exon 1 ENSE00001364464
NRAS Exon 2 ENSE00001450282
KRAS Exon 1 ENSE00001189804
KRAS Exon 2 ENSE00000936617
BRAF Exon 15 ENSE00002324725
www.ensembl.org, release 59, date: 22th of April 2011
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supplementary table s3:
No. of patients (%)
Sex (n=108)
Male 43 (39.8)
Female 65 (60.1)
Age (median, range, days, n=108) 164 (1-360)
WBC counts at diagnosis x 109/L
(median, range, n=101) 263 (1.4-1332)
Infant ALL (n=97 samples)
pro-B 64 (66.0)
common B 8 (8.3)
pre-B 21 (21.7)
B-lineage not classified 1 (1.0)
Biphenotypic 1 (1.0)
T-cell 2 (2.0)
MLL-rearrangement (n=109)
t(4;11) 38 (34.9)
t(9;11) 11 (10.1)
t(11;19) 28 (25.7)
other 11q23* 14 (12.8)
germline-MLL† 18 (16.5)
AF4/ MLL (n=38)
positive 23 (60.5)
negative 15 (39.5)
*11q23; MLL-rearranged infant ALL patients, with unknown or rare partner gene (including one t(1;11)-, 
one t(3;11)-, and three t(10;11)-positive patients), common partner genes (t(4;11), and t(11;19)) were ex-
cluded by PCR,† Germline-MLL; infant ALL patients without MLL-rearrangement Abbreviations: WBC; white 
blood cell.
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supplementary figure s4: optical Density (cell viability) of untreated primary infant aLL cells
In our in vitro cytotoxicity assays (i.e. MTT assays), leukemic cells are cultured in the presence of increasing 
drug concentrations. Cell viability is determined by measuring the optical density (OD) of the blue forma-
zan derivative of the tetrazolium MTT, which is formed only by viable cells. Here we compared the ODs of 
control cells (i.e. cultured in the absence of drug) between RAS-mutated and non-mutated samples derived 
from (A) MLL-rearranged infant ALL patients and (B) t(4;11)-positive infant ALL patients. Differences in the 
ODs between RAS-mutated and non-mutated samples were statistically analyzed by the Mann-Whitney 
U-test. The horizontal lines represent the median OD in each group.
supplementary figure s5: RAS mutations in 
prednisolone exposed infant aLL samples
Representative sequences from time lapse in vitro 
prednisolone exposure experiment (KRAS exon1 
condon12(Gly> Asp mutation). Two infant ALL 
samples (that appeared to have subclonal RAS 
mutations) were exposed to various concentra-
tions of prednisolone (0 µg/ml, 0.488281 µg/ml, 
and 250 µg/ml). Cells were harvested from differ-
ent time-points (Day 0, Day 2, and Day 4) and se-
quenced for the RAS mutations.
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supplementary figure s6: HOXA9 expression of t(4;11)-rearranged infant aLL patients
HOXA9 mRNA expression (Affymetrix HU133plus2.0 microarray data) in t(4;11)-positive infant ALL patients. 
Differences in expression between RAS-mutated and non-mutated were statistically analyzed by the Mann-
Whitney U-test, showing significant lower levels of HOXA9 expression in RAS-mutated cases for both probe-
sets tested: 209905_at (p=0.006) and 214651_s_at (p=0.020).
supplementary table s7:
Patient
Clonality based on
Sanger sequencing
No. of mutated clones
(analyzed clones)
Mutated clones
(%)
Expected mutated 
clones if clonal* (%) p-value
3 subclonal 5 (16) 31.5 48 0.069
6 subclonal 12 (43) 27.9 49.5 0.003
7 clonal 9 (43) 20.9 48.5 <0.001
In order to confirm subclonality of the RAS mutations as implied by our Sanger sequencing results, we used 
TOPO® TA Cloning (Invitrogen Life Technologies, Breda, the Netherlands) to sequence single PCR-amplified 
DNA fragments in three patient samples (i.e. patient #3, #6, and #7). For this, multiple PCR fragments from 
the three patient samples positive for the KRAS1 (Gly13Asp) mutation were individually ligated into the TA 
cloning vector (pCR®2.1), and the constructs were transformed into competent E.coli cells using heat shock. 
Transformed cells were then spread LB agar plates containing X-Gal, 100 mg/ml ampicillin, and incubated 
overnight at 37°C. Next, multiple single colonies (each containing multiple copies of a single PCR frag-
ment) were picked for plasmid isolation using the QiaPrep Spin Miniprep Kit (Qiagen, Venlo, The Nether-
lands). Finally, the inserts of all plasmids were sequenced by Sanger sequencing as described in the Design 
and methods section of the manuscript. In all patients the number of mutated DNA fragments was lower 
than the expected percentage in case the mutation would have been clonal (*corrected for the percentage 
blasts (96-99%) in the patient samples). The results were statistically analyzed using the one-sided Z-test. 
Although the results of patient #3 did not reach statistically significance (which may be due to the relatively 
low number of clones analyzed) these results demonstrate that RAS mutations in infant ALL patients can 
indeed be subclonal. However, results derived from conventional Sanger sequencing must be interpreted 
with care, as the RAS mutation in patient #7 appeared clonal in our initial sequencing data, but clearly 
turned out to be subclonal when analyzing single PCR fragments.
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abstRaCt
Acute lymphoblastic leukemia (ALL) in infants is an aggressive malignancy with a poor 
clinical outcome, and is characterized by translocations of the Mixed Lineage Leukemia 
(MLL) gene. Previously, we identified RAS mutations in 14-24% of infant ALL patients, and 
showed that the presence of a RAS mutation decreased the survival chances even further. 
We hypothesized that targeting the RAS signaling pathway could be a therapeutic strategy 
for RAS-mutant infant ALL patients. Here we show that the MEK inhibitors Trametinib, Se-
lumetinib and MEK162 severely impair primary RAS-mutant MLL-rearranged infant ALL 
cells in vitro. While all RAS-mutant samples were sensitive to MEK inhibitors, we found 
both sensitive and resistant samples among RAS-wildtype cases. We confirmed enhanced 
RAS pathway signaling in RAS-mutant samples, but found no apparent downstream over-
activation in the wildtype samples. However, we did confirm that MEK inhibitors reduced 
p-ERK levels, and induced apoptosis in the RAS-mutant MLL-rearranged ALL cells. Finally, 
we show that MEK inhibition synergistically enhances prednisolone sensitivity, both in 
RAS-mutant and RAS-wildtype cells. In conclusion, MEK inhibition represents a promising 
therapeutic strategy for MLL-rearranged ALL patients harboring RAS mutations, while 
patients without RAS mutations may benefit through prednisolone sensitization.
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intRoDuCtion
Acute lymphoblastic leukemia (ALL) in infants (<1 year of age) represents an aggressive 
malignancy, associated with high relapse rates and a poor clinical outcome.1 The majority 
(~80%) of these patients carry a leukemia-specific chromosomal translocations involv-
ing the Mixed Lineage Leukemia (MLL) gene.1 MLL-rearranged infant ALL patients fare 
significantly worse than infant ALL patients who do not carry MLL translocations, with 
event-free survival (EFS) rates of 30-40% vs. ~80%, respectively.2 Recently, we demonstrated 
that 24% of the infant ALL patients carrying MLL translocation t(4;11), the most frequently 
observed translocation of MLL among these patients, also carry a RAS mutation. Mutations 
in NRAS were found in 11% and KRAS mutations in 13% of cases.3 Moreover, we showed 
that the presence of a RAS mutation in MLL-rearranged patients represented an indepen-
dent predictive factor for an even worse clinical outcome in this high-risk group. Nearly all 
RAS-mutant t(4;11)+ infant ALL patients relapsed within the first year from diagnosis, while 
still on treatment, and all died within 4 years from diagnosis.3
Despite this strong association with an exceedingly poor prognosis, a recent study by 
Emerenciano et al. suggested that RAS mutations in MLL-rearranged infant ALL may not 
act as driver mutations and are not required for disease progression, but rather act only 
at disease onset.4 Yet, our previous data clearly showed that RAS-mutant MLL-rearranged 
infant ALL patients are at extremely high-risk of therapy failure and early death. Moreover, 
RAS pathway inhibition, including MEK inhibition, was previously shown to effectively 
inhibit RAS-mutant MLL-rearranged AML in vitro.5, 6 Therefore, we decided to investigate 
the potential of RAS pathway inhibition and found that RAS-mutant MLL-rearranged ALL 
cells are remarkably sensitive to MEK inhibitors.
MEthoDs
Patient samples and cell lines
Bone marrow and peripheral blood samples from untreated infant ALL patients were 
collected at the Sophia Children’s Hospital (Rotterdam, The Netherlands) as part of the 
international collaborative Interfant treatment protocols.2 Approval for these studies was 
obtained from the Erasmus MC Institutional Review Board. Informed consent was obtained 
according to the Declaration of Helsinki. All samples were processed within 24 hours after 
sampling as described before, with optional removal of contaminating non-leukemic cells 
by immunomagnetic beads, to ensure leukemic blast content for all samples was >90%.7 
The t(4;11)-rearranged ALL cell line SEM and t(11;19)-rearranged ALL cell line KOPN8 
were purchased from the German Collection of Microorganisms and Cell Cultures (DSMZ, 
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Braunschweig, Germany), while the t(4;11)-rearranged ALL cell line RS4;11 was purchased 
from The Global Biosource Center (ATCC, Middlesex, UK). All cell lines were cultured in 
suspension in RPMI-1640 with GlutaMAX (Invitrogen Life Technologies, Waltham, MA, 
USA) supplemented with 10% Fetal Calf Serum, 100 IU/mL penicillin, 100 IU/mL strepto-
mycin and 0.125 µg/mL amphotericin B (Invitrogen Life Technologies) at 37°C under 5% 
CO2 atmosphere.
In vitro cytotoxicity assay and small molecule inhibitors
The in vitro cytotoxicity of MEK162, Selumetinib and Trametinib (MedChem Express, 
Stockholm, Sweden) was tested by MTS and MTT assays. All inhibitors were weighed, 
dissolved in dimethyl sulfoxide (DMSO) and stored at -20°C until use. Cytotoxicity as-
say dilutions were prepared in cell culture medium, keeping final DMSO concentration 
<0.5%. Final concentrations of the small molecule inhibitors ranged from 50 µM to 0.15 
nM, indicated in the respective figures. The in vitro sensitivity of cell lines was assessed by 
using 4-day MTS conversion assays, as described previously.8 In vitro cytotoxicity of patient 
cells was assessed by using a 4-day MTT conversion assay, as described before.7 Data was 
normalized to vehicle (DMSO) controls.
Western blot analysis
Protein extracts (25 µg) were electrophoretically resolved on pre-cast SDS-polyacrylamide 
gels (anyKD, TGX, Bio-Rad, Veenendaal, The Netherlands) and transferred to nitrocellulose 
membranes. Membranes were blocked with 5% bovine serum albumin and subsequently 
probed with antibodies directed against total or phosphorylated ERK, MEK, ELK-1, Akt, 
or p70S6K (Cell Signaling, Danvers, MA, USA). Membranes were counterstained with 
IRDye® 680/800 conjugated secondary antibodies (Li/COR, Leusden, The Netherlands) and 
were scanned by an Odyssey imaging system (Li/COR). Membranes were re-probed with 
mouse monoclonal anti-β-actin antibodies (Sigma-Aldrich, St. Louis, MO, USA) as loading 
control. Fluorescence was quantified using the Odyssey 3.0 application software.
Ras activation
RAS activation was analyzed using the RAS Activation Assay Kit (17-218, Merck-Millipore, 
Amsterdam, The Netherlands). Briefly, 1x107 cells were isolated and lysed with Mg2+ Lysis 
Buffer (MLB), and stored at -80°C until use. GST-fused RAF-1 RBD bead slurry was added 
to the lysate and incubated for 1 hour at 4°C while agitating. Beads were isolated by cen-
trifugation and washed with MLB, and precipitated protein was denatured with Laemmli 
buffer at 95°C before immunoblotting. As a positive control, total cell lysate was included 
in the immunoblotting procedure. The provided RAS antibody (05-516, Merck-Millipore) 
was used, and GST (Cell Signaling) and β-actin (Sigma-Aldrich) antibodies were used as 
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loading controls for the beads and total protein, respectively. Fluorescence was quantified 
using the Odyssey 3.0 application software.
annexin-V/7-aaD apoptosis and cell cycle assays
For assessment of early and late apoptosis, the PE Annexin-V Apoptosis Detection Kit (BD 
Pharmingen, Breda, The Netherlands) was used according to the manufacturer’s protocol. 
Briefly, drug-exposed cells were isolated, washed with PBS and re-suspended in binding 
buffer. Cells were stained with PE Annexin V and/or 7-AAD for 15 minutes, and sorted 
using fluorescence activated cell sorting (FACS). Cell cycle progression was assessed by per-
meabilization of isolated cells through hypotonic lysis. Subsequently, RNAse treatment was 
performed, and DNA was stained using Propidium Iodide, after which FACS determined 
DNA content. Data was analyzed using FlowJo software (FlowJo, Ashland, OR, USA).
Gene expression data
Recently published gene expression data (Affymetrix HU133plus2.0) for part of the t(4;11)+ 
patient samples was available (i.e. for 6 of 9 MEK inhibitor resistant RAS-wildtype samples, 
4 of 5 sensitive RAS-wildtype samples and 3 of 6 RAS-mutant samples).9 This data is avail-
able in GEO database19 (accession number GSE19475) and was acquired as previously 
described.9 Tyrosine kinase receptor expression was derived from this dataset, using the 
following probe sets: 206674_at (FLT3), 204406_at (VEGFR-1), 203934_at (VEGFR-2), 
234379_at (VEGFR-3), 210973_s_at (FGFR-1), 208225_at (FGFR-2), 204380_s_at (FGFR-
3), 204579_at (FGFR-4), 211551_at (EGFR), 210930_s_at (ERBB2), 226213_at (ERBB3), 
214053_at (ERBB4), 205463_s_at (PDGFR-A), 217112_at (PDGFR-B), 204891_s_at (Lck) 
and 213324_at (Src).
statistical analysis
Statistical analyses were performed with SPSS Statistics version 17.0 (SPSS Inc. Chicago, IL, 
USA). All tests were two-tailed and p-values < 0.05 were considered significant. The effect 
of combining drugs (i.e. synergy, additivity or antagonism) was assessed using Berenbaums 
criteria, as previously described.10, 11 Briefly, we calculated the Synergy Factor (FSyn) with the 
formula FSyn = ([Drug Xin combination with Y]/[Drug X]) + ([Drug Yin combination with X] / [Drug Y]) for 
a particular fractional effect. If the drug combination results in FSyn < 1, this is considered 
synergy.
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REsuLts
RAS-mutant MLL-rearranged aLL cells are sensitive to MEk inhibition
Since the previously identified RAS aberrations are all activating mutations (at residues 
G12, G13 or Q61), we wondered whether small molecule inhibitors targeting RAS pathway 
components could suppress RAS-mutant leukemic cells.3, 12 Therefore, 7 RAS pathway 
inhibitors, already approved for therapeutical use or under clinical investigation for other 
malignancies with RAS pathway mutations, were selected as therapeutic strategies for the 
RAS-mutant infant ALL patients. Using 4-day MTS cell viability assays we tested the in 
vitro anti-leukemic potential of Salirasib (RAS localization inhibitor), Vemurafenib (BRAF 
inhibitor), Sorafenib (pan-kinase inhibitor), Trametinib, Selumetinib and MEK162 (MEK 
inhibitors) and Temsirolimus (mTOR inhibitor) against RAS-mutant MLL-rearranged 
ALL cell line KOPN8, and the RAS-wildtype MLL-rearranged cell lines SEM and RS4;11. 
Interestingly, the RAS-mutant cell line KOPN8 was more sensitive to the MEK inhibitors 
MEK162, Selumetinib and Trametinib (Figure 1). Temsirolimus and Sorafenib potently re-
duced cell viability of both RAS-mutant and RAS-wildtype cell lines. Additionally, Salirasib 
and Vemurafenib did not substantially reduce cell viability, even at high concentrations 
(>10µM). To confirm the efficacy of these inhibitors, we performed 4-day MTT cell viability 
assays on primary diagnostic RAS-mutant (n=6) and RAS-wildtype (n=14) t(4;11)+ infant 
ALL samples. Interestingly, compared to RAS-wildtype t(4;11)+ ALL cases, the RAS-mutant 
t(4;11)+ infant ALL cases were significantly more sensitive to all MEK inhibitors (Figure 
2A) with median IC50 values of <0.1 mM for MEK162 and Selumetinib and <0.01 mM for 
Trametinib (Figure 2B). Additionally, all other tested inhibitors (Salirasib, Temsirolimus, 
Sorafenib and Vemurafenib) reached only IC50 values of >10µM (Supplementary Figure S1).
Also, we included one matched pair of diagnostic/relapse t(4;11)+ samples. For this particu-
lar patient, no RAS mutation was present at diagnosis, but a RAS mutation could be identi-
fied at relapse. Indeed, the RAS-mutant relapse sample of this patient was more sensitive to 
all three MEK inhibitors tested than the RAS-wildtype diagnostic sample (Figure 2B).
Enhanced Ras activation in t(4;11)+ infant aLL cells carrying RAS mutations
The MEK inhibitors MEK162, Selumetinib and Trametinib significantly reduce viability 
of RAS-mutant MLL-rearranged ALL cells. Notably, a subset of the RAS-wildtype primary 
t(4;11)+ infant ALL samples also responded favorably to the MEK inhibitors (Figure 2B). 
We wondered whether other biomarkers, besides RAS mutation status, could predict MEK 
inhibitor sensitivity in MLL-rearranged ALL. Wildtype RAS proteins are under regulation 
of upstream signaling events, often involving tyrosine kinase receptors, while mutant RAS 
proteins are less dependent on upstream activation due to reduced GTPase activity, render-
ing a surplus of activated GTP-bound RAS. Therefore, we determined the RAS protein levels 
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figure 1: MEk inhibitors specifically impede RAS-mutant MLL-rearranged aLL cell line koPn8
Cell viability of MLL-rearranged cell lines exposed to Sorafenib, Salirasib, MEK162, Selumetinib, Temsiroli-
mus, Vemurafenib and Trametinib. All cell lines respond to Sorafenib and Temsirolimus, while RAS-mutant 
KOPN8 (solid line) is more sensitive than RAS-wildtype SEM (large dashed line) or RS4;11 (small dashed line). 
Data are represented as mean +/- sem. n≥3.
70 Chapter 5
0.
00
1
0.
01
0.
1
1
10
10
0
02040608010
0
D
os
e 
(
M
)
**
***
***
***
***
M
EK
16
2
Se
lu
m
et
in
ib
Tr
am
et
in
ib
RA
S-
M
UT
RA
S-
W
T 
R
A
S-
W
T
R
A
S-
M
U
T
0.
00
1
0.
010.
111010
0
p=
0.
00
34
R
A
S-
W
T
R
A
S-
M
U
T
0.
00
1
0.
010.
111010
0
p=
0.
00
39
IC
50
 (µM)
R
A
S-
W
T
R
A
S-
M
U
T
0.
00
1
0.
010.
111010
0
p=
0.
00
74
A B
Viable cells (%)
Viable cells (%)
0.
00
1
0.
01
0.
1
1
10
10
0
02040608010
0
D
os
e 
(
M
)
**
***
***
**
***
0.
00
1
0.
01
0.
1
1
10
10
0
02040608010
0
D
os
e 
(
M
)
Viable cells (%)
*
***
***
***
***
***
IC
50
 (µM)
IC
50
 (µM)
fi
gu
re
 2
: P
ri
m
ar
y 
RA
S-
m
ut
an
t M
LL
-r
ea
rr
an
ge
d 
a
LL
 c
el
ls
 a
re
 s
en
si
ti
ve
 to
 M
Ek
 in
hi
bi
to
rs
(A
) P
at
ie
nt
 d
er
iv
ed
 t(
4;
11
)+
 in
fa
nt
 A
LL
 c
el
ls
 e
xp
os
ed
 to
 M
EK
 in
hi
bi
to
rs
 in
di
ca
te
 R
AS
-m
ut
an
t s
am
pl
es
 (s
ol
id
 li
ne
, n
=6
) a
re
 m
or
e 
se
ns
iti
ve
 c
om
pa
re
d 
to
 R
AS
-w
ild
ty
pe
 sa
m
pl
es
 
(d
as
he
d 
lin
e,
 n
=1
4)
. D
at
a 
ar
e 
re
pr
es
en
te
d 
as
 m
ed
ia
n 
+/
- s
d.
 *
0.
01
<p
<0
.0
5;
 *
*0
.0
01
<p
<0
.0
1;
 *
**
p<
0.
00
1.
 (B
) T
he
 IC
50
 (c
on
ce
nt
ra
tio
n 
ne
ed
ed
 to
 in
hi
bi
t 5
0%
 o
f t
he
 le
uk
em
ic
 
ce
ll 
vi
ab
ili
ty
) o
f t
he
 in
di
vi
du
al
 t(
4;
11
)+
 in
fa
nt
 A
LL
 p
at
ie
nt
 sa
m
pl
es
 sh
ow
n 
in
 A
. M
ed
ia
n 
IC
50
 v
al
ue
s, 
re
pr
es
en
te
d 
by
 h
or
iz
on
ta
l b
ar
s, 
co
nfi
rm
 st
ro
ng
 se
ns
iti
vi
ty
 o
f R
AS
-m
ut
an
t 
pa
tie
nt
 s
am
pl
es
 c
om
pa
re
d 
to
 t
he
 m
aj
or
ity
 o
f R
AS
-w
ild
ty
pe
 s
am
pl
es
. O
pe
n 
ci
rc
le
s 
in
di
ca
te
 m
at
ch
ed
 d
ia
gn
os
is
 (w
ild
ty
pe
) a
nd
 re
la
ps
e 
(m
ut
an
t)
 s
am
pl
es
. T
he
 t
ic
k 
lin
es
 
in
di
ca
te
 s
ep
ar
at
io
n 
be
tw
ee
n 
M
EK
 in
hi
bi
to
r s
en
si
tiv
e 
an
d 
re
si
st
an
t p
at
ie
nt
 s
am
pl
es
 (I
C 5
0<
1μ
M
 a
nd
 IC
50
>1
μM
, r
es
pe
ct
iv
el
y)
.
71MEK inhibition in MLL-rearranged infant ALL
and RAS activity in our primary t(4;11)+ infant ALL cells. No significant difference in RAS 
protein levels was observed between the RAS-mutant and RAS-wildtype t(4;11)+ infant ALL 
samples using Western blot analysis (Figure 3A). Next, we investigated the level of active 
(GTP-bound) RAS in these samples by precipitation with RAF-1 RAS interaction protein, 
followed by immunoblotting. As expected, the RAS-mutant t(4;11)+ infant ALL samples 
showed significant (p=0.013) higher levels of RAS activation as compared to RAS-wildtype 
samples (Figure 3B). No differences in RAS activation were observed between RAS-wildtype 
samples that were sensitive or resistant to MEK inhibition.
A RAS level
Re
la
tiv
e 
RA
S 
pr
ot
ei
n 
le
ve
l
p=n.s.
0.0
0.5
1.0
1.5
WT WT MUT
Res Sens
B RAS-GTP IP
0.0
0.5
1.0
1.5
R
el
at
iv
e 
R
A
S 
ac
tiv
at
io
n
WT WT MUT
Res Sens
n.s.
*
C D ERK activation
ra
tio
 p
-E
R
K
/to
ta
l E
R
K
0.0
0.5
1.0
1.5
WT WT MUT
Res Sens
p=n.s.
ra
tio
 p
-M
EK
/ t
ot
al
 M
EK
MEK activation
0.0
0.5
1.0
1.5
WT WT MUT
Res Sens
n.s.
*
figure 3: RAS-mutant t(4;11)-positive aLL cells have enhanced downstream activation
(A) RAS protein level, relative to β-actin, determined by western blotting in t(4;11)+ infant ALL samples, 
subdivided according to RAS mutation status (WT or MUT) and MEK inhibitor sensitivity. No differences 
in median protein level (horizontal bars) are observed between the different subgroups. (B) Relative RAS 
activation is enhanced in RAS-mutant t(4;11)+ patient samples, though no difference is observed between 
the MEK inhibitor resistant and sensitive RAS-wildtype subgroups. (C) Ratio p-MEK/total MEK in RAS-mutant 
(MUT) and RAS-wildtype (WT) t(4;11)-rearranged infant ALL samples shows increased MEK activation in 
RAS-mutant samples, while the MEK inhibitor resistant (Res) and sensitive (Sens) RAS-wildtype samples 
have comparable MEK activation. (D) Ratio p-ERK/total ERK in RAS-mutant and RAS-wildtype t(4;11)-rear-
ranged infant ALL samples shows no significant differences in ERK activation between subgroups. Open 
circles indicate matched diagnosis (wildtype) and relapse (mutant) samples. Horizontal bars present group 
medians. Open circles indicate matched diagnosis (wildtype) and relapse (mutant) samples. *p<0.05.
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Subsequently, we determined phosphorylation levels of MEK (p-MEK) and ERK (p-ERK) 
by immunoblotting (Supplementary Figure S2A and B, respectively). Quantifi cation of the 
blots indicated a signifi cantly higher level of p-MEK in our RAS-mutant samples, compared 
to RAS-wildtype samples (p=0.0312, Figure S3C), although there was no diff erence in p-
MEK levels between the MEK inhibitor resistant and sensitive RAS-wildtype subgroups. 
Still, we did fi nd a higher p-MEK level in the mutated relapse sample compared to its 
matched wildtype diagnosis sample. Additionally, no diff erences in p-ERK levels were found 
between RAS-wildtype and RAS-mutant samples (Figure 3D), nor between RAS-wildtype 
cells that were sensitive or resistant to MEK inhibition.
In MLL-rearranged AML, MEK inhibitor resistance can occur through activation of tyro-
sine kinase receptor (TKR) signaling (i.e. involving VEGFR-2).5 Furthermore, we previously 
found MLL-rearranged ALL is characterized by high expression of Fms-like tyrosine kinase 
3 (FLT3).7 Th erefore, we interrogated available gene expression profi les of primary samples 
for possible diff erences in TKR expression levels between the MEK inhibitor sensitive and 
resistant subgroups (Supplementary Figure S3). Interestingly, apart from FLT3, expression 
of TKRs is relatively low in the diff erent patient samples. Surprisingly, FGFR-1 expression is 
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figure 4: MEk inhibition results in reduced ERk phosphorylation
(A) Western blot analysis of SEM and KOPN8 (upper and lower panels, respectively) exposed to 500 nM of 
MEK inhibitor or vehicle control (DMSO) for 6, 24 and 48 hours. Both cell lines almost completely lose ERK 
phosphorylation (p-ERK), while total ERK (t-ERK) levels remain unaff ected. (B) Analysis of MEK phosphoryla-
tion (p-MEK) suggests exposure to MEK162 and Selumetinib results in enhanced MEK phosphorylation in 
both cell lines, whereas total MEK (t-MEK) levels remain constant.
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significantly lower in MEK inhibitor resistant RAS-wildtype samples (p=0.02), while there 
are no significant differences in expression of FLT3, VEGFR (1-3), FGFR (2-4), EGFR and 
ERBB (2-4), PDGFR (A-B) or Lck and Src.
MEk inhibition results in reduced ERk phosphorylation
Next, we exposed MLL-rearranged ALL cell lines SEM and KOPN8 to the MEK inhibitors 
(Selumetinib, MEK162 and Trametinib) and determined p-ERK and p-MEK levels by im-
munoblotting (Figure 4). Interestingly, p-ERK levels were drastically reduced in both SEM 
and KOPN8, already after 6 hours of exposure, and this effect was sustained for at least 
48 hours, regardless of the inhibitor used (Figure 4A). Furthermore, prolonged exposure 
(24 and 48 hours) to the MEK inhibitors Selumetinib and MEK162 resulted in an increase 
of p-MEK in SEM and KOPN8 (Figure 4B). Additionally, we determined phosphorylation 
of ERKs downstream effector ELK-1, but ELK-1 activation was not influenced by MEK 
inhibition (Supplementary Figure S4A).
Since SEM cells responded modestly to MEK inhibition but did show a significant loss of 
p-ERK levels, we investigated whether these cells could circumvent loss of ERK activation 
by upregulating RAS-mediated PI3K-Akt-mTOR signaling. Therefore, the downstream 
phosphorylation of Akt (Ser437) and p70S6K (Thr389) was assessed by immunoblotting. 
However, no differences in Akt and p70S6K phosphorylation were observed in response to 
MEK inhibitor exposure (Supplementary Figure S4B and S4C).
MEk inhibitors induce apoptosis
Subsequently, we investigated the phenotypic effects of the MEK inhibitors on SEM and 
KOPN8 through analysis of early and late apoptosis markers (Annexin-V and 7-AAD, re-
spectively), using flow-cytometry. Interestingly, both RAS-wildtype SEM and RAS-mutant 
KOPN8 undergo early apoptosis, after treatment with MEK inhibitor (Figure 5A and B, 
respectively). However, while late apoptosis is barely observed for SEM (Figure 5C), late 
apoptosis in MEK inhibitor exposed KOPN8 cells is enhanced substantially, especially after 
prolonged exposure (Figure 5D), suggesting the response to MEK inhibition is character-
ized by increased apoptosis. Furthermore, MEK inhibitor exposure induced protein levels 
of pro-apoptotic BIM, most evidently for KOPN8, while p53 levels remained unaffected 
(Supplementary Figure S5). Additionally, we investigated cell cycle progression under in-
fluence of MEK inhibition. Interestingly, no considerable differences in SEM or KOPN8 
cell cycle progression are observed after 96 hours exposure to MEK162, Selumetinib or 
Trametinib (Figure 5E and F, respectively), nor after exposure for 24, 48 and 72 hours 
(Supplementary Figure S6A-B, C-D and E-F, respectively).
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figure 5: MEk inhibitors induce apoptosis
(A and B) Early apoptosis (percentage AnnexinV single positive of total) of SEM and KOPN8 cells (respec-
tively) after exposure to DMSO vehicle (white bars) or 500 nM MEK162, Selumetinib or Trametinib (light 
grey, dark grey and black bars, respectively), indicates MEK inhibition slightly induces early apoptosis. Data 
are represented as mean +/- sem. n=3. (C and D) Late apoptosis (percentage AnnexinV and 7-AAD double 
positive cells of total) of SEM and KOPN8 (respectively) show that while SEM cells have no induction of late 
apoptosis in response to MEK inhibition, compared to the DMSO controls, KOPN8 clearly undergoes apop-
tosis, especially after prolonged exposure (>48 hours). Data are represented as mean +/- sem. n=3. (E and 
F) Cell cycle analysis of SEM and KOPN8 (respectively) after 96 hours exposure to vehicle (DMSO) or 500 nM 
MEK162, Selumetinib or Trametinib indicates MEK inhibition does not impinge on the cell cycle progres-
sion. Stacked bar graph indicates percentage of cells in G0/G1 (black), S (grey) and G2/M (white) cell cycle 
stages. Data are represented as mean +/- sem. n=3.
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figure 6: MEk inhibition enhances prednisolone sensitivity
(A) Dose-response curves of the SEM cell line exposed to prednisolone alone (black curve) or in combina-
tion with 0.04 μM, 0.2 μM, 1 μM or 5 μM Trametinib (red, blue, green and grey curves, respectively). Low con-
centrations of Trametinib particularly sensitize cells that escape high concentrations of prednisolone. Data 
are represented as mean +/- sem. n=3. (B) Response of SEM to the single Trametinib concentrations used in 
A. n=3. (C) Dose-response curves of KOPN8 treated with prednisolone (black curve), or in combination with 
the aforementioned Trametinib concentrations (shown in red, blue, green and grey, respectively). KOPN8 
cells are also sensitized towards prednisolone by co-exposure with low concentrations of Trametinib. Data 
are represented as mean +/- sem. n=3 (D) KOPN8 exposed to single Trametinib concentrations. Data are 
represented as mean +/- sem. n=3. (E) Combined exposure to prednisolone and Trametinib (merged data 
from 3 separate experiments) was quantified using FSyn calculations (FSyn<1 indicates synergy) and plot-
ted against fractional effect (i.e. inhibition of cell viability). In SEM (red) moderate to strong synergy was 
observed, while all combinations of Trametinib and prednisolone result in strong to very strong synergy in 
KOPN8 (blue).
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MEk inhibition enhances prednisolone sensitivity
In our previous study, we found that MLL-rearranged infant ALL patient samples harboring RAS 
mutations are more resistant to prednisolone.3 Therefore, we examined whether inhibition of 
MEK could enhance prednisolone sensitivity of RAS-mutant cells. As shown in Figure 6A, pred-
nisolone alone decreases cell viability of SEM cells to only ~50%. Interestingly, while Trametinib 
by itself induces only minor cell viability decrease in SEM cells (Figure 6B), the combination of 
Trametinib and prednisolone greatly enhanced the efficacy of prednisolone, especially at higher 
concentrations (Figure 6A). The combination of prednisolone and Trametinib also strongly 
decreased cell viability in KOPN8 more potently than either drug alone; low concentrations 
of Trametinib nearly eradicated all KOPN8 cells that did not respond to prednisolone treat-
ment (Figure 6C). A similar sensitizing effect was observed when exposing SEM and KOPN8 
to MEK162 or Selumetinib in combination with prednisolone (Supplementary Figure S7A-D 
and 7F-I, respectively). Since Trametinib alone already effectively decreases viability of KOPN8 
cells (Figure 6D), we quantified the combinatorial effect of MEK inhibitors and prednisolone 
using the synergy factor (FSyn) calculation, as previously described.10, 11 The plot in Figure 6E 
shows the fractional effect (i.e. the relative decrease of cell viability) induced by the combination 
of Trametinib with prednisolone, and the corresponding Synergy Factor. Interestingly, in both 
SEM and KOPN8 cells we observed FSyn values < 0.5, indicating strong synergy between Tra-
metinib and prednisolone. Also combining MEK162 or Selumetinib with prednisolone resulted 
in moderate to strong synergistic effects (Supplementary Figure S7E and 7J, respectively). Ad-
ditionally, we investigated whether this enhanced effect was related to differential expression of 
the glucocorticoid receptor (GR), the target of prednisolone. However, MEK inhibitor exposure 
did not alter GR protein levels in either SEM or KOPN8 cells (Supplementary Figure S7K).
DisCussion
MLL-rearranged ALL in infants is a high-risk hematologic malignancy, characterized by a 
high incidence of relapse and high mortality rate.13 Recently, we showed that 14-24% of these 
patients carry a RAS mutation, as an independent predictor of extremely poor outcome.3 
In the present study, we demonstrate that the MEK inhibitors Trametinib, Selumetinib 
and MEK162 display strong anti-leukemic effects against RAS-mutant MLL-rearranged 
ALL cells. Considering the dismal prognosis for infants suffering from MLL-rearranged 
ALL with additional RAS mutations, our data supports application of these inhibitors in 
the treatment of this patient group. Recently, Irving et al. already showed that Selumetinib 
effectively inhibits leukemia progression in an in vivo model of RAS-mutant BCP-ALL, and 
Burgess et al. found Trametinib to prolong the survival of mice transplanted with NRASG12D 
AML cells.14, 15 Moreover, Trametinib has recently been approved for the treatment of adult 
BRAF-mutated melanoma, while different clinical trials show promising results in adult 
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patients with RAS/RAF mutation positive melanoma and non-small-cell lung cancer for 
Selumetinib and MEK162.16-20 Even though most clinical trials focused on solid tumors in 
adult patients, pediatric clinical trials are underway for neurofibromas and gliomas, and 
could expedite clinical application of these MEK inhibitors in MLL-rearranged infant ALL.
Interestingly, while all RAS-mutant MLL-rearranged ALL patient samples are susceptible 
to MEK inhibition, patients without RAS mutations also might benefit from MEK inhibitor 
treatment, since a subgroup of RAS-wildtype patient samples appears sensitive to MEK 
inhibition. While in our previous study, we identified RAS mutations and found no BRAF 
aberrations, mutations of other upstream regulators, i.e. tyrosine kinase receptors, can 
occur in other malignancies.3 Andersson et al. recently showed that additional somatic 
mutations in MLL-rearranged infant ALL, like (sub-)clonal RAS/PI3K pathway aberrations, 
occur in up to 50% of the cases, supporting our previous observation that RAS mutations 
in MLL-rearranged infant ALL frequently occur at a sub-clonal level.3, 21 These findings do 
not support the hypothesis that other (upstream) mutations are driving RAS-MEK-ERK 
signaling, but also do not explain observed extensive MEK inhibitor sensitivity of all (sub-
clonal) RAS-mutant and specified RAS-wildtype patient samples. While we found enhanced 
RAS and MEK activation in RAS-mutant samples, these biomarkers could not differentiate 
MEK inhibitor sensitive and resistant RAS-wildtype samples. Interestingly, Kampen et al. 
recently proposed a MEK inhibitor escape mechanism in MLL-rearranged AML, which was 
mediated by VEGFR-2 and PI3K-signaling, and we wondered whether this could play a role 
in the MEK inhibitor resistance of our wildtype patient cells.5 However, we observed no 
difference in downstream PI3K-signalling (i.e. Akt or p70S6 phosphorylation) in response 
to MEK inhibitor exposure. Additionally, we discovered no significant tyrosine kinase 
receptor expression differences in MLL-rearranged infant ALL patient samples that could 
explain the MEK inhibitor response of RAS-wildtype samples. Surprisingly, FGFR-1 expres-
sion was lower in MEK inhibitor resistant samples, but it is unclear how this would explain 
MEK inhibitor resistance. Alternatively, Minjgee et al. report that RAS-mutant transfected 
cells can induce downstream RAS signaling in a paracrine manner, through excretion of 
cytokines.22 Interestingly, Nakanishi et al. previously demonstrated that MLL-fusion pro-
teins can induce ERK phosphorylation through regulating EphA7 receptor tyrosine kinase 
expression, but this was not accompanied by increased RAF or MEK phosphorylation.23 
Still, their data shows that leukemic cells carrying the t(4;11) translocation are sensitive 
to small molecule inhibitors of ERK phosphorylation. These findings indicate alternative 
regulatory mechanisms for ERK signaling in MLL-rearranged leukemia could explain the 
MEK inhibitor sensitivity we observe in RAS-wildtype cells.
Loss of ERK phosphorylation in response to MEK162, Selumetinib or Trametinib exposure 
confirmed the effect of MEK inhibition. Interestingly, prolonged exposure of cells to MEK162 
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or Selumetinib resulted in increased MEK phosphorylation. Previously, Hatzivassiliou et al. 
showed that the aromatic fluorine of allosteric MEK inhibitor GDC-0973 interacts with 
MEK residue S212.24 Their data indicate this interaction results in exposure of the phos-
phorylation sites S218/S222, which are then susceptible to RAF mediated phosphorylation. 
Since MEK162 and Selumetinib both have this aromatic fluorine, the mechanism of interac-
tion with MEK is probably similar to GDC-0973. Hence, although MEK activation in pres-
ence of GDC-0973, MEK162 or Selumetinib can still occur, the transduction of the signal 
by MEK-mediated phosphorylation of ERK is no longer possible, as we show in Figure 4.
Recently, we found the presence of RAS mutations in MLL-rearranged infant ALL cells cor-
related with prednisolone resistance, an obstacle in the treatment of infant ALL.2, 3 Remark-
ably, our present data shows that MEK inhibition strongly enhances the sensitivity of both 
RAS-wildtype and RAS-mutant MLL-rearranged ALL cells to prednisolone, also further 
exemplifying the possible value of MEK inhibitors for RAS-mutant, as well as RAS-wildtype, 
MLL-rearranged infant ALL patients. The prednisolone-sensitizing effect of MEK inhibitors 
proposes a possible role for RAS-MEK-ERK signaling in the response to glucocorticoids. 
Recent work by Jones et al. shows that MEK plays a key role in drug resistance in relapsed 
pediatric ALL, and that MEK inhibition can sensitize ALL relapse samples to chemothera-
peutics, including methylprednisolone.25 Moreover, Ariës et al. found Trametinib could re-
store prednisolone sensitivity in RAS-mutant BCP-ALL patient samples, whereas Rambal et 
al. showed that MEK activation reduces dexamethasone sensitivity, and the MEK inhibitor 
PD183452 enhanced dexamethasone responses in ALL cells in a BIM-dependent manner. 
26, 27 Activated ERK can phosphorylate BIM, targeting it for proteasomal degradation, and 
thereby diminishing apoptosis induced by dexamethasone.28 Moreover, we established that, 
while glucocorticoid receptor expression remains constant, MEK inhibition upregulates 
pro-apoptotic BIM, which implies that inhibiting MEK, resulting in abrogation of ERK 
phosphorylation, may result in prolonged maintenance of pro-apoptotic BIM activity upon 
prednisolone exposure, leading to enhanced prednisolone sensitivity. This is further sup-
ported by our previous study showing that in MLL-rearranged ALL, prednisolone sensitiza-
tion mediated by pan-BCL-2 family inhibitors was largely driven by the up-regulation of 
pro-apoptotic BID and BIM.29
In summary, our data shows that RAS-mutant MLL-rearranged infant ALL patients may 
benefit from therapeutic strategies administering small-molecule MEK inhibitors. Further-
more, since MEK inhibition sensitizes MLL-rearranged ALL cells to prednisolone regard-
less of the RAS mutations status, RAS-wildtype MLL-rearranged infant ALL patients may 
also benefit from MEK inhibitor treatment through enhanced sensitivity to prednisolone.
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supplementary figure s1: Mtt data primary t(4;11)+ samples
MTT assays of patient derived RAS-mutant (solid line, n=6) and RAS-wildtype (dashed line, n=14) t(4;11)+ in-
fant ALL cells exposed to Sorafenib, Salirasib, Temsirolimus and Vemurafenib. Error bars represent standard 
deviation. *0.01<p<0.05; **0.001<p<0.01; ***p<0.001.
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supplementary figure s2: p-MEk and p-ERk immunoblots of patient samples
(A) Western blots of MEK inhibitor resistant (Res) and sensitive (Sens) RAS-wildtype and RAS-mutant t(4;11)+ 
patient samples (left) and the matched diagnosis/relapse (Dx/Rel) samples (right) for phosphorylated MEK 
(upper), total MEK (middle) and β-actin (lower). (B) Western blots of t(4;11)+ patient samples for phosphory-
lated ERK (upper), total ERK (middle) and β-actin (lower).
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supplementary figure s3: Gene expression of tyrosine kinase receptors
Tyrosine kinase receptor mRNA expression (Affymetrix HU133plus2.0 microarray data) for FLT3, VEGFR-1, 
VEGFR-2, VEGFR-3, FGFR-1, FGFR-2, FGFR-3, FGFR-4, EGFR, ERBB2, ERBB3, ERBB4, PDGFR-A, PDGFR-B, Lck 
and Src in MEK inhibitor resistant RAS-wildtype (WT RES), MEK inhibitor sensitive RAS-wildtype (WT SENS) 
and RAS-mutant (MUT) primary samples.
83MEK inhibition in MLL-rearranged infant ALL
6h 6h 6h 6h24h 48h 24h 48h 24h 48h 48h
p-ELK1
p-ELK1
t-ELK1
t-ELK1
DMSO DMSOSelumetinib MEK162 Trametinib
SEM
KOPN8
p-Akt
p-Akt
t-Akt
t-Akt
SEM
KOPN8
A
B
p-p70S6K
p-p70S6K
t-p70S6K
t-p70S6K
SEM
KOPN8
C
supplementary figure s4: p-ELk-1, p-akt and p-p70s6k immunoblots of MEki treated cells
(A) Western blots of SEM (two upper panels) and KOPN8 (two lower panels), exposed for 6, 24 and 48 hours 
to either vehicle (DMSO) or Selumetinib, MEK162 or Trametinib, detecting phosphorylated ELK-1 and total 
ELK-1. (B) Western blots of SEM and KOPN8, exposed to aforementioned MEK inhibitor conditions, for phos-
phorylated and total Akt. (C) Western blots of SEM and KOPN8, exposed to aforementioned MEK inhibitor 
conditions, for phosphorylated and total p70S6K.
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supplementary figure s5: biM and p53 immunoblots of MEki treated cells
Western blots of SEM and KOPN8 exposed for 48 hours to DMSO (D), Selumetinib (S), MEK162 (M) or Tra-
metinib (T), for determination of BIM and p53 protein levels. Actin was used as loading control.
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supplementary figure s6: Cell cycle progression after MEk inhibitor exposure
Representative graphs of percentages SEM (A, C and E) or KOPN8 (B, D and F) cells in G2/M (white), S (grey) or 
G0/G1 (black) cell cycle stages, as analyzed by DNA staining. Cells were exposed to vehicle control (DMSO) 
or 500 nM MEK162, Selumetinib or Trametinib for 24, 48 or 72 hours (A and B, C and D, E and F, respectively).
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abstRaCt
RAS-pathway mutations, causing a proliferative advantage, occur in acute myeloid leukemia 
(AML) and MLL-rearranged leukemia. Recently, mutations in the Casitas B lineage lympho-
ma (CBL) gene were reported to be involved in RAS-pathway activation in various myeloid 
malignancies, but their role in pediatric AML is still unknown. We performed mutation 
analysis of 283 newly diagnosed and 33 relapsed pediatric AML cases. Only two mutant 
cases (0·7%) were identified in the newly diagnosed pediatric AML samples, of which one 
was MLL-rearranged. Both mutant cases showed CBL mRNA expression in the range of the 
non-mutated cases. Phosphorylated extracellular signal-regulated kinase (pERK) was not 
correlated with CBL protein expression (n=11). In conclusion, we report a very low CBL 
mutation frequency in pediatric AML, which, together with the lack of difference in protein 
and mRNA expression, illustrates the limited role of CBL in pediatric AML.
89CBL mutations in pediatric AML
intRoDuCtion
Enhanced proliferation and disrupted differentiation are known to constitute collabora-
tive key events leading to the onset of leukemogenesis. In acute myeloid leukemia (AML), 
mutations in several members of the RAS-regulated signaling pathway result in proliferative 
advantage1, 2. Recently, Casitas B lineage lymphoma (CBL), a protein involved upstream in 
this pathway, was found to be mutated at high frequency (15%) in juvenile myelomonocytic 
leukemia (JMML), mutually exclusive from other RAS-pathway mutations3. The proto-
oncogene CBL encodes an E3 ubiquitin ligase that negatively regulates receptor tyrosine 
kinases (like FLT3 and EGFR) and associated proteins including Grb2 and SOS, which are 
involved in RAS deactivation4. Mutations in the linker region and RING finger domain of 
CBL reduces its ubiquitin ligase potential, impairing the ability of Grb2 and SOS to suppress 
RAS signaling, and thereby over-activating downstream RAS targets5.
CBL mutations have also been observed in 1–2% of adult AML, 8% of atypical chronic 
myeloid leukemia, and 13% of chronic myelomonocytic leukaemia6-8. RAS-pathway-
associated mutations have been found in about 20% of pediatric AML cases, which mostly 
occur in specific subgroups, such as cytogenetically normal cases with NPM1 mutations 
or MLL-partial tandem duplications, t(8;21), inv(16), and MLL-rearranged patients under 
the age of 2 years9-11. Furthermore, type I mutations in MLL-rearranged AML cases were 
almost always related with the RAS-pathway9. The collaboration of RAS-pathway mutations 
and MLL-rearrangements at a young age was also reported in pediatric MLL-rearranged 
acute lymphoblastic leukemia (ALL) cases (50%)12. The role of RAS-pathway mutations 
in leukemogenesis of MLL-rearranged ALL is further stressed by studies in MLL/ AFF1 
(AF4)+ Kras mutation+ transgenic mice, which develop B-cell lymphoma and/ or leukemia 
with a relatively short latency (6 months), in contrast to transgenic mice models without 
RAS mutations13-15. One recent study reported the co-existence of CBL mutations and MLL-
rearrangements in ~5% of infant ALL patients16.
So far the frequency and clinical value of CBL mutations in pediatric AML is unknown. 
Therefore, we studied the frequency of CBL mutations and expression in a large cohort of 
pediatric AML.
MEthoDs
Patient samples
Viably frozen diagnostic bone marrow or peripheral blood from 319 AML samples, includ-
ing 277 de novo, 9 secondary and 33 relapsed pediatric AML samples, were provided by the 
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Dutch Childhood Oncology Group (DCOG), the AML ‘Berlin-Frankfurt-Münster’ Study 
Group (AML-BFM-SG), the Czech Pediatric Hematology Group (CPH), and the St. Louis 
Hospital in Paris, France. Patient characteristics of the 277 de novo cases are shown in 
Table 1. In order to elucidate the role of CBL related to MLL in general, we used an MLL-
rearranged enriched cohort [18 infant ALL patients, 100% t(4;11)(q21;q23), seven males] as 
controls. Informed consent was obtained from all patients after Institutional Review Board 
approval according to national law and regulations.
Materials
Leukemic cells were isolated and enriched as previously described17-19. All resulting samples 
contained 80% or more leukemic cells, as determined morphologically by May-Grünwald-
Giemsa (Merck, Darmstadt, Germany)–stained cytospins. A minimum of 5 × 106 leukemic 
cells was lysed in Trizol reagent (Gibco BRL/Life Technologies, Breda, the Netherlands) 
and stored at −80°C. Isolation of genomic DNA and total cellular RNA was performed as 
described before20.
AML samples were routinely investigated for MLL-rearrangements as previously de-
scribed21. The other common cytogenetic abnormalities in AML [such as t(8;21), inv(16), 
t(15;17)] were confirmed by conventional karyotyping, fluorescence in situ hybridization 
(FISH) or reverse transcription polymerase chain reaction (RT-PCR). For all infant ALL 
samples, karyotyping and analysis of possible MLL-rearrangements was performed with 
split-signal FISH, PCR or both (Primers are described in Table SI).
CBL mutation analysis
PCR analysis for CBL mutations was performed on genomic DNA using a 2720 Thermal 
cycler (Applied Biosystems, Foster City, CA, USA). Primers and conditions used for CBL 
screening were identical to those used by Loh et al3. Briefly, these primers target exons 8 
and 9, including the intron-exon boundaries of the CBL gene. Primer sequences are listed 
in Supplementary Table S1. Sequencing was done using a BigDye terminator v 1.1 Cycle 
Sequencing kit (PE Applied Biosystems, Foster City, CA, USA) on an Applied Biosystems 
3130x/ Genetic Analyzer. Sequence analysis was done with CLC Workbench software 
(CLCbio, Aarhus, Denmark) with reference sequence ENST00000264033 (www.ensembl.
org, release 59).
Of the mutated cases, germline material was obtained to investigate the CBL mutation status 
in healthy cells. We obtained DNA isolated from a cytospin at remission state from one 
case. From the other case, lymphocytes were isolated by magnetic-activated cell sorting (au-
toMACS; Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s 
guidelines.
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table 1: Patient characteristics de novo aML cohort consisting of 277 patients
No. of samples (%)
Sex (n=274)
Male 159 (58)
Female 115 (42)
Age (median, range, years, n=277) 9,4 (0-18,5)
WBC x 109/l at Dx (median, range, n=247) 43,6 (1,2-483)
FAB (n=270)
M0 14 (5)
M1 34 (13)
M2 52 (19)
M3 21 (8)
M4 77 (29)
M5 61 (23)
M6 4 (1)
M7 7 (3)
Cytogenetics (n=261)
MLL-rearrangements 64 (25)
t(8;21) 25 (10)
inv(16) 35 (13)
t(7;12) 5 (2)
t(15;17) 18 (7)
Cytogenetically Normal (CN)-AML 53 (20)
AML-other 61 (23)
Molecular abnormalities (n samples)
KIT (261) 21 (8)
KRAS or NRAS (261) 54 (21)
FLT3-ITD (269) 54 (20)
FLT3-D835/6 (43) 2 (5)
PTPN11 (261) 3 (1)
CEBPA (238) 17 (7)
NPM1 (252) 18 (7)
MLL-PTD (232) 5 (2)
WT1 (259) 22 (12)
TET2 (38) 1 (3)
DNMT3A (142) 3 (2)
IDH1/2 (199) 12 (6)
NUP98/ NSD1 (261) 12 (5)
CBL (277) 2 (1)
Patient characteristics of the de novo acute myeloid leukemia cohort. Numbers indicate frequency (%) un-
less specified otherwise. AML: acute myeloid leukemia, WBC: white blood cell count, Dx: diagnosis, FAB: 
French American British morphology classification.
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Gene expression profiling and Rt-qPCR
Gene expression profiling (GEP) (Affymetrix HU133plus2.0; Affymetrix, Santa Clara, CA, 
USA) was performed on 272/ 277 of de novo pediatric AML patients as a subset of the recently 
published study (Balgobind et al, 2011c). GEP data were deposited in the GEO database 
under accession number GSE17855. To validate mRNA expression levels, quantitative real-
time PCR(RT-qPCR) was performed on cDNA of 12 AML cell lines and 11 pediatric AML 
patient samples, selected on availability of cDNA, produced as previously described22. An ABI 
PRISM 7900HT sequence detector (Applied Biosystems) was used to validate the GEP results. 
Primers used for CBL are described in Supplementary Table S1. The average cycle threshold 
(Ct) value was used to calculate mRNA expression levels of CBL relative to the expression 
level of GAPDH using the comparative Cycle threshold (ΔCt) method23. For analysis of the 
CBL mutant transcripts we designed primers targeting exon 6 to 11 of CBL (Supplementary 
Table S1).
Western blot
For protein expression analysis 11 AML samples were selected based on CBL mutational 
status. Analysis was performed as previously described (Kuipers et al, 2011)21. Cell lysates 
containing 20 μg of protein were separated on 10% polyacrylamide gels and transferred 
onto nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany). Western Blots 
were probed with rabbit polyclonal IgG CBL (#2179; Cell Signaling, Danvers, MA, USA), 
rabbit polyclonal IgG phospho ERK1/2 (#4377; Cell Signaling) and mouse anti-beta-actin 
(ab6276; Abcam, Cambridge, MA, USA) antisera. Subsequently, the blots were probed with 
IRDye 800CW Goat-anti-Rabbit antibody (#926-32211; LI-COR, Lincoln, NE, USA) and 
IRDye 680 Goat-anti-Mouse antibody (#926-32220; LI-COR). Fluorescence was detected 
by the LI-COR Odyssey system (LI-COR).
functional analysis of CBL in aML
To study the influence of CBL expression on RAS pathway activation in pediatric AML cells 
we used the Kasumi-1 cell line [Deutsche Sammlung von Mikroorganismen und Zellkul-
turen (DSMZ) GmbH, Braunschweig, Germany], originally derived from a pediatric AML 
patient, as a model. Cells were cultured in RPMI-1640 medium supplemented with 20% 
fetal calf serum (FCS; Integro, Zaandam, the Netherlands) and penicillin 100 u/ml, strepto-
mycin 100 μg/ml, and fungizone 0·125 μg/ml (PSF; Invitrogen, Breda, the Netherlands) and 
grown as suspension cultures at 37°C in humidified air containing 5% CO2.
Cells (10×106) were transfected by electroporation in 400 μl of RPMI 1640 with l-alanyl-l-
glutamine (Invitrogen) containing 250 nM of either a mix of equal amounts of CBL siRNAs 
(Dharmacon ON-TARGETplus L-003003; Thermo Fisher Scientific, Etten-Leur, the Neth-
erlands) or Non-targeting siRNA (Dharmacon ON-TARGETplus D-001810-01-05; Thermo 
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Fisher Scientific), in 4-mm electroporation cuvettes (BioRad, Veenendaal, the Netherlands; 
target sequences are described in Supplementary Table S1). Electroporation was performed 
by the use of a BioRad Genepulser MXcell (BioRad) by applying a rectangle pulse of 
400 V for 10 milliseconds. To compensate for the amount of cell death induced merely as 
a consequence of the electroporation procedure, control cells were electroporated in the 
absence of siRNA. After a 15-min incubation at room temperature, the cells were diluted 
in 15 ml RPMI 1640 supplemented with 10% FCS and PSF and incubated at 37°C and 5% 
CO2. They were maintained in culture for 168h. Cell counts were determined daily (t=6, 
24, 48, 72, 96 and 168h). Cell samples of both experimental and control conditions were 
collected from the medium at every time point. They were washed with phosphate-buffered 
saline and stored as dry pellet or lysed in Trizol reagent and stored at −80°C. RT-qPCR and 
Western Blot were used as described above to validate CBL knockdown and consecutive 
phosphorylated extracellular signal-regulated kinase (pERK) up-regulation as a marker for 
RAS-pathway activity. Results from three repetitive experiments were analyzed together.
statistical analysis
Statistical analysis of GEP data was performed as previously reported24, 25. For comparison 
of CBL expression in different cytogenetic AML groups the Kruskal-Wallis test was used. 
For paired analyses of non-parametric variables, the Wilcoxon Signed Ranks Test was used. 
All analyses were performed with the Statistical Package for the Social Sciences (SPSS) 
software version 17.0 (SPSS Inc. Chicago, IL, USA). All tests were two-tailed and a p-value 
<0·05 was considered significant.
REsuLts
Mutation screening
CBL mutation screening was performed in 277 newly diagnosed de novo AML samples, 9 
newly diagnosed secondary AML samples and 33 AML samples at relapse, including 22 
paired diagnosis-relapse samples, and in the enriched MLL/ AF4 +  ALL cohort (n=18).
In 2/277 of the de novo AML patients a heterozygous mutation was found (0.7%, confidence 
interval 0.2-2.6%); case 1 had a 91 base pair deletion combined with a nine base pair inser-
tion of the intron 7-exon 8 boundary; case 2 had a single nucleotide exchange of the exon 
8-intron 8 splice site (Figure 1). Patient characteristics of both mutants are listed in Table 
2. Interestingly, the two patients with CBL mutations did not carry any other AML related 
molecular aberrations (NPM1, WT1, NRAS, KRAS, CEBPA, PTPN11, KIT, FLT3, IDH1/2, 
DNMT3A, NUP98/NSD1). All other AML cases, including all relapses and secondary AML 
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figure 1: Mutation analysis CBL exon 8 of mutant cases
Case 1 has a large deletion at the intron 7-exon 8 boundary, shown in pink (A). A schematic overview is 
shown as well (A). Case 2 has a point mutation at the exon 8-intron 8 splice site, exon 8 +4C>T (B). Figure 
1C shows a PCR electrophoresis on genomic DNA. Lane 1 corresponds to case1, lane 2 corresponds to case 
2, lane 3 and 4 correspond to wild-type controls, and lane 5 corresponds to a negative control. Figure 1D 
shows a PCR electrophoresis on cDNA. Lane 1 corresponds to case 1, lane 2 corresponds to case 2, lane 3 
corresponds to a wild-type control, and lane 4 corresponds to a negative control.
table 2: Patient characteristics CBL mutant cases
case 1 case 2
Sex female male
Age at diagnosis (years) 0.8 15.0
WBC at diagnosis (x 109/L) 475 1.4
FAB M4 M6
Cytogenetic subgroup MLL (FNBP1, 9q34.11) CN
Molecular abnormalities None None
Follow-up data CCR, 27 months LFU, day 0
Patient characteristics of both mutant cases. WBC: white blood cell count, FAB: French American British 
morphology classification, CN: cytogenetically normal, CCR: continuous complete remission, LFU: loss to 
follow-up.
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cases, were homozygous for the wild type allele. No CBL mutations were found in the MLL-
rearranged infant ALL samples.
Germline material of both mutated cases was analyzed. DNA derived from remission mate-
rial of case 1 was wild type for CBL (data not shown), while the sorted lymphocytes of case 
2 showed the same heterozygous point mutation in the exon 8-intron 8 splice site as the 
matched diagnosis sample (Supplementary Figure S1).
CBL mRna expression
Figure 2 shows CBL mRNA expression of pediatric AML patients as measured by gene expres-
sion array (probe 225231_at). RT-qPCR correlated moderately with the results obtained from 
GEP (Spearman r=0.41) (Supplementary Figure S2). CBL mRNA expression was not different 
between the cytogenetic groups in pediatric AML (Kruskal–Wallis test, p=0.55) (Figure 2). 
The two mutated cases expressed CBL mRNA levels within the range of all other cases.
Given that alternative splicing can occur for splice site mutations of CBL, we analyzed the 
transcripts of cases 1 and 2. Case 1 expressed alternative splicing with a full-length tran-
script and one lacking exon 8 (Figure 1D). Case 2 only expressed the full-length transcript 
(Figure 1D).
figure 2: CBL mRna expression of 272 initial pediatric aML patients
Graph showing the expression of probe set 225231_at, representing the CBL gene, after log transformation. 
Bars represent the median expression in each group. The arrows point to mutant cases, given as a triangle 
rather than a dot. CN: cytogenetically normal.
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Western blotting
Western blotting showed no significant differences in protein expression of the two CBL 
mutants versus nine CBL wild type AML cases (p=0.8) (Figure 3). There was no evidence of 
truncated protein in both mutant cases (Figure 3). We could not detect pERK overexpres-
sion in patients with low CBL protein expression (Figure 3). Correlation of CBL protein 
expression with CBL mRNA expression on gene expression array was very poor (Spearman 
r=0.0) (Supplementary Figure S2).
CBL knock-down by siRna transfection
To study whether CBL mRNA down-regulation affects RAS-pathway activation in pediatric 
AML, CBL mRNA knock-down experiments were performed in a pediatric AML cell line. 
A reduction of CBL mRNA and CBL protein expression of 50–60% did not significantly 
affect cell counts and proliferation compared to the non-targeting siRNA control condition 
(Figure 4), whereas CBL protein knock-down did result in pERK up-regulation compared 
to the non-targeting siRNA control (p=0.03), with a maximum threefold increase at t=48h 
(Figure 4).
DisCussion
This study aimed to elucidate the role of CBL in pediatric AML, triggered by reports show-
ing high frequencies of inactivating CBL mutations in various myeloid neoplasms3, 5-8, 26, 27. 
Our results show that CBL mutations occurred only at a very low frequency (0.7%) in our 
well-documented and representative cohort of pediatric AML (n=319)9. This report showed 
similar low frequencies of CBL mutations as in adult AML (1–2%)6, 7. In adults CBL muta-
tions were associated with core-binding factor leukaemia6, which we could not confirm in 
this pediatric AML series, i.e., one of the mutated patients carried an MLL-rearrangement 
figure 3: Western blot analysis of CbL from 11 aML patients
Figure displaying three western blot sections. The 120 kD product represents CBL protein, the bands on 
42/44 kD represent pERK. Actin was used as loading control (45 kD). Both lanes marked as + represent posi-
tive controls (cell lines HL60 and ME1 respectively), lanes 1 to 9 correspond to protein lysates of patients 
from diverse cytogenetic subgroups of pediatric AML, lane 10 corresponds to mutant case 1, lane 11 cor-
responds to mutant case 2. At the thin line one lane was spliced out. Differences in the protein levels of CBL 
do not correspond with CBL mutation status. There is no strict correlation between CBL protein levels and 
pERK protein levels in pediatric AML samples.
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and the karyotype of the second mutated patient was normal. Like in the adult AML co-
horts, in our two patients the identified mutations were heterozygous, which is in contrast 
to findings reported in JMML and CMML3, 6, 7, 28-32.
Given that CBL mutations occur in high frequency in the RAS-pathway mediated disease 
JMML, the study design enabled us to test our hypothesis, that CBL mutations may reveal 
a new, more upstream mechanism for RAS-pathway activation in pediatric AML. For 
that reason, we anticipated that CBL mutations could be related to MLL-rearrangements, 
given the previously observed association between MLL-rearrangements and RAS-pathway 
mutations in pediatric acute leukaemias9, 11, 12. Surprisingly, only 1/64 (1.6%) of our MLL-
rearranged AML samples was mutated and no mutations were found in the MLL-rearranged 
enriched cohort of infant ALL samples. Thus, we could not confirm the previously suggested 
relationship between MLL-rearrangements and CBL mutations16.
The splice site CBL mutation of case 2 was previously reported in JMML and CMML3, 8. 
RT-PCR confirmed that this specific mutation does not affect the CBL splicing, as recently 
figure 4: CBL knockdown by siRna transfection
Figure showing results from CBL knockdown by siRNA transfection by electroporation in Kasumi cell line. 
CBL mRNA expression is shown relative to the non-target siRNA over time (A); mean and standard error of 
3 consecutive experiments are shown. CBL protein expression normalized to the loading control actin is 
shown relative to non-target siRNA (B); mean and standard error of 3 consecutive experiments are shown. 
pERK protein expression normalized to the loading control actin is shown relative to non-target siRNA (C); 
mean and standard error of 3 consecutive experiments are shown. Cell counts during culture of both the 
experimental (CBL siRNA) and control (non-target siRNA) condition (D); mean and standard error of 3 con-
secutive experiments are shown. Western blot of both control (non-target siRNA) and experimental (CBL 
siRNA) condition (E); CBL, pERK and actin levels were determined. Time is shown in hours after electropora-
tion in all panels. NT: non-target siRNA.
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reported in a study on adult myeloproliferative neoplasms8. Analysis of germline material 
showed that the point mutation was also present in sorted lymphocytes. In the previous 
reports, the patients that harbored this specific nucleotide change were not analyzed for 
the presence of the mutation in their germline material3, 8. Therefore, the relevance of this 
specific germline mutation for leukemogenesis is not clear.
Even though several studies have reported on CBL mutations in myeloid neoplasms, we 
are the first to study CBL mRNA and CBL protein expression concomitantly in diagnostic 
patient AML material. We found that CBL mRNA expression of the two mutated cases was 
not different from other pediatric AML cases, that there was no differential expression 
between the cytogenetic subgroups, and that mRNA levels were highly variable. The CBL 
protein expression of CBL mutants was low, and the expression in non-mutants showed a 
wide range. No evidence of truncated protein was found, and protein expression did not 
correlate with mRNA expression, suggesting post-transcriptional mechanisms for CBL 
protein regulation.
Nevertheless, in JMML where mRNA and protein levels were not compared, CBL mutated 
cases clearly demonstrated aberrant RAS-pathway activation3. Others have demonstrated 
interaction between CBL and FLT3 or KIT, and have shown cytokine independent growth 
for co-expression of these receptor tyrosine kinases with mutant CBL in murine myeloid 
cells5, 33. Co-expression of wild-type CBL, which is the case in our patients, significantly 
reduced this potential34. So far, it has not been reported whether CBL protein inactiva-
tion in pediatric AML leads to RAS-pathway activation like in JMML. We found that CBL 
protein knock-down results in RAS-activation by means of pERK protein up-regulation in 
an AML cell line Kasumi-1. This may suggest that low levels of CBL protein or dysfunctional 
CBL protein may activate the RAS-pathway in AML. This is important, as RAS-pathway 
activation is known to play an important proliferative role in pediatric AML, which can be 
targeted by currently available therapy, such as MEK-inhibitors9, 11, 35-37. Nevertheless, pERK 
activation was not uniformly apparent in our patient samples, or well correlated with CBL 
protein levels.
In conclusion, this study shows that CBL mutations are very rare in pediatric AML. Never-
theless, we showed that decreased CBL protein expression may be a mechanism for RAS-
pathway activation in pediatric AML, like in JMML3. Therefore other factors besides CBL 
mutations, such as post-translational processing or enhanced degradation, may be involved 
in this process, in at least a subset of pediatric AML patients.
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supplementary figure s1: Mutation analysis CBL exon 8 of case 2 germline material
The electropherogram is shown of sorted lymphocytes and myeloid blasts at diagnosis. An identical het-
erozygous point mutation is found: exon 8 + 4 C>T. Dx: diagnosis.
supplementary table s1: sequences of primers and probes
Primer/Probe Sequence (5’-3’)
MLL Forward CGT CGA GGA AAA GAG TGA
AF6 Reverse TCC CGA TCA TCT TTG TTC
AF10 Reverse CTG GAA ATT TGC ATT TGT AA
AF9 Reverse ATG TTT CCA GGT AAC TCT GTA GT
ENL Reverse TAC CCC GAC TCC TCT ACT T
ELL Reverse CCC ATG ACT GGA GAC ATA CT
AF4 Reverse CTG-GGG-TTT-GTT-CAC
CBL-8F ACC CAG ACT AGA TGC TTT CTG
CBL-8R AGG CCA CCC CTT GTA TCA GT
CBL-9F TTC AGA TGC ATC TGT TAC TAT CT
CBL-9R AGT GTT TTA CGG CTT TAG AAG ACA
CBL Forward (RT-qPCR) GCC GCC TTC TCC ATT CT
CBL Reverse (RT-qPCR) CAG GGG GCA GTT TGT CTC
GAPDH Forward GTC GGA GTC AAC GGA TT
GAPDH Reverse AAG CTT CCC GTT CTC AG
GAPDH Probe (FAM)-TCA ACT ACA TGG TTT ACA TGT TCC AA (TAMRA)
CBL Forward (RT-PCR) TCC GGC TGA GCT GTA CTC
CBL Reverse (RT-PCR) GTG GTG GTG GAA GAT CTC
CBL siRNA J-003003-09 AAUCAACUCUGAACGGAAA
CBL siRNA J-003003-10 GACAAUCCCUCACAAUAAA
CBL siRNA J-003003-11 UAGCCCACCUUAUAUCUUA
CBL siRNA J-003003-12 GGAGACACAUUUCGGAUUA
Note: for siRNAs described sequences are target sequences. CBL PCR conditions for genomic DNA: 95ºC for 
2 minutes, 35 cycles of 94ºC for 40 seconds, 58ºC for 30 seconds, and 72ºC for 40 seconds, one cycle of 72ºC 
for 5 minutes. CBL and GAPDH RT-qPCR conditions: 50 ºC for 2 minutes, 95ºC for 10 minutes, 40 cycles of 
95ºC for 15 seconds, 60ºC for 60 seconds. CBL RT-PCR conditions: 95ºC for 5 minutes, 35 cycles of 95ºC for 15 
seconds, 58ºC for 45 seconds, and 72ºC for 2 minutes, one cycle of 72ºC for 10 minutes.
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supplementary figure s2: Cor-
relation of CbL protein and CBL 
mRna expression
Graph showing CBL mRNA expres-
sion from GEP (probe set 225231_
at) in correlation with CBL mRNA 
expression measured by RT-qPCR 
(A); CBL mRNA expression from GEP 
(probe set 225231_at) in correlation 
with CBL protein expression from 
western blot (B); and CBL mRNA 
expression measured by RT-qPCR 
in correlation with protein expres-
sion from western blot (C). Panel A 
shows data from 10 patient samples 
and 12 cell lines, panel B shows data 
from 10 patient samples and panel 
C from 11 patient samples. GEP: 
gene expression profiling, RET: rela-
tive expression calculation from RT-
qPCR relative to GAPDH levels.
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intRoDuCtion
Acute lymphoblastic leukemia (ALL) in infants (<1 year of age) represents an aggressive 
type of leukemia, associated with a poor clinical outcome due to early relapses1. This poor 
prognosis is associated with a high incidence (~80% of the cases) of MLL translocations, 
which are independent predictors of an adverse outcome1, 2. In an attempt to identify genes 
that improve risk classification for MLL-rearranged infant ALL patients, Kang et al. recently 
build a prediction model for outcome based on gene expression profiling, which separated 
MLL-AF4 cases in a low and a high risk-group. This model was based on the expression 
of 29 Affymetrix microarray probesets, including all probesets (n=5) corresponding to 
VCAN.3 The human VCAN gene encoding for the hyaluronan-binding proteoglycan protein 
Versican, has four different splice variants designated V0, V1, V2 and V34. Versican is 
known to be an important component of the extracellular matrix and plays a role in various 
cellular processes, including cell adhesion, proliferation, apoptosis, angiogenesis, migration 
and invasion5. Moreover, elevated VCAN expression has been observed in several types of 
human cancer, including leukemia, and is associated with clinical outcome in prostate and 
breast cancer6-8.
Because VCAN expression was shown to contribute in the prediction model of 29 probes 
for outcome in MLL-rearranged infant ALL3 and the prognostic value of VCAN expression 
alone has never been studied in MLL-rearranged infant ALL, we here studied the prognostic 
value of VCAN expression in a relatively large cohort of infant ALL patients.
MEthoDs
Patient samples and characteristics, RNA, and cDNA were obtained as previously de-
scribed9. We studied the VCAN mRNA expression in 68 infant ALL cases, including both 
patients carrying any MLL translocation (t(4;11), t(11;19), t(9;11), or other), and patients 
with germline MLL. We extracted the data of the probesets corresponding to VCAN 
(204619_s_at,204620_s_at, 211571_s_at, 215646_s_at) from our previously generated gene 
expression profiling data (Affymetrix HU133plus2.0 GeneChip microarray)9. Microarray 
data was normalized according to the Variance Stabilization and Normalization (VSN) 
method, as previously described9. VSN expression values of <4 typically represent expression 
levels that do not exceed the background noise levels, and are considered to correspond to 
expression levels that are very low or absent. The levels of mRNA expression were validated 
by quantitative RT- PCR analysis, as previously described 9. The following primer com-
binations used for transcript amplification were used 5’to 3’; ‘CCACGCTTCCTATGTGA’ 
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and ‘TTTCCCACTTTGACTTTATGT’ for VCAN and ‘GTCGGAGTCAACGGATT’ and 
‘AAGCTTCCCGTTCTCAG‘ for reference gene GAPDH.
The in vivo prednisone response was assessed as part of the Interfant protocols2. In vitro 
prednisolone cytotoxicity data was available for a subset of patients and was determined by 
4-day MTT assays as previously described10. Outcome was evaluated in terms of event-free 
survival (EFS) estimated by Kaplan-Meier and compared by Log-rank test in univariate 
and subgroup analyses, while multivariable analysis used the Cox regression model. Patient 
characteristics were analyzed using Fisher’s Exact and Mann Whitney U-tests. Analysis was 
performed using SPSS Statistics version 20.0 (SPSS Inc. Chicago, IL, USA) and SAS version 
9.2. p-values (two-tailed) less than 0.05 was considered statistically significant.
REsuLts
As shown in Figure 1A, in most of the 68 patient samples analyzed, VCAN is not expressed, 
or expressed at a very low level. Patients carrying MLL translocation t(4;11) express VCAN 
in a broad range, including patients showing high expression levels (Figure 1A). To validate 
the results from our Affymetrix microarray data we also performed quantitative RT-PCR 
analysis on the majority (n=58) of the samples used in microarray analysis. We found a 
strong correlation between the microarray and RT-PCR expression data (Spearman r=0.83, 
p<0.0001) (Figure 1B).
Data on outcome was available on 60 patients. Overall, we found that VCAN expression at 
diagnosis is associated with poor outcome in MLL-rearranged infant ALL patients, with a 
5-year EFS of 15.2% (SE 11.2%) for patients showing VCAN expression vs. 47.1% (SE 8.2%) 
for patients lacking VCAN expression (p=0.002, Figure 1C). Young age and high WBC 
counts at diagnosis, as well as a poor response to prednisone in vivo, are known risk factors 
in infant ALL2, 11 and are used in the Interfant protocol to stratify MLL-rearranged cases 
into a high-risk group (HR, with age <6 months and either WBC counts ≤ 300x10-9/L or 
PPR) and a medium-risk group (MR, including all others). Therefore, we studied the rela-
tion of these prognostic factors with VCAN expression and their joint impact on outcome. 
Patients showing VCAN expression at diagnosis presented at a younger age compared with 
patients without VCAN expression: 86.4% (19/22) of patients expressing VCAN at diagnosis 
presented with ALL before 6 months of age, in contrast to 44.7% (17/38) of patients lack-
ing VCAN expression (p=0.002). Furthermore, we found a significant negative correlation 
between age and VCAN mRNA expression at diagnosis among our MLL-rearranged infants 
(Spearman r= -0.498, p<0.0001). VCAN expression was significantly associated with WBC 
count at diagnosis (p=0.012): infants with VCAN expression were more likely to have high 
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WBC counts, ≥300x10-9/L (59.1%), compared to those without VCAN expression (42.1%). 
None of the VCAN expressing cases had WBC counts below 100x10-9/L, compared to 28.9% 
of the cases lacking VCAN expression. For patients with WBC counts ≥ 300x10-9 there was 
no difference in outcome between those with and without VCAN expression (Table 1). How-
ever for patients with WBC counts < 300x10-9/L VCAN expression was associated with a had 
worse outcome (p=0.0004, Table1). In addition, we analysed VCAN expression by MLL-
rearrangement and observed that VCAN expression mostly occurs in t(4;11)-rearranged as 
compared to other MLL-rearranged cells (51.9% vs 32.0%, p=0.034). We found that t(4;11)-
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figure 1: VCAN mRna expression in diagnostic MLL-rearranged infant aLL samples
(A) VSN normalized microarray data (Affymetrix HU133plus2.0 GeneChips) showing the average expression 
of the five probesets (204619_s_at, 204620_s_at, 211571_s_at and, 215646_s_at.) corresponding to VCAN, 
in infant ALL patients carrying MLL translocation t(4;11) (n=30), t(9;11) (n=8), t(11;19) (n=23), other MLL 
translocations (i.e. 11q23; n=7), infant ALL patients without MLL translocations (i.e. germline MLL; n=18 ) 
and childhood ALL patients older than 1 year of age without MLL translocations (i.e. B-ALL; n=16) (B) Corre-
lation between VCAN expression as determined by microarray analysis and quantitativeRT-PCR analysis for 
n=58 primary MLL-rearranged infant ALL samples. (C) 5-year EFS for VCAN expression-positive and negative 
MLL-rearranged. Survival data was available for 60 MLL-rearranged infant ALL cases. (D) In vitro predniso-
lone cytotoxicity in MLL-rearranged infant ALL patients, with (n=35) and without (n=25) VCAN expression 
at diagnosis, as determined by MTT-assays. Mean in vitro cytotoxicity responses were statistically analyzed 
using two-tailed Mann-Whitney U-test. Error bars represent standard error of the mean. (*0.05> p >0.01, 
**0.01> p >0.001, ***p<0.001).
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rearranged infant ALL patients positive for VCAN expression had a 5-year EFS of 15.5% 
compared to 69.2% in t(4;11)-rearranged infants without VCAN expression (p=0.0032, table 
1). No significant association between VCAN expression at diagnosis and in vivo prednisone 
response was found (p=0.766), while a highly significant correlation was observed between 
in vitro resistance to prednisolone and VCAN expression (Figure 1D). As shown in Table 1, 
within the subgroup of prednisone good responders (PGR, i.e. patients with <1000 cells/mL 
in peripheral blood after 7 days of treatment with prednisone and a single intrathecal dose 
of methotrexate) there was a significant difference in EFS according to VCAN expression 
(p=0.013), while this was not observed in prednisone poor responders (PPR). Infants with 
VCAN expression (59.1%) were more likely at HR, compared to patients without VCAN 
expression (42.1%, p=0.011), but this did not translate into a poorer outcome (p=0.4650). 
On the contrary, MR patients with VCAN expression showed a significantly worse outcome 
than MR lacking VCAN expression (p=0.0006, Table 1).
In order to evaluate the independent prognostic impact of VCAN expression, we applied 
a Cox model including the risk group stratification described above. Interestingly, there 
was a significant interaction between VCAN expression and risk stratification, indicating 
table 1: univariate analysis of VCAN expression and prognostic factors in MLL-rearranged infant aLL
 
VCAN negative VCAN positive  
Patients Events 5-year EFS (SE) Patients Events 5-year EFS (SE) P-value
Age at diagnosis (months)
0-6 17 10 41.2% (12.1) 19 15 16.8% (11.8) 0.1604
6-12 21 10 51.4% (11.1) 3 2 - -
WBC count (x 109/ L)
< 300 22 8 62.9% (10.5) 9 7 - 0.0004
≥ 300 16 12 25.0% (12.5) 13 10 16.7% (14.4) 0.5164
11q23 abnormality
t(4;11) 13 4 69.2% (12.8) 14 11 15.5% (13.8) 0.0032
other positive 25 16 36.0% (10.0) 8 6 - 0.0415
Risk Stratification
MR 29 12 58.2% (9.2) 9 7 - 0.0006
HR 9 8 11.1% (16.6) 13 10 16.7% (14.4) 0.4650
Univariate survival analysis of the prognostic factors, including age at diagnosis, white blood cell (WBC) 
count at diagnosis, 11q23 abnormality (t;411 vs. other), prednisone response and risk stratification in MLL-
rearranged infant ALL patients for VCAN expression-positive and negative cases. WBC= white blood cell 
count, PGR=prednisone good responder, PPR=prednisone poor responder, MR=medium risk, HR=high risk.
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that VCAN expression had a different impact in HR vs. MR patients (p=0.01). This model 
showed that the outcome of MR patients with VCAN expression was significantly worse than 
that of MR lacking VCAN expression (Hazard ratio=4.43, 95%CI=1.72–11.36, p=0.002). On 
the contrary, VCAN expression in HR patients did not have any impact (Hazard ratio=0.67, 
95% CI=0.26-1.70, p=0.399).
DisCussion
Inhibiting VCAN synthesis could be a potential therapy-strategy in MLL-rearranged infant 
ALL cells. Genistein, a tyrosine kinase inhibitor, has been reported to inhibit VCAN syn-
thesis in vascular smooth muscle cells and malignant mesothelioma cell lines12, 13. Besides, 
it was shown recently that Genistein induces apoptotic cell death, inhibits cell growth and a 
G2/M arrest in adult T-cell leukemia (ATL) cells 14. Pre-clinical studies showed that prostate, 
breast, and colon cancer cells were sensitized by Genistein to other chemotherapeutics15, 16. 
However, Genistein has also been reported to make childhood ALL cells more resistant to 
daunorubicin17.
In conclusion, VCAN expression in MLL-rearranged infant ALL patients is associated with 
a poor prognosis and could be used in combination with Interfant-06 stratification criteria 
to identify MR patients at high risk of treatment failure. Therefore, VCAN inhibition may 
represent an attractive therapeutic strategy that should be explored in pre-clinical studies.
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abstRaCt
Acute lymphoblastic leukemia (ALL) in infants is a high-risk malignancy characterized by 
a high rates of early relapses originating from the bone marrow. To decipher the role of the 
bone marrow microenvironment (BMME) in this type of childhood leukemia, we initially 
performed microarray-based gene expression profiling of leukemic cells cultured in vitro 
on supportive mesenchymal stromal cell (MSC) layers. As such we intended to identify 
transcriptional changes involved in the BMME-leukemic cell interactions. Unfortunately, 
in the course of these experiments, we became aware that contaminating MSCs in the 
leukemia samples were compromising our results. In order to characterize to what extent 
contaminating MSCs influenced our data, we set out to perform a series of comprehensive 
experiments which led us to conclude that as little as 1% MSC contamination is sufficient to 
establish a significant MSC expression profile within our leukemic samples. As co-culturing 
of malignant hematological cells on MSC layers represents a widely used method, we de-
cided to report and share all of our findings. With this, we would like to emphasize that 
transcriptional data obtained from in vitro co-culture experiments should be interpreted 
with great caution.
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intRoDuCtion
In recent years the relevance of the bone marrow microenvironment (BMME) in leukemia 
maintenance and progression has become evident, revealing that reciprocal interactions 
between leukemic and bone marrow (BM) stromal cells favor leukemic cells survival 1-3. 
Acute lymphoblastic leukemia (ALL) in infants (<1 year of age) represents an aggressive 
type of leukemia that is associated with a high incidence (~80% of the cases) of transloca-
tions of the MLL (Mixed Lineage Leukemia) gene 4, 5. Despite the fact that MLL-rearranged 
infant ALL cells typically are resistant to important chemotherapeutics 5-7, morphological 
complete remission (CR) is achieved in the majority of patients. Yet, favorable treatment 
results are hampered by exceedingly high relapse rates during treatment 5, 7-9. As the vast ma-
jority of relapses originate from the BM, it is plausible to assume that the BMME provides a 
protective sanctuary for small subsets of leukemic cells that evade initial chemotherapy and 
give rise to the re-emergence of the leukemia. Hence, the BMME is likely to play a pivotal 
role in MLL-rearranged infant ALL.
A commonly used method to study BMME-leukemia interactions in vitro involves culturing 
of leukemic cells on top of layers of mesenchymal stromal cells (MSCs) 10-16. Such co-culture 
studies revealed that MSCs support hematopoietic and leukemic cell maintenance in vitro 
through cell-cell contact and/or via the secretion of propitious soluble factors 10, 11. More-
over, several studies demonstrated changes in miRNA, mRNA, and protein expression in 
various hematologic malignancies induced by supportive stromal layers 13-17. Encouraged by 
these results, we studied the role of the BMME in MLL-rearranged infant ALL. We observed 
that, when cultured on mesenchymal stromal cell (MSC) layers, part of the MLL-rearranged 
ALL cells adhere to the MSCs, while another portion of the leukemic cells failed to adhere 
and remained in suspension. From this we reasoned that applying microarray-based gene 
expression profiling (GEP) on the separated adherent and non-adherent MLL-rearranged 
ALL cell fractions should potentially reveal important transcriptomic changes involved in 
the interactions between MLL-rearranged ALL cells and MSC layers. Obviously, interacting 
membrane receptors and/or adhesion molecules would represent attractive candidates for 
targeted inhibition in order to impede the ability of MLL-rearranged ALL cells to interact 
with the BMME.
However, based on our initial results and subsequent validation experiments we increas-
ingly raised doubts regarding our seemingly promising GEP data, and felt that our results 
may have been compromised by contaminating MSCs (although minute) in the adherent 
leukemic cell fractions. On top of that, our concerns were significantly strengthened 
by Paggetti et al. who demonstrated that a contamination as small as 0.01% of MSC in 
leukemic chronic lymphocytic leukemia (CLL) samples derived from in vitro co-culture 
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experiments substantially influenced miRNA expression profiles, inevitably leading to 
false-positive results 18. During the course of our study, we were forced to conclude that our 
mRNA profiles were indeed corrupted by minute contaminations of interfering MSCs. Yet, 
as the in vitro co-culturing of malignant hematological cells on MSC layers is a widely used 
method, we decided to report our results, including evidence of the profound consequences 
of contaminating MSCs. With this we strive to strengthen the warning from Paggetti et al., 
and hope to alert researchers to interpret data obtained from in vitro co-culturing experi-
ments with caution.
MEthoDs
MLL-rearranged aLL and mesenchymal cell lines
The t(4;11)-positive cell lines SEM and RS4;11 were purchased from the German Collection 
of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany), BEL-1 was a kind 
gift from Dr. Tang (University Paris, France). All cell lines were maintained as suspension 
cultures in RPMI 1640 with L-Alanyl-L-Glutamine (Invitrogen Life Technologies, Breda, 
the Netherlands) supplemented with 10% fetal calf serum (FCS) (Integro, Zaandam, the 
Netherlands)
The human embryonal mesenchymal cell line H92-1 was a kind gift from Dr. Dzierzak 
(Erasmus University Rotterdam, The Netherlands) and were cultured in Myelocult H5100 
(Stem cell technologies, Grenoble, France) with 35% MEM Alpha (Invitrogen) supple-
mented with 10% FCS (Integro), 1% Glutamax (Invitrogen), 100 IU/ml penicillin, 100 μg/
ml streptomycin, and 0.125 μg/ml fungizone (Invitrogen), and 12.5 μM/ml β-mercapto-
ethanol. The murine OP9 stromal cells (ATCC, Wesel, Germany) were cultured in MEM 
Alpha (Invitrogen) supplemented with 10% FCS (Integro), 1% Glutamax (Invitrogen), 
100 IU/ml penicillin, 100 μg/ml streptomycin, and 0.125 μg/ml fungizone (Invitrogen). All 
cell lines and patient cells were cultured at 37 °C in humidified air containing 5% CO2.
Patient samples and cell lines
Bone marrow or peripheral blood samples from untreated infants (below one year of age) 
diagnosed with ALL were collected at the institutes participating in the international col-
laborative Interfant protocol 5. Informed consent was obtained according to the Helsinki 
declaration, and approved by the Institutional Review Board of the Erasmus University 
Medical Center. All samples were processed as described before19.
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Co-culture of MLL-rearranged cell lines with mesenchymal stromal layers
Human and murine stromal cells were cultured on a 0.01% porc gelatin A (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) coated culture dishes and cultured until 90% confluency, 
upon which the cells were irradiated with 30 Gray to prevent overgrowth. Medium was 
refreshed one day after irradiation. Four days after irradiation MLL-rearranged leukemic 
cells were resuspended in AIMV medium (Invitrogen) and were plated at a density of 3x104 
cells/cm2 on the confluent irradiated stromal layers at 37ºC in 5% CO2.
harvesting cells from the co-culture
After four days of co-culture the leukemic and mesenchymal cells were collected by their 
distinctive phenotype, as previously described 11. Briefly, the non-adherent (NA) leukemic 
cells were harvested by aspiration of the supernatant, the stromal layer was gently washed 
twice with PBS to remove the remaining NA cells. The adherent (AD) cells, which adhere 
to the mesenchymal stromal layer, were harvesting by extensive washing with PBS. The 
mesenchymal cells were collected by incubating the stromal layer with trypsin. To establish 
the contamination of the leukemic cell faction with stromal cells, the purity was determined 
morphologically on May-Grünwald-Giemsa (Merck)–stained cytospins. All used leukemic 
cell samples had a purity of >97% blasts, more specific the NA samples were 99-100% pure 
and the AD samples 97-99% pure.
Rna extraction
Genomic RNA were extracted from ~0.5x106 leukemic cells using All prep DNA/RNA 
Microkit (Qiagen, Venlo, The Netherlands) according to the manufacturer’s guidelines, and 
quantified on a Nanodrop ND-1000 spectrophotometer (Isogen). The integrity of RNA was 
assessed on standard 0.8% agarose gels and on an Agilent 2100 Bioanalyzer (Agilent).
Gene expression profiles
Gene expression profiles were generated as previously described 20. Briefly, high-quality 
RNA was reverse transcribed using T7-linked oligo-dT primers, and the obtained cDNA 
was used as a template to synthesize biotinylated cRNA. Labeled cRNA was then fragmented 
and hybridized to HU133plus2.0 GeneChips (Affymetrix) according to the manufacturer’s 
guidelines. The infant ALL patient gene expression data presented in this study have been 
deposited in the National Center for Biotechnology Information Gene Expression Omnibus 
21 and is accessible via GEO Series accession number GSE19475.
Quantitative real-time PCR analysis
cDNA was obtained by reverse transcriptase of the total RNA and used to validate mRNA 
expression by quantitative real-time PCR analysis using the DyNAmo SYBR Green qPCR 
kit (Finnzymes, Espoo, Finland), as previously described 22. Primer combinations used for 
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transcript amplification of selected target genes as well as the housekeeping reference genes 
glyceraldehyde-3-phosphate dehydrogenise (GAPDH), tyrosine 3-monooxygenase/tryptophan 
5-monooxygenase activation protein, theta polypeptide (YWHAQ), β2 microglobulin (B2M), 
and beta-actin (ACTB) are listed in Supplementary Table S1. All samples were analyzed in 
duplicate.
statistical analysis
Statistical analyses of gene expression profiles were performed in R using Bioconductor 
packages (R Development Core Team, 2011). A p-value, corrected for multiple testing by the 
false discovery rate step-up procedure of Benjamini & Hochberg 23, of <0.05 was considerate 
significant. GenePattern version 3.7.0 was used to generate heatmaps.24 The other statistical 
analyses were performed with SPSS Statistics version 17.0 (SPSS Inc. Chicago, IL, USA). All 
tests were two-tailed and a p-value below 0.05 was considered significant.
REsuLts
Gene expression profiling in MLL-rearranged aLL cells obtained from MsC co-
culture experiments
In order to study the role of the BMME in MLL-rearranged infant ALL, we co-cultured 
t(4;11)-positive ALL cell lines (n=3, in duplicate) and primary t(4;11)-positive infant ALL 
patient samples (n=2) on MSC layers and observed two distinct phenotypes. A portion 
of the leukemic cells adhered to the MSCs (i.e. adherent leukemic cells), while others 
remained in suspension (i.e. non-adherent leukemic cells). Upon observing these differ-
ent phenotypes, we were interested if differential gene expression between adherent and 
non-adherent leukemic cells could reveal genes that play a role in cell-cell contact between 
MLL-rearranged ALL cells and MSCs. Therefore, we separately harvested non-adherent and 
adherent leukemic cell fractions and generated GEP data using Affymetrix HU133plus2.0 
GeneChips. In addition we generated GEP data from the mentioned MLL-rearranged ALL 
cell line and patient samples cultured in the absence of MSCs, as well as from MSCs cultured 
in the absence of leukemic cells. Next, the obtained GEP data was subjected to Limma (Lin-
ear models for microarray data) analysis, identifying a core signature consisting of n=55 
significantly differentially expressed probesets (corresponding to n=43 genes) between 
adherent and non-adherent MLL-rearranged ALL cells (Figure 1). Remarkably, all of these 
genes appeared to be up-regulated in the adherent cells. Most of these genes encode for 
proteins involved in cell-cell adhesion and the extracellular matrix (ECM). Up-regulation 
in the adherent fraction of the primary MLL-rearranged infant ALL patient samples could 
be confirmed for most of these genes (Figure 2). The up-regulation of the identified core 
signature could be validated by quantitative RT-PCR analysis in adherent and non-adherent 
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       AD             NA 
figure 1: heatmap visualization of the 55 differentially up-regulated probesets
Heatmap visualization (corresponding to 43 genes) in t(4;11)-rearranged ALL cells that were able to adhere 
(adherent; AD) to mesenchymal stromal cells and those that were not able to adhere (non-adherent; NA). 
Data was obtained from three different t(4;11)-rearranged ALL cell lines in duplicate experiments. Columns 
represent samples and rows represent genes. Relative high expression is shown in red and low expression 
in blue.
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leukemic cell fractions obtained from independent experiments using the t(4;11)-positive 
ALL cell lines SEM and RS4;11 (Supplementary Figure S1). Based on our quantitative 
RT-PCR data, the genes in the identified core signature appeared to be up-regulated up to 
~750-fold. Next we studied the expression of these genes in diagnostic infant ALL samples, 
from our recent published GEP dataset. 20 The majority of these genes were hardly expressed 
in diagnostic MLL-rearranged infant ALL samples (Figure 3).
the cell-cell interaction-associated gene expression signature solely originates 
from contaminating MsCs
Initially our observations led us to assume that the observed up-regulation of genes in-
volved in cell-cell interactions and ECM remodeling in MLL-rearranged ALL cells involved 
a specific gene signature that is rapidly induced upon adherence to MSCs, and which is 
readily down-regulated once the physical contact with the MSCs is lost. Yet, an alterna-
tive explanation could be that the observed gene expression signature was influenced by 
contaminating MSCs, despite the high purity (97-99.9% leukemic cells) of our extracted 
adherent MLL-rearranged ALL fractions. This alternative explanation became increasingly 
plausible with the publication of Paggetti et al., showing that even a contamination of 0.01% 
of MSCs could lead to misinterpretations of miRNA expression data in the co-cultured 
leukemic cells 18.
Therefore we studied the expression of genes seemingly up-regulated in adherent MLL-rear-
ranged ALL cells in our MSCs. We found that all of the genes were abundantly expressed in 
the MSCs, and at much higher levels than observed in the adherent leukemic cell fractions. 
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figure 2: mRna expression of genes from t(4;11)-toplist
mRNA expression of gens was determined by GEP in non-adherent and adherent co-culture samples in 
two different diagnostic t(4;11)-rearranged infant ALL patients samples. Each line represents one probeset. 
Wilcoxon matched pairs test was used to determine the upregulation of the toplist overall.
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This is exemplified in Figure 4A, showing data for two Affymetrix HU133plus2.0 probesets 
corresponding to the COL1A2 gene, encoding the human collagen I, alpha-2 polypeptide. 
The distribution of COL1A2 expression as shown in Figure 4A is representative for all differ-
entially expressed genes. The observation that all of the up-regulated genes appeared to be 
abundantly expressed in the MSCs advocated in favor of cell contamination. We wondered 
if such small numbers of contaminating cells could cause the enormous up-regulation of 
genes in the adherent fraction. Therefore, we performed experiments in which we delib-
erately mixed varying percentages of MSCs into MLL-rearranged ALL samples that were 
cultured in the absence of MSC layers. Immediately after mixing the cells, the samples were 
subjected to RNA extraction to avoid possible transcriptomic changes as a result of cell-cell 
interactions between the leukemic and MSCs. In addition we added the supernatant derived 
from 4-day MSC cultures to leukemic cells in order to explore the possibility of extracellular 
vesicles or cells debris was responsible for the observed up-regulation of gene expression. 
Next we performed quantitative RT-PCR analysis on the following genes: COL1A2, FN1, 
LGALS3, LOX, LOXL1, SPARC, THBS1 and VCAN. We found that the mRNA expres-
sion of all of these genes increased with an increasing percentage of MSC contamination 
(Figure 4B, Supplementary Figure S2). Next, we compared the levels of expression in these 
deliberately contaminated samples to that of our adherent and non-adherent leukemic cell 
fractions derived from our co-culture experiments. As demonstrated in Figure 4C-D, the 
level of COL1A2 expression in the non-adherent leukemic cells was comparable to that of 
0.1% contamination, whereas in adherent leukemic cells the level of expression correlated 
with 1-10% contamination. Again, the example of COL1A2 was representative for the other 
genes studied (data not shown). We also observed up-regulation of gene expression in SEM 
cells to which we only added the supernatant derived from MSCs, suggesting that even cell 
debris in the supernatant is potentially influencing gene expression.
MLL-rearrangend infant ALL patients
AD
AM
TS
1
CA
LD
1
CA
V1
CN
N3
CO
L1
A1
CO
L1
A2
CO
L2
1A
1
CO
L3
A1
CO
L4
A5
CO
L5
A2
CO
L6
A3 DC
N
DK
K3
ED
IL3
F2
RL
1
F2
RL
2
FB
N1
FH
L2 FN
1
FS
TL
1
GJ
A1
ITG
BL
1
JA
G1
KIA
A1
19
9
LG
AL
S3 LO
X
LO
XL
1
MG
ST
1
NN
MT
PC
DH
7
PL
S3
PO
ST
N
PT
X3
SP
AR
C
TH
BS
1
TIM
P3
TP
M2
VC
AN
0
2
4
6
8
10
VS
N 
no
rm
al
is
ed
 e
xp
re
ss
io
n
figure 3: mRna expression in MLL-rearranged infant aLL samples
VSN normalized mRNA expression based on GEP from diagnostic infant ALL samples. All plots are based 
on one probeset, except for the following genes, which the plot is based on the average of multiple probe-
sets; COL1A2 (n=2), FBN1 (n=2), MGST1 (n=2), POSTN (n=2), COL3A1 (n=3), PRSS23 (n=3), VCAN (n=4) and, 
FN1 (n=4). Expression value of 4 is used as cutoff for expression, below 4 it is considerated that there is no 
expression (dashed line).
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We studied the correlation of the expression levels of eight randomly picked genes in our 
core signature between leukemic samples with increasing percentages of contaminating 
MSCs with that of pure MSC samples. We found that with an increasing contamination 
of MSCs in the leukemic cell samples, the correlation with pure MSC samples improved. 
In fact, at levels of contamination between 1-10% MSC in the leukemic cell samples, the 
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figure 4: Vsn normalized GEP in MLL-rearranged aLL cell lines
(A) SN normalized GEP expression of the COL1A2 probesets, in cells MLL-rearranged ALL cell lines (before 
co-culture (BL), non-adherent (NA), adherent (AD)) and in stromal cells (no co-culture(MSC BL), from co-
culture (MSC CC)) The trend in expression is representive for all the probesets from the t(4;11)-toplist. (B) 
mRNA expression of COL1A2 relative to GAPDH housekeeping gene in SEM samples contaminated with 
increasing percentages of stromal cells (H92-1). The expression for FN1, LGALS3, LOX, LOXL1, SPARC, THBS1 
and, VCAN demonstrate the same trend as for COL1A2, all genes are depicted in supplementary figure 2.(C)
COL1A2 mRNA expression relative to GAPDH housekeeping gene in co-culture samples and contamina-
tion samples (D) and corrected for the baseline expression of SEM cells. The white bars represent the con-
tamination samples and the grey bars represent the co-culture samples. mRNA expression of FN1, LGALS3, 
LOX, LOXL1, SPARC, THBS1 and, VCAN demonstrate the same trend as for COL1A2, all genes are depicted in 
supplementary figure 3.
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correlation of gene expression with that of pure MSC samples was nearly perfect (spearman 
R=1.000, p<0.0001) (Figure 5). Hence, 1-10% contamination of MSCs in a leukemic cell 
population apparently is sufficient to alter the mRNA expression levels entirely towards a 
MSC profile.
One alternative possibility that could explain the observed up-regulation of genes in our 
adherent leukemic cell samples apart from contaminating MSCs would be the transfer 
of mRNAs from MSCs to leukemic cells via secreted extracellular vesicles. The fact that 
we found up-regulation of gene expression in leukemic cells to which we only added the 
supernatant of cultured MSCs seem to be in favor of such a mechanism. To explore this 
possibility, we also performed additional co-culture experiments in which the leukemic 
cells were separated from the MSCs by inserted Transwell membrames with pore sizes of 1.0 
µm or 0.4 µm. In case of a 1.0 µm pore size, extracellular vesicles like microvesicles secreted 
by the MSCs should still be able to reach the leukemic cells. In contrast, the membrames 
Relative expression to GAPDH (%)
0.01 0.1 1 10 100 1000
0.00001
0.0001
0.001
0.01
0.1
1
10
100


r= 0.024
p= 0.977
100% H92-1
10
0%
 S
EM
Relative expression to GAPDH (%)
0.01 0.1 1 10 100 1000
0.00001
0.0001
0.001
0.01
0.1
1
10
100


r= 0.7143
p= 0.0576
100% H92-1
0.
1%
 h
92
-1
 in
 S
EM
Relative expression to GAPDH (%)
0.01 0.1 1 10 100 1000
0.00001
0.0001
0.001
0.01
0.1
1
10
100
 
r= 0.9524
p= 0.0011
100% H92-1
1%
 H
92
-1
 in
 S
EM
Relative expression to GAPDH (%)
0.01 0.1 1 10 100 1000
0.00001
0.0001
0.001
0.01
0.1
1
10
100


r= 1.000
p< 0.0001
100% H92-1
10
%
 H
92
-1
 in
 S
EM
figure 5: stromal mRna expression in contaminated leukemic samples
Correlation of stromal mRNA expression and stromal contaminated leukemic samples, based on eight of 
the t(4;11)-toplist genes (▲COL1A2, ○FN1, ■LGALS3, □LOX, ●LOXL1, ▼SPARC, êTHBS1, ♦VCAN). On the x-
axis the mRNA expression of 100% stromal cells (H92-1) and on the y-axis the expression in of stromal (H92-
1) contaminated leukemic samples, in varies percentages (0-10%) is displayed.
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with a 0.4 µm pore size should largely block vesicle transfer. The results from these ex-
periments demonstrated that the up-regulation of gene expression in the leukemic cells was 
completely lost by using either of the membranes (data not shown). This excludes the option 
that extracellular vesicles secreted by MSCs were responsible for (part of) the observed 
up-regulation of the genes in our core signature.
Co-culture murine stromal cells and leukemic sEM cell line
Another approach to study whether or not the observed increases in gene expression was 
due to contamination is to perform co-culture experiments using murine instead of human 
MSCs. Therefore we used the OP9 murine stromal cell line as an supportive layer for the 
human leukemic SEM cell line. After four days of co-culture we harvested the adherent and 
non-adherent leukemic cells. Next, we performed quantitative RT-PCR analysis using species 
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figure 6: mRna expression in co-culture samples
(A) mRNA expression relative to GAPDH housekeeping gene, as determined by RT-PCR, in human leuke-
mic SEM cells (SEM BL), non-adherent human leukemic cells (SEM NA) and adherent human leukemic cells 
(SEM AD), and blank murine stromal OP9 cells (OP9 BL). SEM NA and SEM AD samples were derived from a 
co-culture of 4 days. (B) Human specific FN1 expression, human specific VCAN expression, (C) human and 
murine specific FN1 expression.
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specific primers (as enlisted in Supplementary Table S1) for the following genes; COL1A2, FN1, 
LOXL1, THBS1, and VCAN. We found that the expression of human COL1A2, THBS1, and 
LOXL1 was absent in all samples. Human VCAN and FN1 were expressed, but we could not 
observe an up-regulation in the adherent leukemic cell fraction (Figure 6A-B). On the other 
hand, we did observe high expression of all murine genes, except for VCAN, in the both the 
non-adherent and adherent leukemic cell fractions, as well as in pure OP9 cells. Furthermore, 
when we visualize the human (leukemic) and murine (stromal) expression of these genes in 
one graph it becomes very clear that there is hardly any leukemic expression of these genes 
(Figure 6C). This indicates that the expression of these genes found in our human-human co-
cultures was stromal expression, so very likely to be caused by the contaminating stromal cells.
DisCussion
In the present study we used a co-culture approach to study the influence of stromal-
leukemic interations in Initially we identified a strong core signature of genes differentially 
expressed, but as all genes were highly expressed in the MSCs and barely in leukemic cells. 
This, together with the recent publication of Paggetti et al.18, raised the question whether 
our results were actually caused by leukemic-stromal cell interactions or perhaps by MSC 
contamination in our leukemic cell fractions. Subsequently we performed various analyses 
and experiments, all of which strongly suggested that the obtained results were solely due to 
contaminating MSCs in our leukemic samples in our co-culture system.
In conclusion, we demonstrate that contaminating MSCs have large effects on GEP of leu-
kemic cells derived from co-culture systems. This is in concordance with the recent findings 
of compromised miRNA expression, as described by Paggetti et al.18 We expect that similar 
problems will occur with protein analyses in direct co-culture experiments. Although we do 
not question the value of in vitro co-culture models, we would like to emphasize the potential 
danger of contaminating stromal cells in the cell population of interest. Therefore, to evaluate 
results derived from such co-culture experiments should be analyzed with great caution, and 
a proper experimental design using relevant controls, as well as critical data analysis, are war-
ranted in order to avoid misinterpretation of obtained data.
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supplementary figure s1: mRNA expression of genes from t(4;11)-toplist as determined by GEP in non-
adherent and adherent co-culture samples in two different t(4;11)-rearranged cell lines. Each line represents 
one probeset. Wilcoxon matched pairs test was used to determine the upregulation of the toplist overall.
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supplementary figure s2: mRNA expression of t(4;11)-toplist genes (COL1A2, FN1, LGALS3, LOX, LOXL1, 
SPARC, THBS1, VCAN) relative to GAPDH housekeeping gene in SEM samples contaminated with increasing 
percentages of stromal cells (H92-1).
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supplementary table s1: sequences of primers
Primer Sequence (5’-3’)
ADAMTS1 Forward AAGCTGCTCCGTCATAGA
ADAMTS1 Reverse GTCCTCCCCAAATGTAAAC
CALD1 Forward CTCCCAAACCTTCTGACTT
CALD1 Reverse CAGCATGGGTTTCTTTAGA
CAV1 Forward CGGAGGGACATCTCTACA
CAV1 Reverse CAAGCGGTAAAACCAGTATT
CNN3 Forward GACCCAGGTTCAGACTACTC
CNN3 Reverse TGGCTGGCTCCTTTATT
COL1A1 Forward CCTCGGAGGAAACTTTG
COL1A1 Reverse CAGCTTCCCCATCATCT
COL1A2 Forward TCAGACCCAAGGACTATGA
COL1A2 Reverse CTGCCAGCATTGATAGTTT
COL1A2 Forward (human specific) ATGGTCGCACTGGACAT
COL1A2 Reverse (human specific) AGCCCTGTAGAAGTCTCCA
COL1A2 Forward (murine specific) CGGACCCAGTGGTATTG
COL1A2 Reverse (murine specific) CAGACCACGTTCACCTCTA
COL21A1 Forward TGACCCAGAACAGAACAAC
COL21A1 Reverse TCCCGGAGGACAAATAC
COL3A1 Forward CATGCCAAATATGTGTCTGT
COL3A1 Reverse CTGGGGAGAATAGTTCTGAG
COL4A5 Forward GAGCCTGGTGGAATTACTT
COL4A5 Reverse CCGGCTGGGTTATAGTC
COL5A2 Forward TTCCGCAAAGCAGAGT
COL5A2 Reverse AGGCGCAAAAAAGTCAT
COL6A3 Forward GGTGCTGGTCCTCATAAG
COL6A3 Reverse TTCCGGGACAGTAAACAC
DCN Forward TCAGCCGGATTGTGTT
DCN Reverse GTGGCCTTCATGATTTATCT
DKK3 Forward GCCACCCTCAATGAGAT
DKK3 Reverse TTTGCCAGGTTCACTTCT
EDIL3 Forward AGTTCGGCAAAGGTGATA
EDIL3 Reverse CCTCGGTATGCTTCACTTA
F2RL1 Forward CATCCAAGGAACCAGTAGAT
F2RL1 Reverse CAGGGTGCTTCTTCTTAGTT
F2RL2 Forward TGTGCTCCATGATTTTACAG
F2RL2 Reverse TTTGCCAAGTTGTTTGTATC
FBN1 Forward AACCGAGGATTTCAACAA
FBN1 Reverse ACAGGGGTTTTTCTCACA
FHL2 Forward AAGCGGCTCTCTGACTC
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supplementary table s1: sequences of primers (continued)
Primer Sequence (5’-3’)
FHL2 Reverse CTCCCGCAGGATGTACT
FN1 Forward GGAGGAGACCACATGAGA
FN1 Reverse TCCCAGGCAAGTACAATC
FN1 Forward (human specific) CCTGCACCTGGAGTCTAC
FN1 Reverse (human specific) CGTGCCCAGAATTGTT
FN1 Forward (murine specific) AAAGGGAACGACAGT
FN1 Reverse (murine specific) ACAATCGGTGCATCTCTC
FSTL1 Forward CCAGCCCAGTTGTTTG
FSTL1 Reverse TGGCAGTTTCATTCTGTTC
GAPDH Forward (human specific) GTCGGAGTCAACGGATT
GAPDH Reverse (human specific) AAGCTTCCCGTTCTCAG
GAPDH Forward (murine specific) CTCCTGCGACTTCAACAG
GAPDH Reverse (murine specific) TCTGGGATGGAAATTGTG
GJA1 Forward TGCCTTTTCATTTTACTTCA
GJA1 Reverse GATTGGGAAAGACTTGTCAT
JAG1 Forward CTGGCCGAGGTCCTATA
JAG1 Reverse GGGCGGCAGAACTTAT
KIAA1199 Forward AGGGGAAGGAGTTTTGAG
KIAA1199 Reverse GGAAGCAGGTCAGAGTGA
LGALS3 Forward CCTGCACCTGGAGTCTAC
LGALS3 Reverse CGTGCCCAGAATTGTTAT
LOX Forward CAGCCGACCAAGATATTC
LOX Reverse GCTGGGGTTTACACTGAC
LOXL1 Forward CTGCGGAGGAGAAGTGT
LOXL1 Reverse GGTTGCCGAAGTCACA
LOXL1 Forward (human specific) CTGCGGAGGAGAAGTGT
LOXL1 Reverse (human specific) GGTTGGGGAGGAAGTCT
LOXL1 Forward (murine specific) GGGCAGGTGTTCAGTC
LOXL1 Reverse (murine specific) CACGCAGCAGAAGAATG
MGST1 Forward TTGCCAATCCAGAAGACT
MGST1 Reverse CGTGCTCCGACAAATAGT
NNMT Forward AGAAGGGCTGAACTGATG
NNMT Reverse AATCCCGAGGGTTAAAAT
PCDH7 Forward TCCCAGAGGACAACTATGA
PCDH7 Reverse AGCTGCACTGAAGGTCTC
PGCP Forward TGGGAAGCACTCTCACTT
PGCP Reverse CCCTGGCCTTTTCACT
PLS3 Forward TGGGTGGAACTTCAGAGT
PLS3 Reverse CCAGCCCTCAAATCTTC
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supplementary table s1: sequences of primers (continued)
Primer Sequence (5’-3’)
POSTN Forward TTGCCCTGGTTATATGAGA
POSTN Reverse ACTCGGTGCAAAGTAAGTG
PTX3 Forward TTGCGATTCTGTTTTGTG
PTX3 Reverse TTCCGAGTGCTCCTGA
SPARC Forward CTGCGGGTGAAGAAGAT
SPARC Reverse TCCAGGGCGATGTACTT
THBS1 Forward TTCACCGCCTACAGATG
THBS1 Reverse CTGGGGGTTTTCTCAAG
THBS1 Forward (human specific) TCCCCTAGTCTATCACAAC
THBS1 Reverse (human specific) TGCCACAGCTCGTAGAA
THBS1 Forward (murine specific) ATCCGCACCACCTACATC
THBS1 Reverse (murine specific) GTTCTGGCAGTGACACTCT
TIMP3 Forward GCCCCATGTGCAGTAC
TIMP3 Reverse TGTCGGTCCAGAGACACT
TPM2 Forward ACCAGGCCCTCAAGTC
TPM2 Reverse TCTGCTCGGGTCTCAG
VCAN Forward CCACGCTTCCTATGTGA
VCAN Reverse TTTCCCACTTTGACTTTATGT
VCAN Forward (human specific) GTCCGGGATTGAAGACACA
VCAN Reverse (human specific) GGATGGGATATCTGACAGTC
VCAN Forward (murine specific) ACGCAAACACATGAATCA
VCAN Reverse (murine specific) CAAGGTGAATCCATAGTGACT
WWTR1 Forward TGACCCCAGACATGAGAT
WWTR1 Reverse CTGCGTTTTCTCCTGTATC
RT-PCR thermocycling conditions: 95ºC for 5 minutes, 35 cycles of 95ºC for 15 seconds, 58ºC for 45 seconds, 
and 72ºC for 2 minutes, one cycle of 72ºC for 10 minutes.
Chapter 9
Summary and 
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In this final chapter we summarize and discuss our main findings from this thesis. First we 
will recapitulate main characteristics of infant acute lymphoblastic leukemia (ALL). Next 
we will discuss our most important results, relevant prognostic factors in infant ALL, the 
potential clinical impact, and suggestions for treatment strategies.
infant aCutE LyMPhobLastiC LEukEMia
Over de past decades therapeutic strategies and outcome for pediatric acute ALL improved 
enormously, leading to current survival-rates approaching 90%1. Although treatment of 
infant (<1 year of age) ALL patients usually involves more aggressive chemotherapeutic 
regimes, clinical outcome for these young patients remains poor, with event free survival 
(EFS) rates of ~50%2, 3. A strong independent prognostic factor of poor outcome in infant 
ALL is the presence of an MLL translocation2. MLL translocation occur in ~80% of all infant 
ALL cases4. The most recurrent MLL translocations are t(4;11), t(11;19) and t(9;11), which 
generate the chimeric fusion proteins MLL-AF4, MLL-ENL and MLL-AF9, respectively. In 
approximately 95% of MLL-rearranged infant ALL cases morphologically complete remis-
sion is achieved 5, 6. Despite the initial good response on chemotherapeutics, good prognoses 
in infant ALL patients are hampered by high relapse-rates (30-50%). Most relapses occur 
within the first year after diagnosis, while still on treatment5-7. Relapsed infant ALL is gener-
ally assumed to be inevitably fatal.
RELaPsED infant aCutE LyMPhobLastiC LEukEMia
In chapter 2 we describe the clinical outcome of a large cohort of relapsed infant ALL pa-
tients treated with the interfant-99 treatment protocol2. Overall we found a 20.9% survival 
for all relapsed infant ALL patients and 24.9% for those treated with curative intent. This 
is in concordance with the 25.6% 5-year overall survival (OS) in recurrent or refractory 
infant ALL reported by Tomizawa et al.8. We found that young age (< 6 months of age) and 
high white blood cell (WBC) counts (>300x109/L) at initial diagnosis were associated with 
inferior outcome after the first relapse, but response to a prednisone prophase prior to first 
line of treatment did not. Furthermore, patients who relapsed earlier (<24 months after 
diagnosis) and patients with bone marrow (BM) involvement (either isolated or combined) 
had a worse outcome. In concordance with previous studies we found that the majority of 
relapses (56.9%) in our cohort occured within the first year after diagnosis. We demonstrate 
that time of relapse is of prognostic relevance. Patients who relapsed within 24 months after 
diagnosis had a 1.5-fold increase in the risk of death. Most of the relapses originated from 
the BM (71.8%), which was associated with a dismal outcome compared with patients with 
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isolated extramedullary relapses. We have demonstrated that relapsed infant ALL is not 
invariably lethal, and with that underlined the relevance of offering treatments with cura-
tive intents. However, the majority of relapsed infant ALL patients remain to be challenged 
with a very poor prognosis. Hence, the development of therapeutic strategies specifically 
designed to increase the prognosis for relapsed infant ALL patients is warranted. Yet, to 
accomplish this, better insights into the biology and underlying mechanisms of relapse are 
required.
In this thesis we discuss different factors that contribute to infant ALL disease outcome, 
disease progression and relapse. As we discuss in chapter 3 we found that in vitro resistance 
to standard chemotherapeutic agents as currently used in the treatment for infant ALL, is 
associated with a high risk of therapy failure and consequently poor event-free survival 
(EFS) rates, with the majority of events being relapses. These data confirm that relapsed 
infant ALL cells are indeed more resistant to chemotherapy as compared with the leukemic 
cells at diagnosis. In other words, in most of the cases the current treatment protocol for 
infant ALL patients fails to eliminate all leukemic cells, and selects for the most resistant 
cells that subsequently are able to give rise to disease relapses that are even more difficult 
to treat.
As the vast majority of relapses originate from the BM (see chapter 2), we hypothesized 
that the bone marrow microenvironment (BMME) plays an important supportive role in 
therapy-resistance and relapses in infant ALL patients. Furthermore, we describe in chapter 
4 that almost all infants harboring a RAS mutation suffer from a relapse within the first 
3 years after achieving complete remission. We hypothesize that relapses in infant ALL 
are caused by a inter-play between biological factors of the leukemic clone as well as the 
biological supportive environmental factors. Unraveling the biological mechanism causing 
leukemic relapse could lead to new targets for therapy strategies. Treatment options reduc-
ing the risk of relapse as well as more effective relapse-treatment for infant ALL patients.
bonE MaRRoW MiCRoEnViRonMEnt
In recent years the relevance of the BMME in leukemia maintenance and disease progres-
sion has become evident, revealing that reciprocal interactions between leukemic and BM 
stromal cells favor leukemic cells survival9-11. As the majority of infant ALL relapses origi-
nate from the BM, it is plausible to assume that the BMME plays a role in relapsed infant 
ALL, by providing a protective sanctuary for small subsets of leukemic cells that evade 
initial chemotherapy and give rise to the re-emergence of the leukemia. A commonly used 
method to study BMME-leukemia interactions involves in vitro co-culturing of leukemic 
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cells with supportive mesenchymal stromal cell (MSC) layers12-17 . To decipher the role of 
the BMME in infant ALL, we initially performed microarray-based gene expression profil-
ing (GEP) of leukemic cells co-cultured in vitro with MSC layers, as described in chapter 
8. Unfortunately, in the course of these experiments, we became aware that contaminating 
MSCs in the leukemic samples were compromising our results. In order to characterize 
to what extent contaminating MSCs influenced our data, we set out to perform a series of 
comprehensive experiments.
We concluded that minute contaminating MSCs have large effects on GEP data of leukemic 
cells derived from co-cultures, which appeared in line with recent findings of Paggetti et 
al.18. As co-culturing of malignant hematological cells on MSC layers represents a widely 
used method, we would like to emphasize the potential danger of contaminating MSCs 
in order to avoid misinterpretation of obtained data. Therefore based on these results we 
could not demonstrate the role of the BMME in (relapsed) infant ALL within the duration 
of this research project. Admittedly, MSC contamination may have been prevented by plac-
ing fine-grained filters between the MSC layers and the leukemic cells during co-culture 
experiments. However, this would also prevent direct contact between the leukemic cells 
and MSCs, limiting communication between the two cell types to cytokine and chemokine 
exchange via the culture medium only. However, as demonstrated by Polak et al., ALL cells 
depend on direct interactions with MSCs via tunneling nanotubes (TNTs) for intercellular 
communication19. Hence, performing co-culture experiments in which the MSC layers are 
separated from the leukemic cells by fine-grained filters would likely not have resulted in 
relevant data.
With current advanced technologies, we would re-design our original experiments in which 
infant ALL cells are co-cultured in direct contact with MSC layers, following a cell sorting 
strategy to eliminate contaminating cells in either cell fraction. To further exclude the risk 
of contaminating cells, we would suggest to replace GEP of bulk cell populations with a 
currently available single-cell sequencing approach.
PRoGnostiC faCtoRs
The presence of an MLL-rearrangement is known as one of the most predictive factors of 
poor clinical outcome in infant ALL patients2. In turn, among MLL-positive infant ALL 
patients other important risk factors have been identified, including young age (<6 months), 
WBC at diagnosis, a pro- B-cell immunophenotype characterized by the absence of the 
CD10 cell surface marker, and a poor in vivo response to a 7-day prophase of prednisone 
treatment 2, 20, 21. In the Interfant treatment protocols for infant ALL patients, age, WBC 
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counts, and in vivo prednisone response are used to stratify MLL-rearranged cases into 
risk groups and allocate cases to corresponding treatment strategies. Infants younger than 
6 months at diagnosis, displaying high WBC counts (≥300x10-9/L) or a poor prednisone 
response are allocated to the high-risk (HR) arm of the treatment protocol, whereas all 
other cases are allocated to the medium-risk (MR) treatment arm. Yet, to further improve 
patient stratification and better prediction which of the patients are at high risk of develop-
ing disease relapses, additional risk factors and/or prognostic markers are required. In this 
thesis we identified the presence of (sub)clonal RAS mutations (chapter 4) and high VCAN 
expression (chapter 7) to represent two novel prognostic markers for MLL-rearranged 
infant ALL.
RAS-PathWay
In search of new therapeutic targets in MLL-rearranged acute leukemia, recent studies 
focused on the RAS-pathway22-27. In chapter 4 we indentify the presence of RAS mutations 
as an independent predictor of an very poor outcome in infant ALL. In a substantial subset 
(14-24%) of our cohort of infant ALL samples we detected RAS mutations. The highest fre-
quency of RAS mutations was found in patients carrying the t(4;11)-translocation. In fact, 
none of the t(4;11)-positive infant ALL patients, carrying a RAS mutation, survived their 
malignancy and deceased within 4 years from diagnosis. Interestingly, patients harboring 
a RAS mutation appeared to have higher WBC counts at diagnosis (p=0.013), and were 
found to be more resistant to glucocorticoids in vitro (p<0.05). Thus, the presence of a RAS 
mutation seemed to coincide with already known risk factors. Yet, in a multivariate analyses 
including known risk factors in infant ALL, the presence of a RAS mutation represented an 
independent predictor of a poor clinical outcome.
About half of our detected RAS mutations appeared to be present at a subclonal level. This 
observation was recently confirmed by studies demonstrating high frequencies 47-63.8% of 
(sub)clonal RAS/PI3K pathway mutations in pediatric MLL-rearranged ALL samples27, 28. 
Trentin et al. demonstrate that the mutational clones present at relapse were in almost all 
cases also detectable at diagnosis28. Combined these data suggest that the RAS-mutated 
clone may represent the chemoresistant cell fraction that evades initial chemotherapy to 
give rise to disease relapses. Hence, targeting the RAS pathway, for instance using MEK 
inhibitors such as Trametinib or Selumetinib, could be beneficial for MLL-rearranged infant 
ALL patients carrying (sub)clonal RAS mutations, especially since Trametinib exposure ap-
peared to sensitize MLL-rearranged ALL cell to prednisolone in vitro (chapter 5).
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However, our research group recently published a validation study in which in vivo efficacy 
of the MEK inhibitor Trametinib was tested against an MLL-rearranged infant ALL cell line 
carrying a clonal RAS mutation in a xenograft mouse model29. This study demonstrated 
that Trametinib mono-therapy was not sufficient to significantly inhibit overall leukemia 
progression in mice29, despite similar studies showing Selumetinib and Trametinib to effec-
tively inhibit leukemia progression in xenograft mouse models of childhood ALL and AML 
30, 31 . Nonetheless, Trametinib did seem to specifically target MLL-rearranged ALL cells in 
the BM of the mice, showing reduced leukemic cell numbers present in the BM in ~50% of 
the mice upon Trametinib treatment29. Thus, the implementation of a MEK inhibitor within 
the current treatment protocol for infant ALL patients may well reduce the frequency of 
disease relapses of the RAS mutated clone, and at the same time could potentiate the effects 
of prednisone which already is part of the standard treatments of childhood ALL. Such 
an implementation may well be feasible in the near future as promising results with MEK 
inhibitors are being reported in clinical trials for various adult malignancies 32-36.
In chapter 6 we set out experiments to identify mutations in the Casitas B lineage lymphoma 
(CBL) gene, another important gene from the RAS-pathway. Recently, mutations in CBL 
were found in other types of hematological malignancies and appeared to exist mutually 
exclusive from other RAS-pathway mutations37-39. However, we were not able to detect mu-
tations in CBL among our cohort of infant ALL samples.
VeRSICAN ExPREssion
Recently high Versican (VCAN) expression was identified to be of prognostic value in a pre-
diction model based on Affymetrix microarray probesets associated with a poor outcome 
in MLL-rearranged infant ALL patients. Elevated VCAN expression has been observed in 
various types of human cancer, including leukemia, and is associated with poor clinical 
outcome40-42. In chapter 7 we describe the relation of clinical outcome and VCAN expres-
sion in a large cohort of infant ALL patients. VCAN expression at diagnosis was associated 
with a poor outcome in MLL-rearranged infant ALL patients. Furthermore we found a 
different impact of VCAN expression in the risk-stratification groups. Infant ALL patients 
who display VCAN expression were more likely to be allocated to the HR arm of the treat-
ment protocol, without an effect on outcome. On the contrary, patients allocated to the MR 
group who displayed VCAN expression showed a significantly worse outcome compared as 
compared to patients lacking VCAN expression. VCAN expression could therefore be used 
to identify patients within the MR group, with high risk of therapy-resistance or relapse. We 
hypothesized that indentifying these “high-risk” patients within the MR group could lead to 
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re-allocation of these patients to the HR arm of the treatment protocol, which seems more 
appropriate for these patients.
Moreover, investigating VCAN expression as a potential target for novel therapeutic strate-
gies could be of interest. For instance, Genistein, a tyrosine kinase inhibitor, has been 
reported to inhibit VCAN synthesis in various malignancies43-45, and pre-clinical studies 
showed that Genistein sensitizes various types of malignant cells, including childhood ALL 
cells, to other chemotherapeutic agents46-48. Therefore we hypothesize that Genistein, be-
cause of its chemotherapeutic-sensitizing effects, could especially be beneficial for therapy-
resistant and relapsed infant ALL patients.
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In de afgelopen decennia zijn de overlevingskansen voor kinderen met acute lymfatische 
leukemie (ALL) sterk verbeterd tot ongeveer 90%. De overlevingskansen voor zuigelingen 
(kinderen jonger dan 1 jaar) met ALL blijven helaas nog steken op 50%. Dit ondanks de 
meer agressieve chemotherapie waar deze jonge kinderen mee behandeld worden. ALL bij 
zuigelingen is in verschillende opzichten anders dan bij kinderen ouder dan 1 jaar. Bij on-
geveer 80% van de zuigelingen is er een genetisch defect aanwezig, wat bij oudere kinderen 
slechts voorkomt bij 1% van de patiënten. Dit genetische defect is een herschikking van het 
zogenaamde MLL gen. Dit betekent dat een deel van het MLL gen gekoppeld wordt aan 
een deel van een ander gen. Hierdoor wijzigt de functie van het MLL gen, welke normaliter 
een belangrijke rol speelt in de ontwikkeling van witte bloedcellen. Een verandering van 
de functie van het MLL gen kan leiden tot het ontstaan van ALL. De aanwezigheid van 
deze MLL-herschikking is bij zuigelingen met ALL een belangrijke voorspeller voor een 
slechte kans op overleving. Ongeveer 95% van de zuigelingen met een MLL-herschikking 
in de leukemiecellen komt na de initiële chemotherapie in remissie. Dat houdt in dat de 
leukemiecellen niet meer aantoonbaar zijn in het bloed en beenmerg. Ondanks dat de 
meeste zuigelingen in remissie komen, hebben ze een grote kans (~50%) dat de ziekte weer 
terug komt, oftewel een recidief. De meeste recidieven ontstaan tijdens het eerste jaar na de 
diagnose en dus daarmee nog tijdens de behandeling met chemotherapie.
Er werd over het algemeen verondersteld dat een recidief bij zuigelingen met ALL altijd 
fataal is. Echter, in hoofdstuk 2 beschrijven we de klinische uitkomsten van een grote groep 
zuigelingen met een ALL recidief. Uit ons onderzoek bleek dat na 5 jaar ongeveer 20% 
van deze zuigelingen nog in leven was. Verschillende factoren waren van invloed op de 
genezingskans na het recidief. Jonge leeftijd (<6 maanden) en een zeer hoog aantal witte 
bloedcellen in het bloed bij diagnose bleken geassocieerd met een slechte uitkomst na het 
eerste recidief. Hiernaast bleek dat zuigelingen, die binnen 2 jaar na diagnose een recidief 
kregen of waarbij het recidief in het beenmerg plaats vond een slechtere kans op overleving 
hebben. Ruim de helft van de recidieven in onze groep zuigelingen vond plaats in het eerste 
jaar na diagnose, dus nog tijdens behandeling. Het tijdstip van het recidief is een belangrijke 
voorspeller voor de overleving. Patiënten, die binnen 2 jaar na de diagnose een recidief 
kregen, hebben een 1.5 maal vergroot risico om te overlijden, dan kinderen die een later 
recidief kregen. De meeste recidieven ontstaan in het beenmerg, wat geassocieerd wordt 
met een slechtere uitkomst ten opzichte van patiënten waarbij het recidief op een andere 
plaats in het lichaam ontstaat. Ons onderzoek laat zien dat een recidief van zuigelingen 
ALL niet altijd fataal hoeft te zijn. Dit geeft voldoende reden om deze groep patiënten te 
behandelen met een curatieve intentie. Het gros van de patiënten met een recidief heeft 
echter nog steeds een erg slechte prognose. Daarom is het van belang om therapeutische 
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opties te ontwikkelen voor deze groep patiënten. Om dit te bereiken is meer inzicht nodig in 
de biologie van ALL bij zuigelingen en hoe een recidief ontstaat. We denken dat recidieven 
worden veroorzaakt door een samenspel tussen biologische factoren van de leukemiecellen 
en de biologische omgevingsfactoren in het beenmerg. Nader onderzoek naar deze biolo-
gische mechanismes, die een rol spelen bij het ontstaan van een recidief, kunnen bijdragen 
aan het ontwikkelen van nieuwe therapeutische mogelijkheden om het risico op recidief te 
verlagen, en het effectiever behandelen van recidieven.
In hoofdstuk 3 testen we in het laboratorium de gevoeligheid van de leukemiecellen van 
patiënten voor de standaard chemotherapeutica, die gebruikt worden bij de behandeling. 
Het blijkt dat, wanneer leukemiecellen in het laboratorium minder gevoelig zijn voor che-
motherapeutica, er een verhoogd risico is op een recidief ALL en overlijden. Met andere 
woorden, met het huidige behandelingsprotocol voor ALL bij zuigelingen lukt het niet altijd 
om alle leukemiecellen volledig te elimineren. De meest resistente leukemiecellen krijgen de 
kans om uit te groeien tot een recidief en een nog moeilijker te behandelen ALL.
Zoals we in hoofdstuk 2 beschrijven ontstaat de meerderheid van de recidieven in het 
beenmerg. Omdat bloedcellen geproduceerd worden in het beenmerg, is dit de meest voor-
komende locatie voor een leukemierecidief. We denken dat het beenmerg een belangrijke 
omgevingsrol speelt in therapieresistentie en het ontstaan van recidieven van ALL bij zuige-
lingen. Gedacht wordt dat leukemiecellen in staat zijn om interacties met de beenmergcel-
len aan te gaan en zich zo in het beenmerg kunnen verschuilen voor de chemotherapie. Zeer 
kleine aantallen leukemiecellen, welke met de huidige technieken niet meer te detecteren 
zijn in het beenmerg van de patiënt, overleven zo de chemotherapie en groeien later uit tot 
een recidief. In hoofdstuk 8 beschrijven we hoe we de interacties tussen deze cellen onder-
zocht hebben en welke genen daarbij van belang waren. Helaas kwamen we tijdens deze 
experimenten tot de conclusie dat ons model, welke ook veel door anderen gebruikt wordt 
om dit soort interacties te bestuderen, de onderzoekresultaten onbetrouwbaar maakte. 
Hierdoor konden we geen conclusies verbinden aan de behaalde resultaten.
Zoals eerder genoemd is de aanwezigheid van een MLL-herschikking een van de belang-
rijkste voorspellers voor een lagere kans op overleving voor zuigelingen met ALL. Andere 
belangrijke voorspellers zijn jonge leeftijd (< 6 maanden) bij diagnose, zeer hoge aantal-
len witte bloedcellen bij diagnose en een slechte reactie op de eerste week van prednison 
behandeling. Deze verschillende voorspellers worden gebruikt om zuigelingen in te delen 
in verschillende risicogroepen, met meer en minder kans op overleving. De behandelings-
protocollen zijn aangepast op deze risicogroepen. Zuigelingen met hoog risico zullen een 
agressievere chemotherapie ontvangen en soms beenmergtransplantatie. Om nog beter te 
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kunnen voorspellen welke zuigelingen een groot risico op een slechte uitkomst hebben is 
het noodzakelijk meer risicofactoren te identificeren.
In hoofdstuk 4 onderzoeken we of de aanwezigheid van een defect van het RAS gen een 
dergelijke risicofactor is. Het blijkt dat bij een significant aantal (14-25%) van de zuigelin-
gen met ALL een mutatie in het RAS gen in de leukemiecellen aanwezig is. Hiernaast blijkt 
dat bijna alle zuigelingen met een mutatie van het RAS gen in de leukemiecellen binnen 3 
jaar na complete remissie een recidief krijgen. Binnen 5 jaar na de diagnose is nog maar 
11% van deze zuigelingen in leven in tegenstelling tot 45% bij de zuigelingen zonder deze 
RAS mutatie. De aanwezigheid van een RAS mutatie in de leukemiecellen blijkt dus een 
voorspeller voor een zeer slechte klinische uitkomst, onafhankelijk van andere bekende 
risicofactoren bij zuigelingen met ALL. Omdat deze uitkomsten gebaseerd zijn op een 
klein aantal onderzochte zuigelingen, zouden deze bevestigd moeten worden in een grotere 
groep zuigelingen met ALL. Naast het screenen van RAS mutaties hebben we in hoofdstuk 
6 een screening uitgevoerd voor mutaties in het Casitas B lineage lymphoma (CBL) gen. Het 
CBL gen is een ander belangrijk gen binnen het RAS-pathway. We hebben echter geen CBL 
mutaties gevonden in de onderzochte leukemiecellen van zuigelingen met ALL en dus geen 
relatie kunnen vaststellen.
Therapeutische middelen gericht op het RAS-pathway, zoals Trametinib of Selumetinib, 
zouden gunstig kunnen zijn voor patiënten met een RAS mutatie in de leukemiecellen. Ze-
ker aangezien we in hoofdstuk 5 laten zien dat blootstelling van leukemiecellen aan Trame-
tinib in het laboratorium, deze gevoeliger maakt voor prednisolon, een van de belangrijkste 
middelen tegen leukemie. Prednison is een niet-werkzame stof welke in het lichaam wordt 
omgezet in het werkzame prednisolon. Een goede reactie op prednison bij de start van de 
chemothepeutische behandeling is een voorspeller voor een hogere overlevingskans. Recent 
heeft onze onderzoeksgroep in een in vivo muismodel niet kunnen aantonen dat Trame-
tinib als monotherapie de leukemieprogressie van RAS-gemuteerde MLL-herschikte ALL 
cellen voldoende kon remmen. Wel werd aangetoond dat de behandeling van Trametinib 
het aantal leukemiecellen met 50% reduceerde in een deel van deze muizen. Trametinib 
zou dus mogelijk het effect van prednison, reeds aanwezig in de standaard behandeling, 
kunnen versterken. Er zijn veelbelovende resultaten met therapeutische middelen, die het 
RAS-pathway remmen, bij maligniteiten bij volwassenen beschreven. Het implementeren 
van zo’n middel in de behandeling voor zuigelingen met ALL zou in de nabije toekomst 
haalbaar kunnen zijn.
Een andere potentiële kandidaat om nieuwe therapeutische opties tegen te ontwikkelen is 
het zogenaamde Versican (VCAN) gen. Recent onderzoek heeft aangetoond dat een ver-
hoogde activiteit (expressie) van het VCAN gen samen gaat met een lagere overlevingskans 
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bij verschillende maligniteiten, waaronder zuigelingen met een MLL-herschikte ALL. In 
hoofdstuk 7 bevestigen we deze associatie tussen hoge VCAN expressie in de leukemiecel-
len tijdens diagnose en lagere overlevingskans in ons cohort van zuigelingen met ALL. We 
vonden ook een verschil van impact van VCAN expressie in de verschillende risicogroepen. 
Patiënten met een hogere VCAN expressie in de leukemiecellen waren vaker toegewezen tot 
het hoog-risico behandelprotocol, zonder effect op de klinische uitkomst. Patiënten uit de 
medium-risico behandelgroep en met hoge VCAN expressie hadden een significant lagere 
overlevingskans vergeleken met patiënten zonder VCAN expressie. VCAN expressie zou dus 
gebruikt kunnen worden om binnen de medium-risicogroep, patiënten te identificeren met 
een verhoogd risico op therapieresistentie of een recidief. We denken dat het identificeren 
van deze hoog-risico patiënten binnen de medium-risicogroep zou kunnen leiden tot her-
verdeling van deze patiënten naar de hoog-risico behandelgroep, met een meer passende 
behandeling voor deze patiënten. Hiernaast is het interessant om te onderzoeken of VCAN 
een potentieel aangrijpingspunt geeft voor nieuwe behandelingsopties. Van het middel 
Genistein is bijvoorbeeld beschreven dat het de synthese van het VCAN eiwit remt in ver-
schillende maligniteiten. Preklinische studies lieten zien dat Genistein verschillende typen 
maligne cellen, waaronder leukemiecellen van kinderen, gevoeliger maakt voor andere 
chemotherapeutica. Door deze sensibiliserende eigenschappen zou Genistein met name 
geschikt kunnen zijn voor zuigelingen met een therapieresistente of recidief ALL.
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